# EDGAR Filing Document

**Accession Number:** 0001355064
**File Stem:** 0001580642-26-001744
**Filing Date:** 2026-3
**Character Count:** 439420
**Document Hash:** 92af08447b70c3fc3c0b3cef61f834b2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001580642-26-001744.hdr.sgml**: 20260311

**ACCESSION NUMBER**: 0001580642-26-001744

**CONFORMED SUBMISSION TYPE**: N-CSRS

**PUBLIC DOCUMENT COUNT**: 25

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260311

**DATE AS OF CHANGE**: 20260311

**EFFECTIVENESS DATE**: 20260311

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MUTUAL FUND SERIES TRUST
- **CENTRAL INDEX KEY:** 0001355064

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** OH
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** N-CSRS
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-21872
- **FILM NUMBER:** 26742662

**BUSINESS ADDRESS:**
- **STREET 1:** C/O GEMINI FUND SERVICES LLC
- **STREET 2:** 4221 NORTH 203RD STREET, SUITE 100
- **CITY:** ELKHORN
- **STATE:** NE
- **ZIP:** 68022-3474
- **BUSINESS PHONE:** 631 549 1859

**MAIL ADDRESS:**
- **STREET 1:** C/O GEMINI FUND SERVICES LLC
- **STREET 2:** 4221 NORTH 203RD STREET, SUITE 100
- **CITY:** ELKHORN
- **STATE:** NE
- **ZIP:** 68022-3474

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATALYST FUNDS
- **DATE OF NAME CHANGE:** 20060303

## Series and Classes Contracts Data

### Eventide Gilead Fund (Series ID: S000022598)

| Class ID   | Class Name                   | Ticker Symbol   |
|:---|:---|:---|
| C000065340 | Eventide Gilead Fund Class N | ETGLX           |
| C000080457 | Eventide Gilead Fund Class A | ETAGX           |
| C000080458 | Eventide Gilead Fund Class C | ETCGX           |
| C000080459 | Eventide Gilead Fund Class I | ETILX           |

### Eventide Healthcare & Life Sciences Fund (Series ID: S000039514)

| Class ID   | Class Name                                              | Ticker Symbol   |
|:---|:---|:---|
| C000121707 | Eventide Healthcare & Life Sciences Fund Class A Shares | ETAHX           |
| C000121708 | Eventide Healthcare & Life Sciences Fund Class C Shares | ETCHX           |
| C000121709 | Eventide Healthcare & Life Sciences Fund Class N Shares | ETNHX           |
| C000121710 | Eventide Healthcare & Life Sciences Fund Class I Shares | ETIHX           |

### Eventide Balanced Fund (Series ID: S000049985)

| Class ID   | Class Name                     | Ticker Symbol   |
|:---|:---|:---|
| C000157835 | Eventide Balanced Fund Class A | ETAMX           |
| C000157836 | Eventide Balanced Fund Class C | ETCMX           |
| C000157837 | Eventide Balanced Fund Class I | ETIMX           |
| C000157838 | Eventide Balanced Fund Class N | ETNMX           |

### Eventide Dividend Growth Fund (Series ID: S000059102)

| Class ID   | Class Name                                   | Ticker Symbol   |
|:---|:---|:---|
| C000193764 | Eventide Dividend Growth Fund Class A Shares | ETADX           |
| C000193765 | Eventide Dividend Growth Fund Class C Shares | ETCDX           |
| C000193766 | Eventide Dividend Growth Fund Class I Shares | ETIDX           |
| C000193767 | Eventide Dividend Growth Fund Class N Shares | ETNDX           |

### Eventide Limited-Term Bond Fund (Series ID: S000062486)

| Class ID   | Class Name                              | Ticker Symbol   |
|:---|:---|:---|
| C000202730 | Eventide Limited-Term Bond Fund Class A | ETABX           |
| C000202731 | Eventide Limited-Term Bond Fund Class C | ETCBX           |
| C000202732 | Eventide Limited-Term Bond Fund Class I | ETIBX           |
| C000202733 | Eventide Limited-Term Bond Fund Class N | ETNBX           |

### Eventide Exponential Technologies Fund (Series ID: S000068813)

| Class ID   | Class Name                                           | Ticker Symbol   |
|:---|:---|:---|
| C000219891 | Eventide Exponential Technologies Fund Class N Share | ETNEX           |
| C000219892 | Eventide Exponential Technologies Fund Class A Share | ETAEX           |
| C000219893 | Eventide Exponential Technologies Fund Class C Share | ETCEX           |
| C000219894 | Eventide Exponential Technologies Fund Class I Share | ETIEX           |

### Eventide Core Bond Fund (Series ID: S000069085)

| Class ID   | Class Name                             | Ticker Symbol   |
|:---|:---|:---|
| C000220843 | Eventide Core Bond Fund Class N Shares | ETNRX           |
| C000220844 | Eventide Core Bond Fund Class A Shares | ETARX           |
| C000220845 | Eventide Core Bond Fund Class C Shares | ETCRX           |
| C000220846 | Eventide Core Bond Fund Class I Shares | ETIRX           |

### Eventide Large Cap Focus Fund (Series ID: S000076523)

| Class ID   | Class Name                            | Ticker Symbol   |
|:---|:---|:---|
| C000236479 | Eventide Large Cap Focus Fund Class N | ETLNX           |
| C000236480 | Eventide Large Cap Focus Fund Class A | ETLAX           |
| C000236481 | Eventide Large Cap Focus Fund Class C | ETLCX           |
| C000236482 | Eventide Large Cap Focus Fund Class I | ETLIX           |

?xml version='1.0' encoding='ASCII'?

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

**FORM N-CSR**

**CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES**

Investment Company Act file number <u>811-21872</u>

<u>Mutual Fund Series Trust</u> <br> (Exact name of registrant as specified in charter)

<u>225 Pictoria Drive, Suite 450, Cincinnati, OH</u> <u>45246</u> <br> (Address of principal executive offices) (Zip code)

<u>CT CORPORATION SYSTEM</u> <br> <u>1300 EAST NINTH STREET, CLEVELAND, OH 44114</u> <br> (Name and address of agent for service)

Registrant's telephone number, including area code: <u>631-470-2600</u>

Date of fiscal year end: <u>6/30</u> <br>Date of reporting period: <u>12/31/2025</u>

**Item 1. Reports to Stockholders.** 

(a)&nbsp;&nbsp;&nbsp;&nbsp;

#### Eventide Balanced Fund

#### Class A (ETAMX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Balanced Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $54 | 1.05%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $378669628 |
| Number of Portfolio Holdings | 159 |
| Portfolio Turnover | 18% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 2.5% |
| Nasdaq, Inc. | 2.1% |
| nVent Electric PLC | 1.8% |
| Entergy Corporation | 1.8% |
| STERIS plc | 1.7% |
| EastGroup Properties, Inc. | 1.6% |
| KLA Corporation | 1.6% |
| Prologis, Inc. | 1.6% |
| Rollins, Inc. | 1.6% |
| Targa Resources Corporation | 1.6% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ibe64d8b3a4a0e3515e9f4238.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 1.2% |
| Collateralized Mortgage Obligations | 0.5% |
| Common Stocks | 51.9% |
| Corporate Bonds | 22.9% |
| Money Market Funds | 0.0% |
| Municipal Bonds | 4.2% |
| U.S. Government & Agencies | 19.3% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETAMX

TSR-SAR 123125-ETAMX

#### Eventide Balanced Fund

#### Class C (ETCMX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Balanced Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $92 | 1.80%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $378669628 |
| Number of Portfolio Holdings | 159 |
| Portfolio Turnover | 18% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 2.5% |
| Nasdaq, Inc. | 2.1% |
| nVent Electric PLC | 1.8% |
| Entergy Corporation | 1.8% |
| STERIS plc | 1.7% |
| EastGroup Properties, Inc. | 1.6% |
| KLA Corporation | 1.6% |
| Prologis, Inc. | 1.6% |
| Rollins, Inc. | 1.6% |
| Targa Resources Corporation | 1.6% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ibe64d8b3a4a0e3515e9f4238.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 1.2% |
| Collateralized Mortgage Obligations | 0.5% |
| Common Stocks | 51.9% |
| Corporate Bonds | 22.9% |
| Money Market Funds | 0.0% |
| Municipal Bonds | 4.2% |
| U.S. Government & Agencies | 19.3% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETCMX

TSR-SAR 123125-ETCMX

#### Eventide Balanced Fund

#### Class I (ETIMX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Balanced Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $41 | 0.80%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $378669628 |
| Number of Portfolio Holdings | 159 |
| Portfolio Turnover | 18% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 2.5% |
| Nasdaq, Inc. | 2.1% |
| nVent Electric PLC | 1.8% |
| Entergy Corporation | 1.8% |
| STERIS plc | 1.7% |
| EastGroup Properties, Inc. | 1.6% |
| KLA Corporation | 1.6% |
| Prologis, Inc. | 1.6% |
| Rollins, Inc. | 1.6% |
| Targa Resources Corporation | 1.6% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ibe64d8b3a4a0e3515e9f4238.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 1.2% |
| Collateralized Mortgage Obligations | 0.5% |
| Common Stocks | 51.9% |
| Corporate Bonds | 22.9% |
| Money Market Funds | 0.0% |
| Municipal Bonds | 4.2% |
| U.S. Government & Agencies | 19.3% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETIMX

TSR-SAR 123125-ETIMX

#### Eventide Balanced Fund

#### Class N (ETNMX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Balanced Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $51 | 1.00%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $378669628 |
| Number of Portfolio Holdings | 159 |
| Portfolio Turnover | 18% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 2.5% |
| Nasdaq, Inc. | 2.1% |
| nVent Electric PLC | 1.8% |
| Entergy Corporation | 1.8% |
| STERIS plc | 1.7% |
| EastGroup Properties, Inc. | 1.6% |
| KLA Corporation | 1.6% |
| Prologis, Inc. | 1.6% |
| Rollins, Inc. | 1.6% |
| Targa Resources Corporation | 1.6% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ibe64d8b3a4a0e3515e9f4238.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 1.2% |
| Collateralized Mortgage Obligations | 0.5% |
| Common Stocks | 51.9% |
| Corporate Bonds | 22.9% |
| Money Market Funds | 0.0% |
| Municipal Bonds | 4.2% |
| U.S. Government & Agencies | 19.3% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETNMX

TSR-SAR 123125-ETNMX

#### Eventide Core Bond Fund

#### Class A (ETARX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Core Bond Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $39 | 0.76%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $161282948 |
| Number of Portfolio Holdings | 98 |
| Portfolio Turnover | 14% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32 | 1.8% |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.7% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.7% |
| Freddie Mac Pool, 4.000%, due 08/1/52 | 1.6% |
| Freddie Mac Pool, 3.000%, due 04/1/52 | 1.6% |
| Fannie Mae Pool, 3.500%, due 06/1/52 | 1.6% |
| Federal Farm Credit Banks Funding Corporation, 4.125%, due 08/1/29 | 1.5% |
| Fannie Mae Pool, 4.500%, due 11/1/52 | 1.5% |
| American Express Company, 4.918%, due 07/20/33 | 1.4% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.4% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i905b90f398ed98d97e86a84e.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.4% |
| Corporate Bonds | 49.9% |
| Municipal Bonds | 7.7% |
| U.S. Government & Agencies | 40.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETARX

TSR-SAR 123125-ETARX

#### Eventide Core Bond Fund

#### Class C (ETCRX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Core Bond Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $77 | 1.51%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $161282948 |
| Number of Portfolio Holdings | 98 |
| Portfolio Turnover | 14% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32 | 1.8% |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.7% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.7% |
| Freddie Mac Pool, 4.000%, due 08/1/52 | 1.6% |
| Freddie Mac Pool, 3.000%, due 04/1/52 | 1.6% |
| Fannie Mae Pool, 3.500%, due 06/1/52 | 1.6% |
| Federal Farm Credit Banks Funding Corporation, 4.125%, due 08/1/29 | 1.5% |
| Fannie Mae Pool, 4.500%, due 11/1/52 | 1.5% |
| American Express Company, 4.918%, due 07/20/33 | 1.4% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.4% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i905b90f398ed98d97e86a84e.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.4% |
| Corporate Bonds | 49.9% |
| Municipal Bonds | 7.7% |
| U.S. Government & Agencies | 40.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETCRX

TSR-SAR 123125-ETCRX

#### Eventide Core Bond Fund

#### Class I (ETIRX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Core Bond Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $26 | 0.51%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $161282948 |
| Number of Portfolio Holdings | 98 |
| Portfolio Turnover | 14% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32 | 1.8% |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.7% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.7% |
| Freddie Mac Pool, 4.000%, due 08/1/52 | 1.6% |
| Freddie Mac Pool, 3.000%, due 04/1/52 | 1.6% |
| Fannie Mae Pool, 3.500%, due 06/1/52 | 1.6% |
| Federal Farm Credit Banks Funding Corporation, 4.125%, due 08/1/29 | 1.5% |
| Fannie Mae Pool, 4.500%, due 11/1/52 | 1.5% |
| American Express Company, 4.918%, due 07/20/33 | 1.4% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.4% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i905b90f398ed98d97e86a84e.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.4% |
| Corporate Bonds | 49.9% |
| Municipal Bonds | 7.7% |
| U.S. Government & Agencies | 40.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETIRX

TSR-SAR 123125-ETIRX

#### Eventide Core Bond Fund

#### Class N (ETNRX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Core Bond Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $36 | 0.71%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $161282948 |
| Number of Portfolio Holdings | 98 |
| Portfolio Turnover | 14% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32 | 1.8% |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.7% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.7% |
| Freddie Mac Pool, 4.000%, due 08/1/52 | 1.6% |
| Freddie Mac Pool, 3.000%, due 04/1/52 | 1.6% |
| Fannie Mae Pool, 3.500%, due 06/1/52 | 1.6% |
| Federal Farm Credit Banks Funding Corporation, 4.125%, due 08/1/29 | 1.5% |
| Fannie Mae Pool, 4.500%, due 11/1/52 | 1.5% |
| American Express Company, 4.918%, due 07/20/33 | 1.4% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.4% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i905b90f398ed98d97e86a84e.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.4% |
| Corporate Bonds | 49.9% |
| Municipal Bonds | 7.7% |
| U.S. Government & Agencies | 40.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETNRX

TSR-SAR 123125-ETNRX

#### Eventide Dividend Growth Fund

#### Class A (ETADX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Dividend Growth Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $60 | 1.18%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1151739963 |
| Number of Portfolio Holdings | 54 |
| Portfolio Turnover | 22% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies plc | 4.8% |
| Nasdaq, Inc. | 4.1% |
| Entergy Corporation | 3.5% |
| nVent Electric PLC | 3.5% |
| STERIS plc | 3.2% |
| KLA Corporation | 3.2% |
| Targa Resources Corporation | 3.0% |
| Rollins, Inc. | 3.0% |
| Prologis, Inc. | 2.9% |
| EastGroup Properties, Inc. | 2.8% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](iea1a822c83b1c0e88ec597b9.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 100.0% |
| Money Market Funds | 0.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETADX

TSR-SAR 123125-ETADX

#### Eventide Dividend Growth Fund

#### Class C (ETCDX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Dividend Growth Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $98 | 1.93%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1151739963 |
| Number of Portfolio Holdings | 54 |
| Portfolio Turnover | 22% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies plc | 4.8% |
| Nasdaq, Inc. | 4.1% |
| Entergy Corporation | 3.5% |
| nVent Electric PLC | 3.5% |
| STERIS plc | 3.2% |
| KLA Corporation | 3.2% |
| Targa Resources Corporation | 3.0% |
| Rollins, Inc. | 3.0% |
| Prologis, Inc. | 2.9% |
| EastGroup Properties, Inc. | 2.8% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](iea1a822c83b1c0e88ec597b9.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 100.0% |
| Money Market Funds | 0.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETCDX

TSR-SAR 123125-ETCDX

#### Eventide Dividend Growth Fund

#### Class I (ETIDX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Dividend Growth Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $47 | 0.93%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1151739963 |
| Number of Portfolio Holdings | 54 |
| Portfolio Turnover | 22% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies plc | 4.8% |
| Nasdaq, Inc. | 4.1% |
| Entergy Corporation | 3.5% |
| nVent Electric PLC | 3.5% |
| STERIS plc | 3.2% |
| KLA Corporation | 3.2% |
| Targa Resources Corporation | 3.0% |
| Rollins, Inc. | 3.0% |
| Prologis, Inc. | 2.9% |
| EastGroup Properties, Inc. | 2.8% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](iea1a822c83b1c0e88ec597b9.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 100.0% |
| Money Market Funds | 0.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETIDX

TSR-SAR 123125-ETIDX

#### Eventide Dividend Growth Fund

#### Class N (ETNDX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Dividend Growth Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $57 | 1.13%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1151739963 |
| Number of Portfolio Holdings | 54 |
| Portfolio Turnover | 22% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies plc | 4.8% |
| Nasdaq, Inc. | 4.1% |
| Entergy Corporation | 3.5% |
| nVent Electric PLC | 3.5% |
| STERIS plc | 3.2% |
| KLA Corporation | 3.2% |
| Targa Resources Corporation | 3.0% |
| Rollins, Inc. | 3.0% |
| Prologis, Inc. | 2.9% |
| EastGroup Properties, Inc. | 2.8% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](iea1a822c83b1c0e88ec597b9.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 100.0% |
| Money Market Funds | 0.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETNDX

TSR-SAR 123125-ETNDX

#### Eventide Exponential Technologies Fund

#### Class A (ETAEX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Exponential Technologies Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $85 | 1.63%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $90797991 |
| Number of Portfolio Holdings | 54 |
| Portfolio Turnover | 64% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| ServiceNow, Inc. | 4.9% |
| Beta Bionics, Inc. | 4.4% |
| Taiwan Semiconductor Manufacturing Company Ltd. - ADR | 4.2% |
| Guardant Health, Inc. | 4.1% |
| Intuit, Inc. | 4.0% |
| Toast, Inc. - Class A | 3.9% |
| ServiceTitan, Inc. - Class A | 3.3% |
| Axon Enterprise, Inc. | 3.3% |
| HubSpot, Inc. | 3.2% |
| Arista Networks, Inc. | 3.1% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ia1b34e042f409a555b4a7253.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.2% |
| Corporate Bonds | 0.8% |
| Money Market Funds | 0.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETAEX

TSR-SAR 123125-ETAEX

#### Eventide Exponential Technologies Fund

#### Class C (ETCEX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Exponential Technologies Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $124 | 2.38%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $90797991 |
| Number of Portfolio Holdings | 54 |
| Portfolio Turnover | 64% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| ServiceNow, Inc. | 4.9% |
| Beta Bionics, Inc. | 4.4% |
| Taiwan Semiconductor Manufacturing Company Ltd. - ADR | 4.2% |
| Guardant Health, Inc. | 4.1% |
| Intuit, Inc. | 4.0% |
| Toast, Inc. - Class A | 3.9% |
| ServiceTitan, Inc. - Class A | 3.3% |
| Axon Enterprise, Inc. | 3.3% |
| HubSpot, Inc. | 3.2% |
| Arista Networks, Inc. | 3.1% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ia1b34e042f409a555b4a7253.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.2% |
| Corporate Bonds | 0.8% |
| Money Market Funds | 0.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETCEX

TSR-SAR 123125-ETCEX

#### Eventide Exponential Technologies Fund

#### Class I (ETIEX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Exponential Technologies Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $72 | 1.38%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $90797991 |
| Number of Portfolio Holdings | 54 |
| Portfolio Turnover | 64% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| ServiceNow, Inc. | 4.9% |
| Beta Bionics, Inc. | 4.4% |
| Taiwan Semiconductor Manufacturing Company Ltd. - ADR | 4.2% |
| Guardant Health, Inc. | 4.1% |
| Intuit, Inc. | 4.0% |
| Toast, Inc. - Class A | 3.9% |
| ServiceTitan, Inc. - Class A | 3.3% |
| Axon Enterprise, Inc. | 3.3% |
| HubSpot, Inc. | 3.2% |
| Arista Networks, Inc. | 3.1% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ia1b34e042f409a555b4a7253.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.2% |
| Corporate Bonds | 0.8% |
| Money Market Funds | 0.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETIEX

TSR-SAR 123125-ETIEX

#### Eventide Exponential Technologies Fund

#### Class N (ETNEX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Exponential Technologies Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $83 | 1.58%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $90797991 |
| Number of Portfolio Holdings | 54 |
| Portfolio Turnover | 64% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| ServiceNow, Inc. | 4.9% |
| Beta Bionics, Inc. | 4.4% |
| Taiwan Semiconductor Manufacturing Company Ltd. - ADR | 4.2% |
| Guardant Health, Inc. | 4.1% |
| Intuit, Inc. | 4.0% |
| Toast, Inc. - Class A | 3.9% |
| ServiceTitan, Inc. - Class A | 3.3% |
| Axon Enterprise, Inc. | 3.3% |
| HubSpot, Inc. | 3.2% |
| Arista Networks, Inc. | 3.1% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ia1b34e042f409a555b4a7253.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.2% |
| Corporate Bonds | 0.8% |
| Money Market Funds | 0.0% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETNEX

TSR-SAR 123125-ETNEX

#### Eventide Gilead Fund

#### Class A (ETAGX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Gilead Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $75 | 1.40%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $2923206368 |
| Number of Portfolio Holdings | 75 |
| Portfolio Turnover | 9% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Guardant Health, Inc. | 6.0% |
| Xometry, Inc. - Class A | 5.8% |
| Mirum Pharmaceuticals, Inc. | 3.5% |
| Lam Research Corporation | 3.0% |
| Beta Bionics Inc. | 2.9% |
| Toast, Inc. - Class A | 2.9% |
| iRhythm Technologies, Inc. | 2.8% |
| GE Vernova, Inc. | 2.7% |
| Trane Technologies PLC | 2.5% |
| ASML Holding N.V. | 2.4% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i5fc8e262312e7e36dc978d6f.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 98.4% |
| Contingent Value Rights | 0.2% |
| Corporate Bonds | 1.2% |
| Money Market Funds | 0.2% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETAGX

TSR-SAR 123125-ETAGX

#### Eventide Gilead Fund

#### Class C (ETCGX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Gilead Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $116 | 2.15%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $2923206368 |
| Number of Portfolio Holdings | 75 |
| Portfolio Turnover | 9% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Guardant Health, Inc. | 6.0% |
| Xometry, Inc. - Class A | 5.8% |
| Mirum Pharmaceuticals, Inc. | 3.5% |
| Lam Research Corporation | 3.0% |
| Beta Bionics Inc. | 2.9% |
| Toast, Inc. - Class A | 2.9% |
| iRhythm Technologies, Inc. | 2.8% |
| GE Vernova, Inc. | 2.7% |
| Trane Technologies PLC | 2.5% |
| ASML Holding N.V. | 2.4% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i5fc8e262312e7e36dc978d6f.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 98.4% |
| Contingent Value Rights | 0.2% |
| Corporate Bonds | 1.2% |
| Money Market Funds | 0.2% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETCGX

TSR-SAR 123125-ETCGX

#### Eventide Gilead Fund

#### Class I (ETILX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Gilead Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $62 | 1.15%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $2923206368 |
| Number of Portfolio Holdings | 75 |
| Portfolio Turnover | 9% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Guardant Health, Inc. | 6.0% |
| Xometry, Inc. - Class A | 5.8% |
| Mirum Pharmaceuticals, Inc. | 3.5% |
| Lam Research Corporation | 3.0% |
| Beta Bionics Inc. | 2.9% |
| Toast, Inc. - Class A | 2.9% |
| iRhythm Technologies, Inc. | 2.8% |
| GE Vernova, Inc. | 2.7% |
| Trane Technologies PLC | 2.5% |
| ASML Holding N.V. | 2.4% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i5fc8e262312e7e36dc978d6f.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 98.4% |
| Contingent Value Rights | 0.2% |
| Corporate Bonds | 1.2% |
| Money Market Funds | 0.2% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETILX

TSR-SAR 123125-ETILX

#### Eventide Gilead Fund

#### Class N (ETGLX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Gilead Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $73 | 1.35%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $2923206368 |
| Number of Portfolio Holdings | 75 |
| Portfolio Turnover | 9% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Guardant Health, Inc. | 6.0% |
| Xometry, Inc. - Class A | 5.8% |
| Mirum Pharmaceuticals, Inc. | 3.5% |
| Lam Research Corporation | 3.0% |
| Beta Bionics Inc. | 2.9% |
| Toast, Inc. - Class A | 2.9% |
| iRhythm Technologies, Inc. | 2.8% |
| GE Vernova, Inc. | 2.7% |
| Trane Technologies PLC | 2.5% |
| ASML Holding N.V. | 2.4% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i5fc8e262312e7e36dc978d6f.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 98.4% |
| Contingent Value Rights | 0.2% |
| Corporate Bonds | 1.2% |
| Money Market Funds | 0.2% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETGLX

TSR-SAR 123125-ETGLX

#### Eventide Healthcare & Life Sciences Fund

#### Class A (ETAHX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $98 | 1.54%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1688446163 |
| Number of Portfolio Holdings | 90 |
| Portfolio Turnover | 56% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Guardant Health, Inc. | 4.5% |
| Mirum Pharmaceuticals, Inc. | 3.6% |
| Beta Bionics Inc. | 3.2% |
| Insmed, Inc. | 3.2% |
| BeLite Bio Inc | 3.1% |
| Kymera Therapeutics, Inc. | 2.9% |
| Ionis Pharmaceuticals, Inc. | 2.7% |
| Abivax S.A. - ADR | 2.6% |
| Scholar Rock Holding Corporation | 2.5% |
| iRhythm Technologies, Inc. | 2.3% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i86b63a0370e262906babb731.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 96.3% |
| Contingent Value Rights | 0.3% |
| Convertible Bonds | 0.0% |
| Money Market Funds | 0.2% |
| Private Investments | 3.0% |
| Warrant | 0.2% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETAHX

TSR-SAR 123125-ETAHX

#### Eventide Healthcare & Life Sciences Fund

#### Class C (ETCHX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $146 | 2.29%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1688446163 |
| Number of Portfolio Holdings | 90 |
| Portfolio Turnover | 56% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Guardant Health, Inc. | 4.5% |
| Mirum Pharmaceuticals, Inc. | 3.6% |
| Beta Bionics Inc. | 3.2% |
| Insmed, Inc. | 3.2% |
| BeLite Bio Inc | 3.1% |
| Kymera Therapeutics, Inc. | 2.9% |
| Ionis Pharmaceuticals, Inc. | 2.7% |
| Abivax S.A. - ADR | 2.6% |
| Scholar Rock Holding Corporation | 2.5% |
| iRhythm Technologies, Inc. | 2.3% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i86b63a0370e262906babb731.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 96.3% |
| Contingent Value Rights | 0.3% |
| Convertible Bonds | 0.0% |
| Money Market Funds | 0.2% |
| Private Investments | 3.0% |
| Warrant | 0.2% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETCHX

TSR-SAR 123125-ETCHX

#### Eventide Healthcare & Life Sciences Fund

#### Class I (ETIHX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $82 | 1.29%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1688446163 |
| Number of Portfolio Holdings | 90 |
| Portfolio Turnover | 56% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Guardant Health, Inc. | 4.5% |
| Mirum Pharmaceuticals, Inc. | 3.6% |
| Beta Bionics Inc. | 3.2% |
| Insmed, Inc. | 3.2% |
| BeLite Bio Inc | 3.1% |
| Kymera Therapeutics, Inc. | 2.9% |
| Ionis Pharmaceuticals, Inc. | 2.7% |
| Abivax S.A. - ADR | 2.6% |
| Scholar Rock Holding Corporation | 2.5% |
| iRhythm Technologies, Inc. | 2.3% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i86b63a0370e262906babb731.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 96.3% |
| Contingent Value Rights | 0.3% |
| Convertible Bonds | 0.0% |
| Money Market Funds | 0.2% |
| Private Investments | 3.0% |
| Warrant | 0.2% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETIHX

TSR-SAR 123125-ETIHX

#### Eventide Healthcare & Life Sciences Fund

#### Class N (ETNHX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $95 | 1.49%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1688446163 |
| Number of Portfolio Holdings | 90 |
| Portfolio Turnover | 56% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Guardant Health, Inc. | 4.5% |
| Mirum Pharmaceuticals, Inc. | 3.6% |
| Beta Bionics Inc. | 3.2% |
| Insmed, Inc. | 3.2% |
| BeLite Bio Inc | 3.1% |
| Kymera Therapeutics, Inc. | 2.9% |
| Ionis Pharmaceuticals, Inc. | 2.7% |
| Abivax S.A. - ADR | 2.6% |
| Scholar Rock Holding Corporation | 2.5% |
| iRhythm Technologies, Inc. | 2.3% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i86b63a0370e262906babb731.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 96.3% |
| Contingent Value Rights | 0.3% |
| Convertible Bonds | 0.0% |
| Money Market Funds | 0.2% |
| Private Investments | 3.0% |
| Warrant | 0.2% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETNHX

TSR-SAR 123125-ETNHX

#### Eventide Large Cap Focus Fund

#### Class A (ETLAX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Large Cap Focus Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $61 | 1.19%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $176869132 |
| Number of Portfolio Holdings | 47 |
| Portfolio Turnover | 13% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| NVIDIA Corporation | 6.8% |
| American Express Company | 5.8% |
| Broadcom, Inc. | 5.1% |
| S&P Global, Inc. | 5.0% |
| Linde PLC | 4.1% |
| GE Vernova, LLC | 3.9% |
| Trane Technologies PLC | 3.8% |
| O'Reilly Automotive, Inc. | 3.3% |
| Royalty Pharma plc - Class A | 3.3% |
| Intuit, Inc. | 3.1% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i3964d264eb9ff1219cdd04de.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Large Cap | 70.2% |
| Mid Cap | 27.6% |
| Cash/Other | 2.2% |
| Small Cap | 0.0% |

---

Source:© Morningstar, Inc. (2025). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Allocation percentages are subject to change at any time, and should not be considered investment advice.

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETLAX

TSR-SAR 123125-ETLAX

#### Eventide Large Cap Focus Fund

#### Class C (ETLCX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Large Cap Focus Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $99 | 1.94%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $176869132 |
| Number of Portfolio Holdings | 47 |
| Portfolio Turnover | 13% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| NVIDIA Corporation | 6.8% |
| American Express Company | 5.8% |
| Broadcom, Inc. | 5.1% |
| S&P Global, Inc. | 5.0% |
| Linde PLC | 4.1% |
| GE Vernova, LLC | 3.9% |
| Trane Technologies PLC | 3.8% |
| O'Reilly Automotive, Inc. | 3.3% |
| Royalty Pharma plc - Class A | 3.3% |
| Intuit, Inc. | 3.1% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i3964d264eb9ff1219cdd04de.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Large Cap | 70.2% |
| Mid Cap | 27.6% |
| Cash/Other | 2.2% |
| Small Cap | 0.0% |

---

Source:© Morningstar, Inc. (2025). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Allocation percentages are subject to change at any time, and should not be considered investment advice.

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETLCX

TSR-SAR 123125-ETLCX

#### Eventide Large Cap Focus Fund

#### Class I (ETLIX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Large Cap Focus Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $48 | 0.94%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $176869132 |
| Number of Portfolio Holdings | 47 |
| Portfolio Turnover | 13% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| NVIDIA Corporation | 6.8% |
| American Express Company | 5.8% |
| Broadcom, Inc. | 5.1% |
| S&P Global, Inc. | 5.0% |
| Linde PLC | 4.1% |
| GE Vernova, LLC | 3.9% |
| Trane Technologies PLC | 3.8% |
| O'Reilly Automotive, Inc. | 3.3% |
| Royalty Pharma plc - Class A | 3.3% |
| Intuit, Inc. | 3.1% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i3964d264eb9ff1219cdd04de.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Large Cap | 70.2% |
| Mid Cap | 27.6% |
| Cash/Other | 2.2% |
| Small Cap | 0.0% |

---

Source:© Morningstar, Inc. (2025). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Allocation percentages are subject to change at any time, and should not be considered investment advice.

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETLIX

TSR-SAR 123125-ETLIX

#### Eventide Large Cap Focus Fund

#### Class N (ETLNX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Large Cap Focus Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $58 | 1.14%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $176869132 |
| Number of Portfolio Holdings | 47 |
| Portfolio Turnover | 13% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| NVIDIA Corporation | 6.8% |
| American Express Company | 5.8% |
| Broadcom, Inc. | 5.1% |
| S&P Global, Inc. | 5.0% |
| Linde PLC | 4.1% |
| GE Vernova, LLC | 3.9% |
| Trane Technologies PLC | 3.8% |
| O'Reilly Automotive, Inc. | 3.3% |
| Royalty Pharma plc - Class A | 3.3% |
| Intuit, Inc. | 3.1% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i3964d264eb9ff1219cdd04de.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Large Cap | 70.2% |
| Mid Cap | 27.6% |
| Cash/Other | 2.2% |
| Small Cap | 0.0% |

---

Source:© Morningstar, Inc. (2025). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Allocation percentages are subject to change at any time, and should not be considered investment advice.

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETLNX

TSR-SAR 123125-ETLNX

#### Eventide Limited-Term Bond Fund

#### Class A (ETABX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Limited-Term Bond Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $37 | 0.73%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $206620872 |
| Number of Portfolio Holdings | 112 |
| Portfolio Turnover | 1% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.6% |
| Federal Home Loan Mortgage Corporation, 6.750%, due 03/15/31 | 1.5% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.5% |
| Duke Energy Florida, LLC, 2.500%, due 12/1/29 | 1.5% |
| Truist Financial Corporation, 5.071%, due 05/20/31 | 1.4% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.4% |
| Freddie Mac Pool, 3.500%, due 12/1/39 | 1.4% |
| National Rural Utilities Cooperative Finance, 4.850%, due 02/7/29 | 1.3% |
| Aflac, Inc., 1.125%, due 03/15/26 | 1.3% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.3% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i6cb046176659b8025cf85267.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.0% |
| Corporate Bonds | 68.2% |
| Municipal Bonds | 3.1% |
| U.S. Government & Agencies | 26.7% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETABX

TSR-SAR 123125-ETABX

#### Eventide Limited-Term Bond Fund

#### Class C (ETCBX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Limited-Term Bond Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $75 | 1.48%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $206620872 |
| Number of Portfolio Holdings | 112 |
| Portfolio Turnover | 1% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.6% |
| Federal Home Loan Mortgage Corporation, 6.750%, due 03/15/31 | 1.5% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.5% |
| Duke Energy Florida, LLC, 2.500%, due 12/1/29 | 1.5% |
| Truist Financial Corporation, 5.071%, due 05/20/31 | 1.4% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.4% |
| Freddie Mac Pool, 3.500%, due 12/1/39 | 1.4% |
| National Rural Utilities Cooperative Finance, 4.850%, due 02/7/29 | 1.3% |
| Aflac, Inc., 1.125%, due 03/15/26 | 1.3% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.3% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i6cb046176659b8025cf85267.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.0% |
| Corporate Bonds | 68.2% |
| Municipal Bonds | 3.1% |
| U.S. Government & Agencies | 26.7% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETCBX

TSR-SAR 123125-ETCBX

#### Eventide Limited-Term Bond Fund

#### Class I (ETIBX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Limited-Term Bond Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $25 | 0.48%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $206620872 |
| Number of Portfolio Holdings | 112 |
| Portfolio Turnover | 1% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.6% |
| Federal Home Loan Mortgage Corporation, 6.750%, due 03/15/31 | 1.5% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.5% |
| Duke Energy Florida, LLC, 2.500%, due 12/1/29 | 1.5% |
| Truist Financial Corporation, 5.071%, due 05/20/31 | 1.4% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.4% |
| Freddie Mac Pool, 3.500%, due 12/1/39 | 1.4% |
| National Rural Utilities Cooperative Finance, 4.850%, due 02/7/29 | 1.3% |
| Aflac, Inc., 1.125%, due 03/15/26 | 1.3% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.3% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i6cb046176659b8025cf85267.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.0% |
| Corporate Bonds | 68.2% |
| Municipal Bonds | 3.1% |
| U.S. Government & Agencies | 26.7% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETIBX

TSR-SAR 123125-ETIBX

#### Eventide Limited-Term Bond Fund

#### Class N (ETNBX)

#### Semi-Annual Shareholder Report - December 31, 2025
![Image](iaa3951906fa602d5c6345f8f.jpg)

# Fund Overview
This semi-annual shareholder report contains important information about Eventide Limited-Term Bond Fund for the period of July 1, 2025 to December 31, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836.

# What were the Fund's costs for the last six months?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $35 | 0.68%<sup>Footnote Reference\*</sup> |

---

---

| | |
|:---|:---|
| Footnote | Description |
| &nbsp;&nbsp;&nbsp;Footnote<sup>\*</sup> | &nbsp;&nbsp;&nbsp;Annualized |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $206620872 |
| Number of Portfolio Holdings | 112 |
| Portfolio Turnover | 1% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.6% |
| Federal Home Loan Mortgage Corporation, 6.750%, due 03/15/31 | 1.5% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.5% |
| Duke Energy Florida, LLC, 2.500%, due 12/1/29 | 1.5% |
| Truist Financial Corporation, 5.071%, due 05/20/31 | 1.4% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.4% |
| Freddie Mac Pool, 3.500%, due 12/1/39 | 1.4% |
| National Rural Utilities Cooperative Finance, 4.850%, due 02/7/29 | 1.3% |
| Aflac, Inc., 1.125%, due 03/15/26 | 1.3% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.3% |

---

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i6cb046176659b8025cf85267.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.0% |
| Corporate Bonds | 68.2% |
| Municipal Bonds | 3.1% |
| U.S. Government & Agencies | 26.7% |

---

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](i47c4371537fb378079e8ad4a.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.

TSR-SAR 123125-ETNBX

TSR-SAR 123125-ETNBX

(b)&nbsp;&nbsp;&nbsp;&nbsp; Not applicable

**Item 2. Code of Ethics.** 

Not applicable.

**Item 3. Audit Committee Financial Expert.** 

Not applicable.

**Item 4. Principal Accountant Fees and Services.** 

Not applicable.

**Item 5. Audit Committee of Listed Registrants.** 

Not applicable

**Item 6. Investments.** 

The Registrant's schedule of investments in unaffiliated issuers is included in the Financial Statements under Item 7 of this form.

**Item 7. Financial Statements and Financial Highlights for Open-End Management Investment Companies.**

(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| |
|:---|
| ![(LOGO)](ev001_v1.jpg) |
| **SEMI-ANNUAL** |
| **FINANCIAL STATEMENTS AND** |
| **ADDITIONAL INFORMATION** |
| **Eventide Balanced Fund** |
| **Eventide Core Bond Fund** |
| **Eventide Dividend Growth Fund** |
| **Eventide Exponential Technologies Fund** |
| **Eventide Gilead Fund** |
| **Eventide Healthcare & Life Sciences Fund** |
| **Eventide Large Cap Focus Fund** |
| **Eventide Limited-Term Bond Fund** |
| **December 31, 2025** |

---

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 51.3%** |  |
|  | **BANKING - 1.2%** |  |
| 260656 | Huntington Bancshares Inc | $4522382 |
|  | **BIOTECH & PHARMA - 1.5%** |  |
| 150555 | Royalty Pharma plc, Class A | 5817445 |
|  | **CHEMICALS - 1.7%** |  |
| 155054 | Element Solutions, Inc. | 3874799 |
| 8839 | Sherwin-Williams Company (The) | 2864101 |
|  |  | 6738900 |
|  | **COMMERCIAL SUPPORT SERVICES - 1.6%** |  |
| 98054 | Rollins, Inc. | 5885201 |
|  | **CONSTRUCTION MATERIALS - 0.4%** |  |
| 2409 | Martin Marietta Materials, Inc. | 1499988 |
|  | **CONTAINERS & PACKAGING - 1.0%** |  |
| 92239 | International Paper Company | 3633294 |
|  | **ELECTRIC UTILITIES - 5.4%** |  |
| 6987 | Constellation Energy Corporation | 2468297 |
| 74066 | Entergy Corporation | 6845920 |
| 24753 | NextEra Energy, Inc. | 1987171 |
| 15399 | Public Service Enterprise Group, Inc. | 1236540 |
| 9275 | Talen Energy Corporation<sup>(a)</sup> | 3476641 |
| 15311 | Vistra Corporation | 2470124 |
| 18108 | WEC Energy Group, Inc. | 1909670 |
|  |  | 20394363 |
|  | **ELECTRICAL EQUIPMENT - 5.3%** |  |
| 5980 | GE Vernova, Inc. | 3908349 |
| 67316 | nVent Electric PLC | 6864213 |
| 24016 | Trane Technologies PLC | 9347027 |
|  |  | 20119589 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 51.3% (Continued)** |  |
|  | **ENGINEERING & CONSTRUCTION - 0.5%** |  |
| 1085 | Comfort Systems USA, Inc. | $1012620 |
| 2269 | Quanta Services, Inc. | 957654 |
|  |  | 1970274 |
|  | **GAS & WATER UTILITIES - 0.9%** |  |
| 80131 | NiSource, Inc. | 3346271 |
|  | **HOME CONSTRUCTION - 0.8%** |  |
| 21353 | DR Horton, Inc. | 3075473 |
|  | **INDUSTRIAL REIT - 3.2%** |  |
| 34668 | EastGroup Properties, Inc. | 6175758 |
| 46674 | Prologis, Inc. | 5958403 |
|  |  | 12134161 |
|  | **INDUSTRIAL SUPPORT SERVICES - 1.4%** |  |
| 16422 | Applied Industrial Technologies, Inc. | 4216677 |
| 1215 | United Rentals, Inc. | 983324 |
|  |  | 5200001 |
|  | **INSTITUTIONAL FINANCIAL SERVICES - 3.5%** |  |
| 30175 | Houlihan Lokey, Inc. | 5256183 |
| 82025 | Nasdaq, Inc. | 7967088 |
|  |  | 13223271 |
|  | **INSURANCE - 1.1%** |  |
| 16646 | Arthur J Gallagher & Company | 4307818 |
|  | **MACHINERY - 1.9%** |  |
| 14053 | IDEX Corporation | 2500591 |
| 43519 | Pentair PLC | 4532069 |
|  |  | 7032660 |
|  | **MEDICAL EQUIPMENT & DEVICES - 1.8%** |  |
| 25747 | STERIS plc | 6527379 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 51.3% (Continued)** |  |
|  | **OIL & GAS PRODUCERS - 4.6%** |  |
| 29965 | DT Midstream, Inc. | $3586211 |
| 49772 | EQT Corporation | 2667779 |
| 31862 | Targa Resources Corporation | 5878539 |
| 89725 | Williams Companies, Inc. (The) | 5393370 |
|  |  | 17525899 |
|  | **OIL & GAS SERVICES & EQUIPMENT - 1.0%** |  |
| 41611 | Baker Hughes Company | 1894965 |
| 105446 | Liberty Energy, Inc., Class A | 1946533 |
|  |  | 3841498 |
|  | **RETAIL - DISCRETIONARY - 2.5%** |  |
| 17246 | Ferguson Enterprises, Inc. | 3839477 |
| 6825 | Lithia Motors, Inc. | 2268152 |
| 13635 | Lowe's Companies, Inc. | 3288217 |
|  |  | 9395846 |
|  | **SEMICONDUCTORS - 3.3%** |  |
| 5024 | KLA Corporation | 6104562 |
| 12824 | Lam Research Corporation | 2195212 |
| 3350 | Monolithic Power Systems, Inc. | 3036306 |
| 5074 | Teradyne, Inc. | 982123 |
|  |  | 12318203 |
|  | **SOFTWARE - 2.2%** |  |
| 11603 | Roper Technologies, Inc. | 5164843 |
| 6923 | Tyler Technologies, Inc.<sup>(a)</sup> | 3142696 |
|  |  | 8307539 |
|  | **TECHNOLOGY HARDWARE - 2.6%** |  |
| 14181 | Dell Technologies, Inc., Class C | 1785104 |
| 23210 | Flex Ltd.<sup>(a)</sup> | 1402348 |
| 16897 | Garmin Ltd. | 3427556 |
| 8204 | Motorola Solutions, Inc. | 3144757 |
|  |  | 9759765 |
|  | **TECHNOLOGY SERVICES - 1.0%** |  |
| 4241 | MSCI, Inc. | 2433189 |
| 6328 | Verisk Analytics, Inc. | 1415510 |
|  |  | 3848699 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Shares** |  |  |  |  | **Fair Value** |
|  | **COMMON STOCKS — 51.3% (Continued)** | **COMMON STOCKS — 51.3% (Continued)** | **COMMON STOCKS — 51.3% (Continued)** | **COMMON STOCKS — 51.3% (Continued)** |  |
|  | **TRANSPORTATION & LOGISTICS - 0.9%** | **TRANSPORTATION & LOGISTICS - 0.9%** | **TRANSPORTATION & LOGISTICS - 0.9%** | **TRANSPORTATION & LOGISTICS - 0.9%** |  |
| 22153 | Old Dominion Freight Line, Inc. | Old Dominion Freight Line, Inc. | Old Dominion Freight Line, Inc. | Old Dominion Freight Line, Inc. | $3473590 |
|  | **TOTAL COMMON STOCKS (Cost $151,395,601)** | **TOTAL COMMON STOCKS (Cost $151,395,601)** | **TOTAL COMMON STOCKS (Cost $151,395,601)** | **TOTAL COMMON STOCKS (Cost $151,395,601)** | 193899509 |
| **Principal** |  |  | **Coupon Rate** |  |  |
| **Amount ($)** |  | **Spread** | **(%)** | **Maturity** | **Fair Value** |
|  | **ASSET BACKED SECURITIES — 1.2%** | **ASSET BACKED SECURITIES — 1.2%** |  |  |  |
|  | **AUTO LOAN — 0.6%** |  |  |  |  |
| 2230000 | CarMax Auto Owner Trust 2024-2 D |  | 6.4200 | 10/15/30 | 2299266 |
|  | **OTHER ABS — 0.6%** |  |  |  |  |
| 2250000 | PFS Financing Corporation Series C A<sup>(b),(c)</sup> | SOFR30A + 0.800% | 4.7840 | 04/17/28 | 2251858 |
|  | **TOTAL ASSET BACKED SECURITIES (Cost $4,538,975)** | **TOTAL ASSET BACKED SECURITIES (Cost $4,538,975)** |  |  | 4551124 |
| **Principal** |  |  | **Coupon Rate** |  |  |
| **Amount ($)** |  |  | **(%)** | **Maturity** | **Fair Value** |
|  | **COLLATERALIZED MORTGAGE OBLIGATIONS — 0.5%** | **COLLATERALIZED MORTGAGE OBLIGATIONS — 0.5%** | **COLLATERALIZED MORTGAGE OBLIGATIONS — 0.5%** |  |  |
|  | **CMBS — 0.5%** |  |  |  |  |
| 1000000 | Freddie Mac Multifamily Structured Pass Through Series KG01 A10 | Freddie Mac Multifamily Structured Pass Through Series KG01 A10 | 2.9390 | 04/25/29 | 968004 |
| 1000000 | Freddie Mac Multifamily Structured Pass Through Series KG02 A2 | Freddie Mac Multifamily Structured Pass Through Series KG02 A2 | 2.4120 | 08/25/29 | 950423 |
|  |  |  |  |  | 1918427 |
|  | **TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $2,022,745)** | **TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $2,022,745)** | **TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $2,022,745)** |  | 1918427 |
| **Principal** |  |  | **Coupon Rate** |  |  |
| **Amount ($)** |  | **Spread** | **(%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 22.6%** |  |  |  |  |
|  | **BANKING — 3.1%** |  |  |  |  |
| 2300000 | First Horizon Corporation<sup>(c)</sup> | SOFRRATE + 1.766% | 5.5140 | 03/07/31 | 2381911 |
| 2450000 | Huntington Bancshares, Inc.<sup>(c)</sup> | SOFRINDX + 1.870% | 5.7090 | 02/02/35 | 2565049 |
| 3200000 | JPMorgan Chase & Company<sup>(c)</sup> | SOFRRATE + 1.330% | 6.0700 | 10/22/27 | 3251387 |
| 2250000 | M&T Bank Corporation<sup>(c)</sup> | SOFRRATE + 0.930% | 4.8330 | 01/16/29 | 2287024 |
| 1250000 | Truist Financial Corporation Series I<sup>(c)</sup> | SOFRRATE + 1.309% | 5.0710 | 05/20/31 | 1285597 |
|  |  |  |  |  | 11770968 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **CORPORATE BONDS — 22.6% (Continued)** |  |  |  |  |
|  | **COMMERCIAL SUPPORT SERVICES — 0.5%** |  |  |  |  |
| 1790000 | Waste Management, Inc. |  | 4.9500 | 07/03/31 | $1857054 |
|  | **CONSTRUCTION MATERIALS — 0.8%** |  |  |  |  |
| 1300000 | Advanced Drainage Systems, Inc.<sup>(b)</sup> |  | 5.0000 | 09/30/27 | 1302929 |
| 1750000 | Quikrete Holdings, Inc.<sup>(b)</sup> |  | 6.3750 | 03/01/32 | 1822720 |
|  |  |  |  |  | 3125649 |
|  | **CONTAINERS & PACKAGING — 0.3%** |  |  |  |  |
| 1000000 | TriMas Corporation<sup>(b)</sup> |  | 4.1250 | 04/15/29 | 973379 |
|  | **ELECTRIC UTILITIES — 3.3%** |  |  |  |  |
| 1235000 | AES Corporation (The) |  | 1.3750 | 01/15/26 | 1233594 |
| 1900000 | Constellation Energy Generation, LLC |  | 6.1250 | 01/15/34 | 2064295 |
| 1000000 | Duke Energy Florida, LLC |  | 2.5000 | 12/01/29 | 945200 |
| 1000000 | MidAmerican Energy Company |  | 3.1000 | 05/01/27 | 990922 |
| 3475000 | National Rural Utilities Cooperative Finance |  | 1.3500 | 03/15/31 | 3008328 |
| 3600000 | NextEra Energy Capital Holdings, Inc. |  | 1.9000 | 06/15/28 | 3432399 |
| 1000000 | Wisconsin Power and Light Company |  | 1.9500 | 09/16/31 | 878595 |
|  |  |  |  |  | 12553333 |
|  | **ENGINEERING & CONSTRUCTION — 1.5%** |  |  |  |  |
| 1435000 | Installed Building Products, Inc.<sup>(b)</sup> |  | 5.7500 | 02/01/28 | 1441437 |
| 2000000 | MasTec, Inc.<sup>(b)</sup> |  | 4.5000 | 08/15/28 | 1990702 |
| 2000000 | Quanta Services, Inc. |  | 2.9000 | 10/01/30 | 1874925 |
|  |  |  |  |  | 5307064 |
|  | **FORESTRY, PAPER & WOOD PRODUCTS — 0.5%** |  |  |  |  |
| 2000000 | Louisiana-Pacific Corporation<sup>(b)</sup> |  | 3.6250 | 03/15/29 | 1940174 |
|  | **HOME & OFFICE PRODUCTS — 0.5%** |  |  |  |  |
| 1910000 | Somnigroup International, Inc.<sup>(b)</sup> |  | 4.0000 | 04/15/29 | 1863673 |
|  | **HOME CONSTRUCTION — 0.9%** |  |  |  |  |
| 1850000 | M/I Homes, Inc. |  | 3.9500 | 02/15/30 | 1787861 |
| 1800000 | Patrick Industries, Inc.<sup>(b)</sup> |  | 4.7500 | 05/01/29 | 1789054 |
|  |  |  |  |  | 3576915 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **CORPORATE BONDS — 22.6% (Continued)** |  |  |  |  |
|  | **INDUSTRIAL SUPPORT SERVICES — 0.4%** |  |  |  |  |
| 1700000 | United Rentals North America, Inc. |  | 4.8750 | 01/15/28 | $1700986 |
|  | **INSTITUTIONAL FINANCIAL SERVICES — 0.6%** |  |  |  |  |
| 2250000 | Nasdaq, Inc. |  | 5.5500 | 02/15/34 | 2367338 |
|  | **INSURANCE — 2.0%** |  |  |  |  |
| 1015000 | Aflac, Inc. |  | 1.1250 | 03/15/26 | 1009714 |
| 2375000 | Assurant, Inc. |  | 3.7000 | 02/22/30 | 2309483 |
| 2250000 | Brown & Brown, Inc. |  | 4.5000 | 03/15/29 | 2262531 |
| 2000000 | Pacific Life Global Funding II<sup>(b)</sup> |  | 1.3750 | 04/14/26 | 1985728 |
|  |  |  |  |  | 7567456 |
|  | **MACHINERY — 0.8%** |  |  |  |  |
| 1900000 | Mueller Water Products, Inc.<sup>(b)</sup> |  | 4.0000 | 06/15/29 | 1856571 |
| 1375000 | Xylem, Inc. |  | 1.9500 | 01/30/28 | 1320559 |
|  |  |  |  |  | 3177130 |
|  | **OIL & GAS PRODUCERS — 1.9%** |  |  |  |  |
| 1500000 | Cheniere Energy Partners, L.P. |  | 4.5000 | 10/01/29 | 1504178 |
| 1600000 | ConocoPhillips Company |  | 5.0000 | 01/15/35 | 1625825 |
| 1750000 | Diamondback Energy, Inc. |  | 3.5000 | 12/01/29 | 1699871 |
| 2500000 | Plains All American Pipeline, L.P. / PAA Finance |  | 3.5500 | 12/15/29 | 2431551 |
|  |  |  |  |  | 7261425 |
|  | **REAL ESTATE INVESTMENT TRUSTS — 1.4%** |  |  |  |  |
| 1500000 | AvalonBay Communities, Inc. |  | 2.0500 | 01/15/32 | 1318432 |
| 480000 | HAT Holdings I, LLC / HAT Holdings II, LLC<sup>(b)</sup> |  | 8.0000 | 06/15/27 | 498592 |
| 1700000 | Iron Mountain, Inc.<sup>(b)</sup> |  | 6.2500 | 01/15/33 | 1715328 |
| 1500000 | Welltower OP, LLC |  | 2.7000 | 02/15/27 | 1481107 |
|  |  |  |  |  | 5013459 |
|  | **REAL ESTATE SERVICES — 0.1%** |  |  |  |  |
| 500000 | CBRE Services, Inc. |  | 4.9000 | 01/15/33 | 503270 |
|  | **RETAIL - DISCRETIONARY — 1.0%** |  |  |  |  |
| 1750000 | Asbury Automotive Group, Inc. |  | 4.5000 | 03/01/28 | 1751248 |
| 1950000 | Builders FirstSource, Inc.<sup>(b)</sup> |  | 4.2500 | 02/01/32 | 1858470 |
|  |  |  |  |  | 3609718 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **CORPORATE BONDS — 22.6% (Continued)** |  |  |  |  |
|  | **SEMICONDUCTORS — 1.4%** |  |  |  |  |
| 1825000 | Amkor Technology, Inc.<sup>(b)</sup> |  | 5.8750 | 10/01/33 | $1864928 |
| 2800000 | NXP BV / NXP FUNDING, LLC / NXP USA, INC. |  | 2.5000 | 05/11/31 | 2537997 |
| 1200000 | Synaptics, Inc.<sup>(b)</sup> |  | 4.0000 | 06/15/29 | 1162951 |
|  |  |  |  |  | 5565876 |
|  | **SOFTWARE — 0.3%** |  |  |  |  |
| 1000000 | Roper Technologies, Inc. |  | 4.9000 | 10/15/34 | 999971 |
|  | **SPECIALTY FINANCE — 0.3%** | **SPECIALTY FINANCE — 0.3%** |  |  |  |
| 1100000 | American Express Company<sup>(c)</sup> | SOFRRATE + 1.220% | 4.9180 | 07/20/33 | 1121130 |
|  | **TECHNOLOGY SERVICES — 0.3%** | **TECHNOLOGY SERVICES — 0.3%** |  |  |  |
| 1000000 | Verisk Analytics, Inc. |  | 5.7500 | 04/01/33 | 1060179 |
|  | **WHOLESALE - CONSUMER STAPLES — 0.7%** | **WHOLESALE - CONSUMER STAPLES — 0.7%** |  |  |  |
| 2775000 | Sysco Corporation |  | 2.4000 | 02/15/30 | 2586403 |
|  | **TOTAL CORPORATE BONDS (Cost $86,029,717)** | **TOTAL CORPORATE BONDS (Cost $86,029,717)** |  |  | 85502550 |
| **Principal** |  |  | **Coupon Rate** |  |  |
| **Amount ($)** |  |  | **(%)** | **Maturity** | **Fair Value** |
|  | **MUNICIPAL BONDS — 4.1%** | **MUNICIPAL BONDS — 4.1%** |  |  |  |
|  | **COUNTY** — **0.0%<sup>(d)</sup>** |  |  |  |  |
| 150000 | City & County of Honolulu, HI | City & County of Honolulu, HI | 2.5180 | 10/01/26 | 148832 |
|  | **SINGLE-FAMILY HOUSING — 3.5%** | **SINGLE-FAMILY HOUSING — 3.5%** |  |  |  |
| 1655000 | Florida Housing Finance Corporation | Florida Housing Finance Corporation | 5.5610 | 07/01/49 | 1604249 |
| 500000 | Illinois Housing Development Authority | Illinois Housing Development Authority | 5.2440 | 04/01/31 | 521638 |
| 500000 | Illinois Housing Development Authority | Illinois Housing Development Authority | 5.2940 | 10/01/31 | 521988 |
| 1255000 | Maryland Department of Housing & Community | Maryland Department of Housing & Community | 5.4630 | 03/01/34 | 1301871 |
| 2325000 | Massachusetts Housing Finance Agency | Massachusetts Housing Finance Agency | 5.8360 | 12/01/42 | 2346338 |
| 2220000 | Minnesota Housing Finance Agency | Minnesota Housing Finance Agency | 5.5880 | 07/01/39 | 2229773 |
| 645000 | Ohio Housing Finance Agency | Ohio Housing Finance Agency | 5.4390 | 09/01/40 | 639817 |
| 1250000 | Ohio Housing Finance Agency | Ohio Housing Finance Agency | 5.6670 | 09/01/45 | 1235347 |
| 1715000 | Virginia Housing Development Authority | Virginia Housing Development Authority | 4.9140 | 04/01/30 | 1768878 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **MUNICIPAL BONDS — 4.1% (Continued)** |  |  |  |
|  | **SINGLE-FAMILY HOUSING — 3.5% (Continued)** |  |  |  |
| 1000000 | Virginia Housing Development Authority | 5.6620 | 10/01/39 | $1007079 |
|  |  |  |  | 13176978 |
|  | **STATE — 0.1%** |  |  |  |
| 500000 | State of Oregon | 1.3150 | 05/01/27 | 485823 |
|  | **WATER AND SEWER — 0.5%** |  |  |  |
| 2000000 | City of Aurora, CO Water Revenue | 2.0980 | 08/01/34 | 1682531 |
| 200000 | City of Los Angeles, CA Wastewater System Revenue | 3.6940 | 06/01/32 | 193452 |
|  |  |  |  | 1875983 |
|  | **TOTAL MUNICIPAL BONDS (Cost $15,948,091)** |  |  | 15687616 |
| **Principal** |  | **Coupon Rate** |  |  |
| **Amount ($)** |  | **(%)** | **Maturity** | **Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 19.1%** |  |  |  |
|  | **AGENCY FIXED RATE — 14.8%** |  |  |  |
| 39696 | Fannie Mae Pool MA2915 | 3.0000 | 02/01/27 | 39431 |
| 301959 | Fannie Mae Pool BM5976 | 3.0000 | 02/01/47 | 279916 |
| 1172431 | Fannie Mae Pool MA4120 | 2.5000 | 09/01/50 | 1004942 |
| 2162113 | Fannie Mae Pool CB2661 | 3.0000 | 01/01/52 | 1934810 |
| 2216540 | Fannie Mae Pool MA4547 | 2.0000 | 02/01/52 | 1801924 |
| 2845063 | Fannie Mae Pool MA4600 | 3.5000 | 05/01/52 | 2643263 |
| 3579538 | Fannie Mae Pool MA4624 | 3.0000 | 06/01/52 | 3180965 |
| 2176057 | Fannie Mae Pool MA4625 | 3.5000 | 06/01/52 | 2021709 |
| 2962430 | Fannie Mae Pool MA4655 | 4.0000 | 07/01/52 | 2832630 |
| 2989517 | Fannie Mae Pool MA4805 | 4.5000 | 11/01/52 | 2934665 |
| 2524229 | Fannie Mae Pool MA4869 | 5.5000 | 01/01/53 | 2572723 |
| 3059091 | Fannie Mae Pool MA4916 | 4.0000 | 02/01/53 | 2923650 |
| 1343424 | Fannie Mae Pool FS7751 | 4.0000 | 03/01/53 | 1282276 |
| 2130198 | Fannie Mae Pool MA5072 | 5.5000 | 06/01/53 | 2169222 |
| 872489 | Fannie Mae Pool FS7279 | 5.0000 | 10/01/53 | 874027 |
| 2134118 | Fannie Mae Pool MA5165 | 5.5000 | 10/01/53 | 2172230 |
| 2687214 | Fannie Mae Pool CB7331 | 5.5000 | 10/01/53 | 2738926 |
| 1107966 | Fannie Mae Pool FS9447 | 6.0000 | 12/01/53 | 1141980 |
| 2623339 | Fannie Mae Pool MA5758 | 4.5000 | 07/01/55 | 2565626 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 19.1% (Continued)** |  |  |  |
|  | **AGENCY FIXED RATE — 14.8% (Continued)** |  |  |  |
| 463160 | Freddie Mac Pool ZS9163 | 3.0000 | 09/01/33 | $451162 |
| 2641548 | Freddie Mac Pool SB8347 | 4.0000 | 01/01/40 | 2611449 |
| 1089288 | Freddie Mac Pool SD8122 | 2.5000 | 01/01/51 | 931918 |
| 1574376 | Freddie Mac Pool RA5696 | 2.5000 | 08/01/51 | 1345258 |
| 2519252 | Freddie Mac Pool SD8214 | 3.5000 | 05/01/52 | 2340562 |
| 808648 | Freddie Mac Pool SD8237 | 4.0000 | 08/01/52 | 773217 |
| 2790759 | Freddie Mac Pool SD8238 | 4.5000 | 08/01/52 | 2742145 |
| 2858076 | Freddie Mac Pool SD8288 | 5.0000 | 01/01/53 | 2866811 |
| 2894783 | Freddie Mac Pool SD8329 | 5.0000 | 06/01/53 | 2902438 |
| 1619958 | Freddie Mac Pool SD3026 | 5.0000 | 06/01/53 | 1627206 |
| 272599 | Ginnie Mae II Pool MA3375 | 3.0000 | 01/20/46 | 249476 |
|  |  |  |  | 55956557 |
|  | **GOVERNMENT OWNED, NO GUARANTEE — 2.8%** |  |  |  |
| 2750000 | Federal National Mortgage Association | 6.2500 | 05/15/29 | 2983074 |
| 1600000 | Federal National Mortgage Association | 7.1250 | 01/15/30 | 1807783 |
| 2900000 | Federal National Mortgage Association | 6.6250 | 11/15/30 | 3273756 |
| 2300000 | Federal National Mortgage Association | 5.6250 | 07/15/37 | 2540812 |
|  |  |  |  | 10605425 |
|  | **GOVERNMENT SPONSORED — 1.5%** |  |  |  |
| 1500000 | Federal Farm Credit Banks Funding Corporation | 4.6250 | 04/05/29 | 1544667 |
| 1000000 | Federal Farm Credit Banks Funding Corporation | 4.0000 | 04/01/30 | 1012663 |
| 1750000 | Federal Farm Credit Banks Funding Corporation | 4.0000 | 01/13/31 | 1767973 |
| 1500000 | Federal Farm Credit Banks Funding Corporation | 3.2500 | 07/28/32 | 1439437 |
|  |  |  |  | 5764740 |
|  | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $72,506,859)** |  |  | 72326722 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **SHORT-TERM INVESTMENTS — 0.0%<sup>(d)</sup>** |  |
|  | **MONEY MARKET FUNDS - 0.0% <sup>(d)</sup>** |  |
| 118974 | Fidelity Money Market Government Portfolio Class I, 3.64% | $118974 |
|  | (Cost $118,974)<sup>(e)</sup> |  |
|  | **TOTAL INVESTMENTS - 98.8% (Cost $332,560,962)** | $374004922 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 1.2%** | 4664706 |
|  | **NET ASSETS - 100.0%** | $378669628 |

---

---

| | |
|:---|:---|
| ABS | - Asset Backed Security |
| CMBS | - Collaterized Mortgage Backed Security |
| LLC | - Limited Liability Company |
| L.P. | - Limited Partnership |
| MSCI | - Morgan Stanley Capital International |
| PLC | - Public Limited Company |
| REIT | - Real Estate Investment Trust |
| SOFR30A | United States 30 Day Average SOFR Secured Overnight Financing Rate |
| SOFRINDX | United States SOFR Index |
| SOFRRATE | United States SOFR Secured Overnight Financing Rate |

---

(a) Non-income
 producing security.

(b) Security exempt
 from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from
 registration, normally to qualified institutional buyers. As of December 31, 2025, the total market value of 144A securities
 is $26,318,494 or 7.0% of net assets.

(c) Variable or floating
 rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying
 pool of assets.

(d) Percentage rounds
 to less than 0.1%.

(e) Rate disclosed
 is the seven day effective yield as of December 31, 2025.

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE CORE BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **ASSET BACKED SECURITIES — 2.3%** |  |  |  |  |
|  | **AUTO LOAN — 1.2%** |  |  |  |  |
| 1925000 | CarMax Auto Owner Trust 2024-2 D |  | 6.4200 | 10/15/30 | $1984793 |
|  | **OTHER ABS — 1.1%** |  |  |  |  |
| 1775000 | PFS Financing Corporation Series C A<sup>(a),(b)</sup> | SOFR30A + 0.800% | 4.7840 | 04/17/28 | 1776466 |
|  | **TOTAL ASSET BACKED SECURITIES (Cost $3,750,794)** |  |  |  | 3761259 |
| **Principal** |  |  | **Coupon Rate** |  |  |
| **Amount ($)** |  | **Spread** | **(%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 48.9%** | **CORPORATE BONDS — 48.9%** |  |  |  |
|  | **ASSET MANAGEMENT — 1.4%** | **ASSET MANAGEMENT — 1.4%** |  |  |  |
| 1000000 | CI Credit GP, LLC<sup>(c),(d),(e),(f)</sup> |  | 5.5000 | 12/15/30 | 1000000 |
| 750000 | Hope Global Investments<sup>(c),(d),(e)</sup> |  | 4.6000 | 10/10/28 | 741233 |
| 500000 | Hope Global Investments<sup>(c),(d),(e)</sup> |  | 5.0000 | 09/11/29 | 494738 |
|  |  |  |  |  | 2235971 |
|  | **BANKING — 6.6%** | **BANKING — 6.6%** |  |  |  |
| 1975000 | First Horizon Corporation<sup>(b)</sup> | SOFRRATE + 1.766% | 5.5140 | 03/07/31 | 2045336 |
| 1000000 | Huntington Bancshares, Inc.<sup>(b)</sup> | SOFRINDX + 1.870% | 5.7090 | 02/02/35 | 1046959 |
| 1450000 | Huntington Bancshares, Inc.<sup>(b)</sup> | H15T5Y + 2.653% | 6.2500 | 01/15/74 | 1456561 |
| 2750000 | JPMorgan Chase & Company<sup>(b)</sup> | SOFRRATE + 1.330% | 6.0700 | 10/22/27 | 2794161 |
| 2000000 | M&T Bank Corporation<sup>(b)</sup> | SOFRRATE + 0.930% | 4.8330 | 01/16/29 | 2032910 |
| 1250000 | Truist Financial Corporation<sup>(b)</sup> | SOFRRATE + 1.852% | 5.1220 | 01/26/34 | 1275889 |
|  |  |  |  |  | 10651816 |
|  | **COMMERCIAL SUPPORT SERVICES — 0.6%** | **COMMERCIAL SUPPORT SERVICES — 0.6%** |  |  |  |
| 1000000 | Waste Management, Inc. |  | 4.9500 | 07/03/31 | 1037460 |
|  | **CONSTRUCTION MATERIALS — 0.5%** | **CONSTRUCTION MATERIALS — 0.5%** |  |  |  |
| 750000 | Quikrete Holdings, Inc.<sup>(a)</sup> |  | 6.3750 | 03/01/32 | 781166 |
|  | **ELECTRIC UTILITIES — 9.8%** | **ELECTRIC UTILITIES — 9.8%** |  |  |  |
| 2000000 | Ameren Illinois Company |  | 5.9000 | 12/01/52 | 2088931 |
| 1900000 | Constellation Energy Generation, LLC |  | 5.7500 | 03/15/54 | 1894915 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE CORE BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **CORPORATE BONDS — 48.9% (Continued)** | **CORPORATE BONDS — 48.9% (Continued)** |  |  |  |
|  | **ELECTRIC UTILITIES — 9.8% (Continued)** | **ELECTRIC UTILITIES — 9.8% (Continued)** |  |  |  |
| 2400000 | DTE Electric Company |  | 3.9500 | 03/01/49 | $1902904 |
| 2000000 | Duke Energy Florida, LLC |  | 2.5000 | 12/01/29 | 1890400 |
| 1000000 | MidAmerican Energy Company |  | 4.2500 | 07/15/49 | 824734 |
| 2600000 | National Rural Utilities Cooperative Finance |  | 1.3500 | 03/15/31 | 2250835 |
| 500000 | NextEra Energy Capital Holdings, Inc. |  | 5.0500 | 02/28/33 | 513976 |
| 1500000 | NextEra Energy Capital Holdings, Inc.<sup>(b)</sup> | US0003M + 2.409% | 4.8000 | 12/01/77 | 1479444 |
| 2725000 | Public Service Company of Oklahoma |  | 3.1500 | 08/15/51 | 1807393 |
| 1700000 | Wisconsin Public Service Corporation |  | 2.8500 | 12/01/51 | 1083480 |
|  |  |  |  |  | 15737012 |
|  | **ENGINEERING & CONSTRUCTION — 3.2%** |  |  |  |  |
| 1000000 | Installed Building Products, Inc.<sup>(a)</sup> |  | 5.7500 | 02/01/28 | 1004486 |
| 2000000 | MasTec, Inc.<sup>(a)</sup> |  | 4.5000 | 08/15/28 | 1990702 |
| 2275000 | Quanta Services, Inc. |  | 2.9000 | 10/01/30 | 2132727 |
|  |  |  |  |  | 5127915 |
|  | **FORESTRY, PAPER & WOOD PRODUCTS — 1.0%** | **FORESTRY, PAPER & WOOD PRODUCTS — 1.0%** |  |  |  |
| 1625000 | Louisiana-Pacific Corporation<sup>(a)</sup> |  | 3.6250 | 03/15/29 | 1576391 |
|  | **HOME CONSTRUCTION — 0.8%** | **HOME CONSTRUCTION — 0.8%** |  |  |  |
| 1275000 | M/I Homes, Inc. |  | 3.9500 | 02/15/30 | 1232174 |
|  | **INSTITUTIONAL FINANCIAL SERVICES — 0.9%** | **INSTITUTIONAL FINANCIAL SERVICES — 0.9%** |  |  |  |
| 2000000 | Nasdaq, Inc. |  | 3.2500 | 04/28/50 | 1396902 |
|  | **INSURANCE — 2.3%** |  |  |  |  |
| 1925000 | Assurant, Inc. |  | 3.7000 | 02/22/30 | 1871897 |
| 2175000 | Brown & Brown, Inc. |  | 4.9500 | 03/17/52 | 1906998 |
|  |  |  |  |  | 3778895 |
|  | **MACHINERY — 0.6%** |  |  |  |  |
| 1000000 | Xylem, Inc. |  | 1.9500 | 01/30/28 | 960406 |
|  | **OIL & GAS PRODUCERS — 5.8%** | **OIL & GAS PRODUCERS — 5.8%** |  |  |  |
| 1775000 | Cheniere Energy Partners, L.P. |  | 4.5000 | 10/01/29 | 1779944 |
| 2125000 | ConocoPhillips Company |  | 5.0000 | 01/15/35 | 2159299 |
| 2250000 | Diamondback Energy, Inc. |  | 3.5000 | 12/01/29 | 2185548 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE CORE BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **CORPORATE BONDS — 48.9% (Continued)** |  |  |  |  |
|  | **OIL & GAS PRODUCERS — 5.8% (Continued)** |  |  |  |  |
| 1000000 | EQT Corporation |  | 5.7500 | 02/01/34 | $1046837 |
| 2250000 | Plains All American Pipeline, L.P. / PAA Finance |  | 3.5500 | 12/15/29 | 2188396 |
|  |  |  |  |  | 9360024 |
|  | **REAL ESTATE INVESTMENT TRUSTS — 3.9%** |  |  |  |  |
| 2100000 | American Tower Corporation |  | 4.0500 | 03/15/32 | 2048132 |
| 2000000 | Equinix, Inc. |  | 3.9000 | 04/15/32 | 1925695 |
| 358000 | HAT Holdings I, LLC / HAT Holdings II, LLC<sup>(a)</sup> |  | 8.0000 | 06/15/27 | 371866 |
| 2000000 | Welltower OP, LLC |  | 3.8500 | 06/15/32 | 1933967 |
|  |  |  |  |  | 6279660 |
|  | **REAL ESTATE SERVICES — 1.0%** |  |  |  |  |
| 1650000 | CBRE Services, Inc. |  | 4.9000 | 01/15/33 | 1660792 |
|  | **RETAIL - DISCRETIONARY — 3.8%** |  |  |  |  |
| 1250000 | AutoZone, Inc. |  | 5.1000 | 07/15/29 | 1287181 |
| 1500000 | Builders FirstSource, Inc.<sup>(a)</sup> |  | 4.2500 | 02/01/32 | 1429592 |
| 2150000 | Home Depot, Inc. (The) |  | 4.9500 | 06/25/34 | 2204174 |
| 1250000 | Lowe's Companies, Inc. |  | 5.6250 | 04/15/53 | 1216807 |
|  |  |  |  |  | 6137754 |
|  | **SEMICONDUCTORS — 1.6%** |  |  |  |  |
| 500000 | Amkor Technology, Inc.<sup>(a)</sup> |  | 5.8750 | 10/01/33 | 510939 |
| 2200000 | NXP BV / NXP Funding, LLC / NXP USA, Inc. |  | 2.5000 | 05/11/31 | 1994140 |
|  |  |  |  |  | 2505079 |
|  | **SOFTWARE — 1.3%** |  |  |  |  |
| 2175000 | Roper Technologies, Inc. |  | 4.9000 | 10/15/34 | 2174936 |
|  | **SPECIALTY FINANCE — 1.4%** |  |  |  |  |
| 2250000 | American Express Company<sup>(b)</sup> | SOFRRATE + 1.220% | 4.9180 | 07/20/33 | 2293221 |
|  | **TECHNOLOGY SERVICES — 1.3%** |  |  |  |  |
| 1950000 | Verisk Analytics, Inc. |  | 5.7500 | 04/01/33 | 2067349 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE CORE BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **WHOLESALE - CONSUMER STAPLES — 1.1%** |  |  |  |  |
| 1875000 | Sysco Corporation |  | 2.4000 | 02/15/30 | $1747570 |
|  | **TOTAL CORPORATE BONDS (Cost $78,645,245)** |  |  |  | 78742493 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **MUNICIPAL BONDS — 7.5%** |  |  |  |
|  | **SINGLE-FAMILY HOUSING — 6.1%** |  |  |  |
| 1750000 | Florida Housing Finance Corporation | 5.5610 | 07/01/49 | 1696336 |
| 1000000 | Illinois Housing Development Authority | 5.6140 | 10/01/39 | 1004721 |
| 1825000 | Massachusetts Housing Finance Agency | 5.8360 | 12/01/42 | 1841750 |
| 1465000 | Minnesota Housing Finance Agency | 5.9000 | 01/01/49 | 1469064 |
| 350617 | Minnesota Housing Finance Agency | 1.5800 | 02/01/51 | 267233 |
| 1650000 | Ohio Housing Finance Agency | 5.7170 | 09/01/50 | 1636156 |
| 2000000 | Virginia Housing Development Authority | 5.6620 | 10/01/39 | 2014157 |
|  |  |  |  | 9929417 |
|  | **STATE — 0.7%** |  |  |  |
| 1250000 | State of Oregon | 2.3370 | 11/01/33 | 1094595 |
|  | **WATER AND SEWER — 0.7%** |  |  |  |
| 1500000 | City of Aurora, CO Water Revenue | 2.6260 | 08/01/41 | 1150693 |
|  | **TOTAL MUNICIPAL BONDS (Cost $12,833,857)** |  |  | 12174705 |
| **Principal** |  | **Coupon Rate** |  |  |
| **Amount ($)** |  | **(%)** | **Maturity** | **Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 39.1%** |  |  |  |
|  | **AGENCY FIXED RATE — 26.5%** |  |  |  |
| 713629 | Fannie Mae Pool BO9355 | 3.0000 | 03/01/50 | 639798 |
| 1612796 | Fannie Mae Pool MA4120 | 2.5000 | 09/01/50 | 1382398 |
| 608772 | Fannie Mae Pool FM4720 | 3.0000 | 10/01/50 | 549180 |
| 1635209 | Fannie Mae Pool CA8256 | 2.5000 | 12/01/50 | 1391799 |
| 1732366 | Fannie Mae Pool CB0199 | 3.0000 | 04/01/51 | 1543668 |
| 1835526 | Fannie Mae Pool MA4379 | 2.5000 | 07/01/51 | 1569554 |
| 1883893 | Fannie Mae Pool MA4600 | 3.5000 | 05/01/52 | 1750269 |
| 2710971 | Fannie Mae Pool MA4625 | 3.5000 | 06/01/52 | 2518682 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE CORE BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 39.1% (Continued)** |  |  |  |
|  | **AGENCY FIXED RATE — 26.5% (Continued)** |  |  |  |
| 1100005 | Fannie Mae Pool MA4700 | 4.0000 | 08/01/52 | $1046584 |
| 2407664 | Fannie Mae Pool MA4805 | 4.5000 | 11/01/52 | 2363489 |
| 1857112 | Fannie Mae Pool MA4869 | 5.5000 | 01/01/53 | 1892789 |
| 1417781 | Fannie Mae Pool MA4916 | 4.0000 | 02/01/53 | 1355009 |
| 1936543 | Fannie Mae Pool MA5072 | 5.5000 | 06/01/53 | 1972020 |
| 1279625 | Fannie Mae Pool CB7331 | 5.5000 | 10/01/53 | 1304250 |
| 2113246 | Fannie Mae Pool MA5758 | 4.5000 | 07/01/55 | 2066754 |
| 1282274 | Freddie Mac Pool SB8346 | 4.0000 | 12/01/39 | 1267664 |
| 1668825 | Freddie Mac Pool SD8090 | 2.0000 | 09/01/50 | 1366571 |
| 1143752 | Freddie Mac Pool SD8122 | 2.5000 | 01/01/51 | 978514 |
| 2183463 | Freddie Mac Pool SD8128 | 2.0000 | 02/01/51 | 1785272 |
| 902171 | Freddie Mac Pool RA5696 | 2.5000 | 08/01/51 | 770878 |
| 2834190 | Freddie Mac Pool SD8206 | 3.0000 | 04/01/52 | 2518963 |
| 1968362 | Freddie Mac Pool RA7587 | 3.5000 | 06/01/52 | 1831168 |
| 2644652 | Freddie Mac Pool SD8237 | 4.0000 | 08/01/52 | 2528775 |
| 2228731 | Freddie Mac Pool SD8238 | 4.5000 | 08/01/52 | 2189908 |
| 2218506 | Freddie Mac Pool SD8288 | 5.0000 | 01/01/53 | 2225287 |
| 1902286 | Freddie Mac Pool SD8329 | 5.0000 | 06/01/53 | 1907317 |
|  |  |  |  | 42716560 |
|  | **GOVERNMENT OWNED, NO GUARANTEE — 6.9%** |  |  |  |
| 2500000 | Federal Home Loan Mortgage Corporation | 6.2500 | 07/15/32 | 2831631 |
| 1000000 | Federal National Mortgage Association | 6.2500 | 05/15/29 | 1084754 |
| 2000000 | Federal National Mortgage Association | 7.1250 | 01/15/30 | 2259729 |
| 2400000 | Federal National Mortgage Association | 6.6250 | 11/15/30 | 2709315 |
| 2000000 | Federal National Mortgage Association | 5.6250 | 07/15/37 | 2209402 |
|  |  |  |  | 11094831 |
|  | **GOVERNMENT SPONSORED — 5.7%** |  |  |  |
| 2350000 | Federal Farm Credit Banks Funding Corporation | 4.1250 | 08/01/29 | 2391920 |
| 1000000 | Federal Farm Credit Banks Funding Corporation | 4.3750 | 10/24/29 | 1025217 |
| 1750000 | Federal Farm Credit Banks Funding Corporation | 4.0000 | 01/13/31 | 1767973 |
| 1750000 | Federal Farm Credit Banks Funding Corporation | 2.9400 | 02/23/32 | 1641297 |
| 1000000 | Federal Farm Credit Banks Funding Corporation | 4.5000 | 08/08/33 | 1018182 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE CORE BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 39.1% (Continued)** |  |  |  |
|  | **GOVERNMENT SPONSORED — 5.7% (Continued)** |  |  |  |
| 1500000 | Federal Farm Credit Banks Funding Corporation | 2.9900 | 07/18/34 | $1363249 |
|  |  |  |  | 9207838 |
|  | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $62,860,620)** |  |  | 63019229 |
|  | **TOTAL INVESTMENTS - 97.8% (Cost $158,090,516)** |  |  | $157697686 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 2.2%** |  |  | 3585262 |
|  | **NET ASSETS - 100.0%** |  |  | $161282948 |

---

---

| | |
|:---|:---|
| ABS | - Asset Backed Security |
| LLC | - Limited Liability Company |
| L.P. | - Limited Partnership |
| H15T5Y | US Treasury Yield Curve Rate T Note Constant Maturity 5 Year |
| SOFR30A | United States 30 Day Average SOFR Secured Overnight Financing Rate |
| SOFRINDX | United States SOFR Index |
| SOFRRATE | United States SOFR Secured Overnight Financing Rate |
| US0003M | ICE LIBOR USD 3 Month |

---

(a) Security
 exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt
 from registration, normally to qualified institutional buyers. As of December 31, 2025, the total market value of 144A securities
 is $9,441,608 or 5.9% of net assets.

(b) Variable or floating
 rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying
 pool of assets.

(c) Illiquid security.
 The total fair value of these securities as of December 31, 2025, was $2,235,971, representing 1.4% of net assets.

(d) Restricted security.

(e) Private investment.

(f) The value of this
 security has been determined using significant unobservable inputs in good faith under policies of the Board of Trustees.

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE DIVIDEND GROWTH FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 98.9%** |  |
|  | **BANKING - 2.3%** |  |
| 1522136 | Huntington Bancshares Inc | $26409060 |
|  | **BIOTECH & PHARMA - 2.6%** |  |
| 774108 | Royalty Pharma plc, Class A | 29911533 |
|  | **CHEMICALS - 3.2%** |  |
| 876042 | Element Solutions, Inc. | 21892290 |
| 44122 | Sherwin-Williams Company (The) | 14296852 |
|  |  | 36189142 |
|  | **COMMERCIAL SUPPORT SERVICES - 3.0%** |  |
| 567386 | Rollins, Inc. | 34054508 |
|  | **CONTAINERS & PACKAGING - 1.5%** |  |
| 449411 | International Paper Company | 17702299 |
|  | **ELECTRIC UTILITIES - 9.8%** |  |
| 37206 | Constellation Energy Corporation | 13143764 |
| 440807 | Entergy Corporation | 40743791 |
| 90195 | Public Service Enterprise Group, Inc. | 7242658 |
| 54329 | Talen Energy Corporation<sup>(a)</sup> | 20364682 |
| 105546 | Vistra Corporation | 17027736 |
| 136727 | WEC Energy Group, Inc. | 14419229 |
|  |  | 112941860 |
|  | **ELECTRICAL EQUIPMENT - 10.4%** |  |
| 38219 | GE Vernova, Inc. | 24978792 |
| 395073 | nVent Electric PLC | 40285594 |
| 142596 | Trane Technologies plc | 55498363 |
|  |  | 120762749 |
|  | **ENGINEERING & CONSTRUCTION - 1.0%** |  |
| 6441 | Comfort Systems USA, Inc. | 6011321 |
| 13550 | Quanta Services, Inc. | 5718913 |
|  |  | 11730234 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE DIVIDEND GROWTH FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 98.9% (Continued)** |  |
|  | **GAS & WATER UTILITIES - 1.6%** |  |
| 448657 | NiSource, Inc. | $18735916 |
|  | **HEALTH CARE FACILITIES & SERVICES - 0.6%** |  |
| 61913 | Encompass Health Corporation | 6571446 |
|  | **HOME CONSTRUCTION - 1.9%** |  |
| 154616 | DR Horton, Inc. | 22269342 |
|  | **INDUSTRIAL REIT - 5.6%** |  |
| 177885 | EastGroup Properties, Inc. | 31688434 |
| 259481 | Prologis, Inc. | 33125344 |
|  |  | 64813778 |
|  | **INDUSTRIAL SUPPORT SERVICES - 2.8%** |  |
| 91181 | Applied Industrial Technologies, Inc. | 23412545 |
| 10690 | United Rentals, Inc. | 8651631 |
|  |  | 32064176 |
|  | **INSTITUTIONAL FINANCIAL SERVICES - 6.7%** |  |
| 172973 | Houlihan Lokey, Inc. | 30130167 |
| 487168 | Nasdaq, Inc. | 47318628 |
|  |  | 77448795 |
|  | **INSURANCE - 2.2%** |  |
| 97220 | Arthur J. Gallagher & Company | 25159564 |
|  | **MACHINERY - 3.4%** |  |
| 74132 | IDEX Corporation | 13191048 |
| 250038 | Pentair PLC | 26038957 |
|  |  | 39230005 |
|  | **MEDICAL EQUIPMENT & DEVICES - 5.6%** |  |
| 19974 | Mettler-Toledo International, Inc.<sup>(a)</sup> | 27847551 |
| 144840 | STERIS plc | 36719837 |
|  |  | 64567388 |
|  | **OIL & GAS PRODUCERS - 8.7%** |  |
| 176695 | DT Midstream, Inc. | 21146858 |
| 293211 | EQT Corporation | 15716110 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE DIVIDEND GROWTH FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 98.9% (Continued)** |  |
|  | **OIL & GAS PRODUCERS - 8.7% (Continued)** |  |
| 188845 | Targa Resources Corporation | $34841903 |
| 474177 | Williams Companies, Inc. (The) | 28502779 |
|  |  | 100207650 |
|  | **OIL & GAS SERVICES & EQUIPMENT - 2.0%** |  |
| 244425 | Baker Hughes Company | 11131114 |
| 621778 | Liberty Energy, Inc., Class A | 11478022 |
|  |  | 22609136 |
|  | **RETAIL - DISCRETIONARY - 5.8%** |  |
| 120664 | Ferguson Enterprises, Inc. | 26863426 |
| 55185 | Group 1 Automotive, Inc. | 21704261 |
| 53078 | Lithia Motors, Inc. | 17639412 |
|  |  | 66207099 |
|  | **SEMICONDUCTORS - 6.2%** |  |
| 29952 | KLA Corporation | 36394076 |
| 75409 | Lam Research Corporation | 12908513 |
| 19540 | Monolithic Power Systems, Inc. | 17710274 |
| 29679 | Teradyne, Inc. | 5744667 |
|  |  | 72757530 |
|  | **SOFTWARE - 4.1%** |  |
| 64321 | Roper Technologies, Inc. | 28631207 |
| 40813 | Tyler Technologies, Inc.<sup>(a)</sup> | 18527061 |
|  |  | 47158268 |
|  | **TECHNOLOGY HARDWARE - 3.6%** |  |
| 11212 | Fabrinet<sup>(a)</sup> | 5104599 |
| 136067 | Flex Ltd.<sup>(a)</sup> | 8221168 |
| 45097 | Garmin Ltd. | 9147926 |
| 48052 | Motorola Solutions, Inc. | 18419293 |
|  |  | 40892986 |
|  | **TECHNOLOGY SERVICES - 2.1%** |  |
| 27002 | MSCI, Inc. | 15491857 |
| 36879 | Verisk Analytics, Inc. | 8249464 |
|  |  | 23741321 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE DIVIDEND GROWTH FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 98.9% (Continued)** |  |
|  | **TRANSPORTATION & LOGISTICS - 2.2%** |  |
| 159831 | Old Dominion Freight Line, Inc. | $25061501 |
|  | **TOTAL COMMON STOCKS (Cost $942,474,913)** | 1139197286 |
| **Shares** |  | **Fair Value** |
|  | **SHORT-TERM INVESTMENTS — 0.0%<sup>(b)</sup>** |  |
|  | **MONEY MARKET FUNDS - 0.0% <sup>(b)</sup>** |  |
| 119360 | Fidelity Money Market Government Portfolio, Class I, 3.64% (Cost $119,360)<sup>(c)</sup> | 119360 |
|  | **TOTAL INVESTMENTS - 98.9% (Cost $942,594,273)** | $1139316646 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES- 1.1%** | 12423317 |
|  | **NET ASSETS - 100.0%** | $1151739963 |

---

---

| | |
|:---|:---|
| MSCI | - Morgan Stanley Capital International |
| PLC | - Public Limited Company |
| REIT | - Real Estate Investment Trust |

---

---

| | |
|:---|:---|
| <sup>(a)</sup> | Non-income producing security. |
| |  |
| <sup>(b)</sup> | Percentage rounds to less than 0.1%. |
| |  |
| <sup>(c)</sup> | Rate disclosed is the seven day effective yield as of December 31, 2025. |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE EXPONENTIAL TECHNOLOGIES FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 98.2%** |  |
|  | **AEROSPACE & DEFENSE - 3.3%** |  |
| 5278 | Axon Enterprise, Inc.<sup>(a)</sup> | $2997535 |
|  | **BIOTECH & PHARMA - 4.3%** |  |
| 130856 | Beta Bionics, Inc.<sup>(a)</sup> | 3987182 |
|  | **ELECTRICAL EQUIPMENT - 3.9%** |  |
| 6149 | Generac Holdings, Inc.<sup>(a)</sup> | 838539 |
| 16739 | Vertiv Holdings Company, Class A | 2711885 |
|  |  | 3550424 |
|  | **ENGINEERING & CONSTRUCTION - 0.8%** |  |
| 2313 | Sterling Infrastructure, Inc.<sup>(a)</sup> | 708310 |
|  | **INDUSTRIAL INTERMEDIATE PROD - 3.0%** |  |
| 45879 | Xometry, Inc., Class A<sup>(a)</sup> | 2728424 |
|  | **MEDICAL EQUIPMENT & DEVICES - 4.1%** |  |
| 36039 | Guardant Health, Inc.<sup>(a)</sup> | 3681023 |
|  | **OIL & GAS SERVICES & EQUIPMENT - 1.2%** |  |
| 57712 | Liberty Energy, Inc., Class A | 1065364 |
|  | **SEMICONDUCTORS - 18.4%** |  |
| 2678 | Advanced Micro Devices, Inc.<sup>(a)</sup> | 573520 |
| 537 | ASML Holding N.V. - ADR | 574515 |
| 2399 | Broadcom, Inc. | 830294 |
| 8952 | Coherent Corp.<sup>(a)</sup> | 1652271 |
| 1993 | Impinj, Inc.<sup>(a)</sup> | 346802 |
| 486 | KLA Corporation | 590529 |
| 8408 | Lam Research Corporation | 1439281 |
| 27902 | Lattice Semiconductor Corporation<sup>(a)</sup> | 2053029 |
| 1945 | Monolithic Power Systems, Inc. | 1762870 |
| 5552 | NVIDIA Corporation | 1035448 |
| 10321 | Rambus, Inc.<sup>(a)</sup> | 948397 |
| 3123 | SiTime Corporation<sup>(a)</sup> | 1103012 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE EXPONENTIAL TECHNOLOGIES FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 98.2% (Continued)** |  |
|  | **SEMICONDUCTORS - 18.4% (Continued)** |  |
| 12502 | Taiwan Semiconductor Manufacturing Company Ltd. - ADR | $3799233 |
|  |  | 16709201 |
|  | **SOFTWARE - 36.2%** |  |
| 23919 | Confluent, Inc., Class A<sup>(a)</sup> | 723311 |
| 1059 | Constellation Software, Inc. | 2541328 |
| 4005 | CyberArk Software Ltd.<sup>(a)</sup> | 1786470 |
| 11384 | Doximity, Inc., Class A<sup>(a)</sup> | 504083 |
| 12771 | Gitlab, Inc., Class A<sup>(a)</sup> | 479296 |
| 6979 | Guidewire Software, Inc.<sup>(a)</sup> | 1402849 |
| 7282 | HubSpot, Inc.<sup>(a)</sup> | 2922267 |
| 5445 | Intuit, Inc. | 3606877 |
| 10037 | JFrog Ltd.<sup>(a)</sup> | 626911 |
| 11803 | Klaviyo, Inc., Class A<sup>(a)</sup> | 383243 |
| 6395 | Life360, Inc.<sup>(a)</sup> | 410175 |
| 4430 | MongoDB, Inc.<sup>(a)</sup> | 1859227 |
| 18433 | Nebius Group N.V., Class A<sup>(a)</sup> | 1542934 |
| 3366 | Palo Alto Networks, Inc.<sup>(a)</sup> | 620017 |
| 10559 | Procore Technologies, Inc.<sup>(a)</sup> | 768062 |
| 8791 | Rubrik, Inc., Class A<sup>(a)</sup> | 672336 |
| 52553 | Samsara, Inc., Class A<sup>(a)</sup> | 1863004 |
| 28850 | ServiceNow, Inc.<sup>(a)</sup> | 4419531 |
| 28429 | ServiceTitan, Inc., Class A<sup>(a)</sup> | 3027688 |
| 12801 | Shopify, Inc., Class A<sup>(a)</sup> | 2060577 |
| 2682 | Snowflake, Inc.<sup>(a)</sup> | 588324 |
|  |  | 32808510 |
|  | **TECHNOLOGY HARDWARE - 16.3%** |  |
| 21205 | Arista Networks, Inc.<sup>(a)</sup> | 2778491 |
| 6756 | Ciena Corporation<sup>(a)</sup> | 1580026 |
| 13462 | Credo Technology Group Holding Ltd.<sup>(a)</sup> | 1937047 |
| 4317 | Fabrinet<sup>(a)</sup> | 1965444 |
| 27456 | Flex Ltd.<sup>(a)</sup> | 1658891 |
| 4965 | InterDigital, Inc. | 1580757 |
| 4951 | Lumentum Holdings, Inc.<sup>(a)</sup> | 1824889 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE EXPONENTIAL TECHNOLOGIES FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Shares** |  |  |  | **Fair Value** |
|  | **COMMON STOCKS — 98.2% (Continued)** |  |  |  |
|  | **TECHNOLOGY HARDWARE - 16.3% (Continued)** |  |  |  |
| 22557 | Pure Storage, Inc., Class A<sup>(a)</sup> |  |  | $1511545 |
|  |  |  |  | 14837090 |
|  | **TECHNOLOGY SERVICES - 6.7%** |  |  |  |
| 156895 | Adyen N.V. - ADR<sup>(a)</sup> |  |  | 2505613 |
| 99020 | Toast, Inc., Class A<sup>(a)</sup> |  |  | 3516200 |
|  |  |  |  | 6021813 |
|  | **TOTAL COMMON STOCKS (Cost $69,072,888)** |  |  | 89094876 |
| **Principal** |  | **Coupon Rate** |  |  |
| **Amount ($)** |  | **(%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 0.8%** |  |  |  |
|  | **ASSET MANAGEMENT — 0.8%** |  |  |  |
| 750000 | Vision Fund International<sup>(b),(c),(d)</sup> | 5.0000 | 12/01/28 | 749017 |
|  | **TOTAL CORPORATE BONDS (Cost $750,000)** |  |  | 749017 |
| **Shares** |  |  |  | **Fair Value** |
|  | **SHORT-TERM INVESTMENTS — 0.0%<sup>(e)</sup>** |  |  |  |
|  | **MONEY MARKET FUNDS - 0.0% <sup>(e)</sup>** |  |  |  |
| 13381 | Fidelity Money Market Government Portfolio Class I, 3.64% (Cost $13,381)<sup>(f)</sup> | Fidelity Money Market Government Portfolio Class I, 3.64% (Cost $13,381)<sup>(f)</sup> |  | 13381 |
|  | **TOTAL INVESTMENTS - 99.0% (Cost $69,836,269)** | **TOTAL INVESTMENTS - 99.0% (Cost $69,836,269)** |  | $89857274 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 1.0%** | **OTHER ASSETS IN EXCESS OF LIABILITIES - 1.0%** |  | 940717 |
|  | **NET ASSETS - 100.0%** | **NET ASSETS - 100.0%** |  | $90797991 |

---

---

| | |
|:---|:---|
| ADR | - American Depositary Receipt |
| LTD | - Limited Company |
| N.V. | - Naamioze Vennootschap |

---

 

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Private investment.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of December 31, 2025, was $749,017, representing 0.8% of net assets.

<sup>(d)</sup> Restricted security.

<sup>(e)</sup> Percentage rounds to less than 0.1%.

<sup>(f)</sup> Rate disclosed is the seven day effective yield as of December 31, 2025.

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE GILEAD FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 95.4%** |  |
|  | **ADVERTISING & MARKETING - 0.2%** |  |
| 128676 | Trade Desk, Inc. (The), Class A<sup>(a)</sup> | $4884541 |
|  | **AEROSPACE & DEFENSE - 1.2%** |  |
| 64205 | Axon Enterprise, Inc.<sup>(a)</sup> | 36463946 |
|  | **BIOTECH & PHARMA - 16.4%** |  |
| 75482 | Argenx S.E. - ADR<sup>(a)</sup> | 63476588 |
| 355738 | Axsome Therapeutics, Inc.<sup>(a)</sup> | 64971988 |
| 599317 | Celldex Therapeutics, Inc.<sup>(a)</sup> | 16277450 |
| 1344376 | Collegium Pharmaceutical, Inc.<sup>(a)</sup> | 62244609 |
| 175194 | Insmed, Inc.<sup>(a)</sup> | 30490764 |
| 1309135 | Mirum Pharmaceuticals, Inc.<sup>(a)</sup> | 103408574 |
| 1460906 | Scholar Rock Holding Corporation<sup>(a)</sup> | 64352909 |
| 460684 | TransMedics Group, Inc.<sup>(a)</sup> | 56042208 |
| 376068 | Vaxcyte, Inc.<sup>(a)</sup> | 17351777 |
|  |  | 478616867 |
|  | **COMMERCIAL SUPPORT SERVICES - 1.8%** |  |
| 306479 | Waste Connections, Inc. | 53744157 |
|  | **CONSTRUCTION MATERIALS - 1.6%** |  |
| 166555 | Vulcan Materials Company | 47504817 |
|  | **E-COMMERCE DISCRETIONARY - 1.6%** |  |
| 1388791 | Chewy, Inc., Class A<sup>(a)</sup> | 45899543 |
|  | **ELECTRIC UTILITIES - 2.5%** |  |
| 51151 | Talen Energy Corporation<sup>(a)</sup> | 19173441 |
| 333361 | Vistra Corporation | 53781130 |
|  |  | 72954571 |
|  | **ELECTRICAL EQUIPMENT - 7.1%** |  |
| 135153 | Bloom Energy Corporation, Class A<sup>(a)</sup> | 11743444 |
| 119355 | GE Vernova, Inc. | 78006847 |
| 86685 | Generac Holdings, Inc.<sup>(a)</sup> | 11821234 |
| 48962 | Rockwell Automation, Inc. | 19049645 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE GILEAD FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 95.4% (Continued)** |  |
|  | **ELECTRICAL EQUIPMENT - 7.1% (Continued)** |  |
| 189717 | Trane Technologies PLC | $73837857 |
| 86292 | Vertiv Holdings Company, Class A | 13980167 |
|  |  | 208439194 |
|  | **ENGINEERING & CONSTRUCTION - 1.9%** |  |
| 479463 | Frontdoor, Inc.<sup>(a)</sup> | 27660220 |
| 67645 | Quanta Services, Inc. | 28550249 |
|  |  | 56210469 |
|  | **FOOD - 0.6%** |  |
| 511954 | Vital Farms, Inc.<sup>(a)</sup> | 16351811 |
|  | **GAS & WATER UTILITIES - 0.8%** |  |
| 535784 | NiSource, Inc. | 22374340 |
|  | **HOME CONSTRUCTION - 1.0%** |  |
| 211004 | DR Horton, Inc. | 30390906 |
|  | **INDUSTRIAL INTERMEDIATE PROD - 5.8%** |  |
| 2860079 | Xometry, Inc., Class A<sup>(a)</sup> | 170088898 |
|  | **INDUSTRIAL SUPPORT SERVICES - 5.0%** |  |
| 690508 | Fastenal Company | 27710086 |
| 519570 | RB Global, Inc. | 53448166 |
| 79189 | United Rentals, Inc. | 64089241 |
|  |  | 145247493 |
|  | **MACHINERY - 0.5%** |  |
| 108663 | Xylem Inc | 14797727 |
|  | **MEDICAL EQUIPMENT & DEVICES - 15.2%** |  |
| 2766154 | Beta Bionics Inc.<sup>(a),(b),(c),(e)</sup> | 84284712 |
| 180000 | Beta Bionics, Inc.<sup>(a)</sup> | 5484600 |
| 219392 | DexCom, Inc.<sup>(a)</sup> | 14561047 |
| 1718690 | Guardant Health, Inc.<sup>(a)</sup> | 175546997 |
| 147000 | Inspire Medical Systems, Inc.<sup>(a)</sup> | 13557810 |
| 57024 | Intuitive Surgical, Inc.<sup>(a)</sup> | 32296113 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE GILEAD FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 95.4% (Continued)** |  |
|  | **MEDICAL EQUIPMENT & DEVICES - 15.2% (Continued)** |  |
| 464252 | iRhythm Technologies, Inc.<sup>(a)</sup> | $82376875 |
| 25043 | Mettler-Toledo International, Inc.<sup>(a)</sup> | 34914700 |
|  |  | 443022854 |
|  | **OIL & GAS PRODUCERS - 2.0%** |  |
| 162750 | DT Midstream, Inc. | 19477920 |
| 214336 | Targa Resources Corporation | 39544992 |
|  |  | 59022912 |
|  | **OIL & GAS SERVICES & EQUIPMENT - 0.7%** |  |
| 1092595 | Liberty Energy, Inc., Class A | 20169304 |
|  | **RETAIL - DISCRETIONARY - 3.4%** |  |
| 86692 | Lithia Motors, Inc. | 28810352 |
| 121288 | Lowe's Companies, Inc. | 29249814 |
| 450495 | O'Reilly Automotive, Inc.<sup>(a)</sup> | 41089649 |
|  |  | 99149815 |
|  | **SEMICONDUCTORS - 10.7%** |  |
| 65539 | ASML Holding N.V. - ADR | 70117555 |
| 519244 | Lam Research Corporation | 88884188 |
| 586648 | Lattice Semiconductor Corporation<sup>(a)</sup> | 43165560 |
| 39318 | Monolithic Power Systems, Inc. | 35636262 |
| 110283 | NVIDIA Corporation | 20567779 |
| 151204 | SiTime Corporation<sup>(a)</sup> | 53403741 |
|  |  | 311775085 |
|  | **SOFTWARE - 8.6%** |  |
| 19414 | Crowdstrike Holdings, Inc., Class A<sup>(a)</sup> | 9100507 |
| 45656 | CyberArk Software Ltd.<sup>(a)</sup> | 20365315 |
| 230946 | Datadog, Inc., Class A<sup>(a)</sup> | 31406347 |
| 1205139 | Global-e Online Ltd.<sup>(a)</sup> | 47374014 |
| 80944 | HubSpot, Inc.<sup>(a)</sup> | 32482827 |
| 90530 | Monday.com Ltd.<sup>(a)</sup> | 13358607 |
| 50658 | MongoDB, Inc.<sup>(a)</sup> | 21260656 |
| 121998 | Palo Alto Networks, Inc.<sup>(a)</sup> | 22472032 |
| 86425 | Roper Technologies, Inc. | 38470360 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE GILEAD FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Shares** |  |  |  | **Fair Value** |
|  | **COMMON STOCKS — 95.4% (Continued)** | **COMMON STOCKS — 95.4% (Continued)** | **COMMON STOCKS — 95.4% (Continued)** |  |
|  | **SOFTWARE - 8.6% (Continued)** | **SOFTWARE - 8.6% (Continued)** | **SOFTWARE - 8.6% (Continued)** |  |
| 148613 | ServiceTitan, Inc., Class A<sup>(a)</sup> | ServiceTitan, Inc., Class A<sup>(a)</sup> | ServiceTitan, Inc., Class A<sup>(a)</sup> | $15827284 |
|  |  |  |  | 252117949 |
|  | **TECHNOLOGY SERVICES - 4.7%** | **TECHNOLOGY SERVICES - 4.7%** | **TECHNOLOGY SERVICES - 4.7%** |  |
| 33778 | Adyen N.V.<sup>(a)</sup> | Adyen N.V.<sup>(a)</sup> | Adyen N.V.<sup>(a)</sup> | 54563851 |
| 2352452 | Toast, Inc., Class A<sup>(a)</sup> | Toast, Inc., Class A<sup>(a)</sup> | Toast, Inc., Class A<sup>(a)</sup> | 83535571 |
|  |  |  |  | 138099422 |
|  | **TRANSPORTATION & LOGISTICS - 2.1%** | **TRANSPORTATION & LOGISTICS - 2.1%** | **TRANSPORTATION & LOGISTICS - 2.1%** |  |
| 390981 | Old Dominion Freight Line, Inc. | Old Dominion Freight Line, Inc. | Old Dominion Freight Line, Inc. | 61305821 |
|  | **TOTAL COMMON STOCKS (Cost $1,431,010,583)** | **TOTAL COMMON STOCKS (Cost $1,431,010,583)** | **TOTAL COMMON STOCKS (Cost $1,431,010,583)** | 2788632442 |
| **Shares** |  |  |  | **Fair Value** |
|  | **CONTINGENT VALUE RIGHTS — 0.2%** | **CONTINGENT VALUE RIGHTS — 0.2%** | **CONTINGENT VALUE RIGHTS — 0.2%** |  |
|  | **BIOTECH & PHARMA - 0.2%** | **BIOTECH & PHARMA - 0.2%** | **BIOTECH & PHARMA - 0.2%** |  |
| 3982940 | Peloton Therapeutics, Inc. - CVR<sup>(a),(c),(d),(e),(f)</sup> | Peloton Therapeutics, Inc. - CVR<sup>(a),(c),(d),(e),(f)</sup> | Peloton Therapeutics, Inc. - CVR<sup>(a),(c),(d),(e),(f)</sup> | 4663883 |
|  | **TOTAL CONTINGENT VALUE RIGHTS (Cost $–)** | **TOTAL CONTINGENT VALUE RIGHTS (Cost $–)** | **TOTAL CONTINGENT VALUE RIGHTS (Cost $–)** | 4663883 |
| **Principal** |  | **Coupon Rate** |  |  |
| **Amount ($)** |  | **(%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 1.1%** |  |  |  |
|  | **ASSET MANAGEMENT — 1.1%** |  |  |  |
| 3000000 | CI Credit GP, LLC<sup>(c),(d),(e),(f)</sup> | 5.5000 | 12/15/30 | 3000000 |
| 2000000 | Hope Global Investments<sup>(c),(d),(e)</sup> | 4.0000 | 01/07/28 | 1967882 |
| 5000000 | Vision Fund International<sup>(c),(d),(e)</sup> | 3.2230 | 12/15/26 | 4927330 |
| 5000000 | Vision Fund International<sup>(c),(d),(e)</sup> | 4.7500 | 03/31/28 | 4980030 |
| 5000000 | Vision Fund International<sup>(c),(d),(e)</sup> | 5.5000 | 06/30/28 | 5000000 |
| 5000000 | Vision Fund International<sup>(c),(d),(e)</sup> | 5.0000 | 12/01/28 | 4993445 |
| 4000000 | Vision Fund International<sup>(c),(d),(e)</sup> | 5.0000 | 06/01/29 | 3977312 |
| 5000000 | Vision Fund International<sup>(c),(d),(e),(f)</sup> | 5.1000 | 12/15/29 | 5000000 |
|  |  |  |  | 33845999 |
|  | **TOTAL CORPORATE BONDS (Cost $34,000,000)** | **TOTAL CORPORATE BONDS (Cost $34,000,000)** | **TOTAL CORPORATE BONDS (Cost $34,000,000)** | 33845999 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE GILEAD FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **SHORT-TERM INVESTMENTS — 0.2%** |  |
|  | **MONEY MARKET FUNDS - 0.2%** |  |
| 5556440 | Fidelity Money Market Government Portfolio, Class I, 3.64% (Cost $5,556,440)<sup>(g)</sup> | 5556440 |
|  | **TOTAL SHORT-TERM INVESTMENTS (Cost $5,556,440)** | 5556440 |
|  | **TOTAL INVESTMENTS – 96.9% (Cost $1,470,567,023)** | $2832698764 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITES - 3.1%** | 90507604 |
|  | **NET ASSETS - 100.0%** | $2923206368 |

---

---

| | |
|:---|:---|
| ADR | - American Depositary Receipt |
| CVR | - Contingent Value Rights |
| LTD | - Limited Company |
| N.V. | - Naamioze Vennootschap |
| PLC | - Public Limited Company |
| S.E. | - Societas Europaea |

---

 

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Affiliated Company – Eventide Gilead Fund holds in excess of 5% of outstanding voting securities of this security.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of December 31, 2025, was $122,794,594, representing 4.2% of net assets.

<sup>(d)</sup> Private investment.

<sup>(e)</sup> Restricted security.

<sup>(f)</sup> The value of this security has been determined using significant unobservable inputs in good faith under policies of the Board of Trustees.

<sup>(g)</sup> Rate disclosed is the seven day effective yield as of December 31, 2025.

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE HEALTHCARE & LIFE SCIENCES FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 93.7%** |  |
|  | **BIOTECH & PHARMA - 69.6%** |  |
| 327851 | Abivax S.A. - ADR<sup>(a)</sup> | $44212347 |
| 3364067 | ADC Therapeutics S.A.<sup>(a)</sup> | 11875157 |
| 33093 | Alnylam Pharmaceuticals, Inc.<sup>(a)</sup> | 13159431 |
| 1512444 | Amylyx Pharmaceuticals, Inc.<sup>(a)</sup> | 18270324 |
| 436015 | Apogee Therapeutics, Inc.<sup>(a)</sup> | 32910412 |
| 44911 | Argenx S.E. - ADR<sup>(a)</sup> | 37767905 |
| 370000 | Arrowhead Pharmaceuticals, Inc.<sup>(a)</sup> | 24564300 |
| 523822 | Avidity Biosciences, Inc.<sup>(a)</sup> | 37783281 |
| 211471 | Axsome Therapeutics, Inc.<sup>(a)</sup> | 38623064 |
| 328624 | BeLite Bio Inc<sup>(a)</sup> | 52566695 |
| 54467 | Belite Bio, Inc. - ADR<sup>(a)</sup> | 8712541 |
| 362130 | Bridgebio Pharma, Inc.<sup>(a)</sup> | 27699324 |
| 103013 | Bright Minds Biosciences, Inc.<sup>(a)</sup> | 8039135 |
| 1037000 | CelldexTherapeutics, Inc. <sup>(a)</sup> | 28164920 |
| 312015 | CG oncology, Inc.<sup>(a)</sup> | 12954863 |
| 517159 | Collegium Pharmaceutical, Inc.<sup>(a)</sup> | 23944462 |
| 1257000 | Cybin, Inc.<sup>(a)</sup> | 10282260 |
| 479028 | Cytokinetics, Inc.<sup>(a)</sup> | 30437439 |
| 395235 | Disc Medicine, Inc.<sup>(a)</sup> | 31385611 |
| 679173 | Dyne Therapeutics, Inc.<sup>(a)</sup> | 13284624 |
| 568310 | Edgewise Therapeutics, Inc.<sup>(a)</sup> | 14102613 |
| 950000 | Engene Holdings, Inc.<sup>(a)</sup> | 8578500 |
| 961525 | Evommune, Inc.<sup>(a)</sup> | 16461308 |
| 284069 | Ideaya Biosciences, Inc.<sup>(a)</sup> | 9820265 |
| 2549019 | Immix Biopharma, Inc.<sup>(a)</sup> | 13331369 |
| 305603 | Insmed, Inc.<sup>(a)</sup> | 53187146 |
| 5809256 | Invivyd, Inc.<sup>(a)</sup> | 14348862 |
| 575000 | Ionis Pharmaceuticals, Inc.<sup>(a)</sup> | 45488250 |
| 626000 | Kymera Therapeutics, Inc.<sup>(a)</sup> | 48709060 |
| 324041 | Maze Therapeutics, Inc.<sup>(a)</sup> | 13425019 |
| 890000 | MBX Biosciences, Inc.<sup>(a)</sup> | 28070600 |
| 770383 | Mirum Pharmaceuticals, Inc.<sup>(a)</sup> | 60852553 |
| 1297893 | Nurix Therapeutics, Inc.<sup>(a)</sup> | 24621030 |
| 569000 | Olema Pharmaceuticals, Inc.<sup>(a)</sup> | 14225000 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE HEALTHCARE & LIFE SCIENCES FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 93.7% (Continued)** |  |
|  | **BIOTECH & PHARMA - 69.6% (Continued)** |  |
| 951433 | ORIC Pharmaceuticals, Inc.<sup>(a)</sup> | $7782722 |
| 4285000 | Ovid Therapeutics, Inc.<sup>(a),(c),(f)</sup> | 6984550 |
| 101748 | Palvella Therapeutics, Inc.<sup>(a)</sup> | 10649963 |
| 67100 | Praxis Precision Medicines, Inc.<sup>(a)</sup> | 19777054 |
| 377089 | REVOLUTION Medicines, Inc.<sup>(a)</sup> | 30035139 |
| 954625 | Scholar Rock Holding Corporation<sup>(a)</sup> | 42051231 |
| 639045 | Sionna Therapeutics, Inc.<sup>(a)</sup> | 26290311 |
| 1237492 | Syndax Pharmaceuticals, Inc.<sup>(a)</sup> | 25999707 |
| 716414 | TG Therapeutics, Inc.<sup>(a)</sup> | 21356301 |
| 82628 | TransMedics Group, Inc.<sup>(a)</sup> | 10051696 |
| 2622306 | Trevi Therapeutics, Inc.<sup>(a)</sup> | 32831271 |
| 497912 | uniQure N.V.<sup>(a)</sup> | 11915034 |
| 47004 | United Therapeutics Corporation<sup>(a)</sup> | 22902699 |
| 536726 | Vaxcyte, Inc.<sup>(a)</sup> | 24764538 |
| 500000 | WaVe Life Sciences Ltd.<sup>(a)</sup> | 8500000 |
|  |  | 1173751886 |
|  | **MEDICAL EQUIPMENT & DEVICES - 22.2%** |  |
| 1768644 | Beta Bionics Inc.<sup>(a),(b),(c),(f)</sup> | 53890583 |
| 120000 | Beta Bionics, Inc.<sup>(a)</sup> | 3656400 |
| 305000 | Castle Biosciences, Inc.<sup>(a)</sup> | 11864500 |
| 312585 | Celcuity, Inc.<sup>(a)</sup> | 31177228 |
| 252611 | DexCom, Inc.<sup>(a)</sup> | 16765792 |
| 254546 | Exact Sciences Corporation<sup>(a)</sup> | 25851692 |
| 289275 | Glaukos Corporation<sup>(a)</sup> | 32662040 |
| 737810 | Guardant Health, Inc.<sup>(a)</sup> | 75359913 |
| 291658 | Inspire Medical Systems, Inc.<sup>(a)</sup> | 26899617 |
| 223127 | iRhythm Technologies, Inc.<sup>(a)</sup> | 39591655 |
| 1269338 | Kestra Medical Technologies, Inc.<sup>(a)</sup> | 33662844 |
| 569782 | Veracyte, Inc.<sup>(a)</sup> | 23987822 |
|  |  | 375370086 |
|  | **SOFTWARE - 1.9%** |  |
| 505989 | HeartFlow, Inc.<sup>(a)</sup> | 14749579 |
| 737694 | Privia Health Group, Inc.<sup>(a)</sup> | 17490725 |
|  |  | 32240304 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE HEALTHCARE & LIFE SCIENCES FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Shares** |  |  |  | **Fair Value** |
|  | **COMMON STOCKS — 93.7% (Continued)** | **COMMON STOCKS — 93.7% (Continued)** | **COMMON STOCKS — 93.7% (Continued)** |  |
|  | **TOTAL COMMON STOCKS (Cost $1,058,468,355)** | **TOTAL COMMON STOCKS (Cost $1,058,468,355)** | **TOTAL COMMON STOCKS (Cost $1,058,468,355)** | $1581362276 |
| **Shares** |  |  |  | **Fair Value** |
|  | **CONTINGENT VALUE RIGHTS — 0.3%** | **CONTINGENT VALUE RIGHTS — 0.3%** | **CONTINGENT VALUE RIGHTS — 0.3%** |  |
|  | **BIOTECH & PHARMA - 0.3%** | **BIOTECH & PHARMA - 0.3%** | **BIOTECH & PHARMA - 0.3%** |  |
| 396160 | Metsera, Inc. - CVR<sup>(a),(c),(e),(f)</sup> | Metsera, Inc. - CVR<sup>(a),(c),(e),(f)</sup> | Metsera, Inc. - CVR<sup>(a),(c),(e),(f)</sup> | 3862560 |
| 1528871 | Peloton Therapeutics, Inc. - CVR<sup>(a),(c),(d),(e),(f)</sup> | Peloton Therapeutics, Inc. - CVR<sup>(a),(c),(d),(e),(f)</sup> | Peloton Therapeutics, Inc. - CVR<sup>(a),(c),(d),(e),(f)</sup> | 1790254 |
|  | **TOTAL CONTINGENT VALUE RIGHTS (Cost $–)** | **TOTAL CONTINGENT VALUE RIGHTS (Cost $–)** | **TOTAL CONTINGENT VALUE RIGHTS (Cost $–)** | 5652814 |
|  |  | **Coupon Rate** |  |  |
| **Shares** |  | **(%)** | **Maturity** | **Fair Value** |
|  | **PRIVATE INVESTMENTS — 2.9%** |  |  |  |
|  | **BIOTECH & PHARMA – 2.3%** |  |  |  |
| 20482289 | Avalyn Pharma Inc. Series C1<sup>(a),(c),(d),(e),(f)</sup> | 8.00% |  | 16310047 |
| 4060259 | Avalyn Pharma Inc. Series D1<sup>(a),(c),(d),(e),(f)</sup> | 8.00% |  | 3233184 |
| 295276 | BioSplice Therapeutics, Inc. Series B-1<sup>(a),(c),(d),(e),(f)</sup> |  |  |  |
| 5000000 | Casma Therapeutics, Inc. Series B1<sup>(a),(b),(c),(d),(e),(f)</sup> |  |  | 401925 |
| 5000000 | Casma Therapeutics, Inc. Series B2<sup>(a),(b),(c),(d),(e),(f)</sup> |  |  | 401925 |
| 1820413 | Casma Therapeutics, Inc. Series C1<sup>(a),(b),(c),(d),(e),(f)</sup> |  |  | 146334 |
| 2479882 | Casma Therapeutics, Inc. Series C2<sup>(a),(b),(c),(d),(e),(f)</sup> |  |  | 199345 |
| 1017770 | Evida BioSciences, Inc. <sup>(a),(b),(c),(d),(e),(f)</sup> |  |  | 980825 |
| 1097561 | Flare Therapeutics, Inc. Series A<sup>(a),(c),(d),(e),(f)</sup> |  |  | 1503659 |
| 902439 | Flare Therapeutics, Inc. Series A2<sup>(a),(c),(d),(e),(f)</sup> |  |  | 1236342 |
| 1952962 | Flare Therapeutics, Inc. Series B<sup>(a),(c),(d),(e),(f)</sup> |  |  | 2870854 |
| 930436 | Freenome Holdings, Inc. Series D<sup>(a),(c),(d),(e),(f)</sup> | 6.00% |  | 2276949 |
| 133941 | Freenome Holdings, Inc. Series F<sup>(a),(c),(d),(e),(f)</sup> | 6.00% |  | 327778 |
| 5000000 | Goldfinch Biopharma, Inc. Series A<sup>(a),(b),(c),(d),(e),(f)</sup> | $0.08 |  |  |
| 8474576 | Goldfinch Biopharma, Inc. Series B<sup>(a),(b),(c),(d),(e),(f)</sup> | $0.0944 |  | 971649 |
| 4237288 | Goldfinch Biopharma, Inc. Series B2<sup>(a),(b),(c),(d),(e),(f)</sup> | $0.0944 |  | 485824 |
| 374442 | Kardigan Inc. Series B<sup>(a),(c),(d),(e),(f)</sup> |  |  | 7999983 |
| 763319 | Kojin Therapeutics<sup>(a),(c),(d),(e),(f)</sup> | 3.00% |  |  |
| 763319 | Kojin Therapeutics, Inc.<sup>(a),(c),(d),(e),(f)</sup> | 3.00% |  |  |
|  |  |  |  | 39346623 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE HEALTHCARE & LIFE SCIENCES FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|<br>**Shares** |  | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **PRIVATE INVESTMENTS — 2.9% (Continued)** | **PRIVATE INVESTMENTS — 2.9% (Continued)** | **PRIVATE INVESTMENTS — 2.9% (Continued)** |  |
|  | **MEDICAL EQUIPMENT & DEVICES - 0.6%** | **MEDICAL EQUIPMENT & DEVICES - 0.6%** | **MEDICAL EQUIPMENT & DEVICES - 0.6%** |  |
| 15450219 | Kardium Inc. Series D-8 <sup>(a),(c),(d),(e),(f)</sup> | 8.00% |  | $10000000 |
|  | **TOTAL PRIVATE INVESTMENTS (Cost $96,754,558)** | **TOTAL PRIVATE INVESTMENTS (Cost $96,754,558)** | **TOTAL PRIVATE INVESTMENTS (Cost $96,754,558)** | 49346623 |
| **Principal** |  | **Coupon Rate** |  |  |
| **Amount ($)** |  | **(%)** | **Maturity** | **Fair Value** |
|  | **CONVERTIBLE BONDS — 0.0%<sup>(g)</sup>** |  |  |  |
|  | **BIOTECH & PHARMA** — **0.0%<sup>(g)</sup>** |  |  |  |
| 3500000 | Biosplice Therapeutics Inc. Series C PIK<sup>(c),(d),(e),(f)</sup> | 10.5000 | 03/12/26 | 242533 |
|  | **TOTAL CONVERTIBLE BONDS (Cost $3,500,000)** | **TOTAL CONVERTIBLE BONDS (Cost $3,500,000)** | **TOTAL CONVERTIBLE BONDS (Cost $3,500,000)** | 242533 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Shares** |  | **Expiration <br> Date** | **Exercise <br> Price** | **Fair Value** |
|  | **WARRANT — 0.2%** |  |  |  |
|  | **BIOTECH & PHARMA - 0.2%** |  |  |  |
| 111191 | BiospliceTherapeutics, Inc. Series C Warrant <sup>(a),(c),(d),(e),(f)</sup> | 09/12/2027 | $0.98 |  |
| 2856666 | Ovid Therapeutics Inc. Series A Warrant<sup>(a),(c),(d),(e),(f)</sup> | 10 /4/2030 | 1.40 | 1863975 |
| 2142500 | Ovid Therapeutics Inc. Series BWarrant <sup>(a),(c),(d),(e),(f)</sup> | 10 /4/2030 | 1.40 | 1397981 |
|  |  |  |  | 3261956 |
|  | **TOTAL WARRANT (Cost $–)** | **TOTAL WARRANT (Cost $–)** |  | 3261956 |
| **Shares** |  |  |  | **Fair Value** |
|  | **MONEY MARKET FUNDS - 0.2%** |  |  |  |
| 3628600 | Fidelity Money Market Government Portfolio, Class I, 3.64% (Cost $3,628,600)<sup>(h)</sup> | Fidelity Money Market Government Portfolio, Class I, 3.64% (Cost $3,628,600)<sup>(h)</sup> |  | $3628600 |
|  | **TOTAL SHORT-TERM INVESTMENTS (Cost $3,628,600)** | **TOTAL SHORT-TERM INVESTMENTS (Cost $3,628,600)** |  | 3628600 |
|  | **TOTAL INVESTMENTS - 97.3% (Cost $1,162,351,513)** | **TOTAL INVESTMENTS - 97.3% (Cost $1,162,351,513)** |  | $1643494802 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 2.7%** | **OTHER ASSETS IN EXCESS OF LIABILITIES - 2.7%** |  | 44951361 |
|  | **NET ASSETS - 100.0%** | **NET ASSETS - 100.0%** |  | $1688446163 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE HEALTHCARE & LIFE SCIENCES FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | |
|:---|:---|
| ADR | - American Depositary Receipt |
| CVR | - Contingent Value Rights |
| PIK | - Payment in Kind |
| SE. | - Societas Europaea |

---

---

| | |
|:---|:---|
| <sup>(a)</sup> | Non-income producing security. |
| |  |
| <sup>(b)</sup> | Affiliated company – Eventide Healthcare & Life Sciences Fund holds in excess of 5% of outstanding voting securities of this security. |
| |  |
| <sup>(c)</sup> | Illiquid security. The total fair value of these securities as of December 31, 2025, was $119,379,059, representing 7.1% of net assets. |
| |  |
| <sup>(d)</sup> | The value of this security has been determined using significant unobservable inputs in good faith under policies of the Board of Trustees. |
| |  |
| <sup>(e)</sup> | Private investment. |
| |  |
| <sup>(f)</sup> | Restricted security. |
| |  |
| <sup>(g)</sup> | Percentage rounds to less than 0.1%. |
| |  |
| <sup>(h)</sup> | Rate disclosed is the seven day effective yield as of December 31, 2025. |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE LARGE CAP FOCUS FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 97.8%** |  |
|  | **BANKING - 1.4%** |  |
| 142022 | Huntington Bancshares Inc | $2464082 |
|  | **BIOTECH & PHARMA - 5.6%** |  |
| 4261 | Amgen, Inc. | 1394668 |
| 2514 | Eli Lilly & Company | 2701746 |
| 148912 | Royalty Pharma plc, Class A | 5753960 |
|  |  | 9850374 |
|  | **CHEMICALS - 5.7%** |  |
| 17030 | Linde PLC | 7261422 |
| 8762 | Sherwin-Williams Company (The) | 2839151 |
|  |  | 10100573 |
|  | **COMMERCIAL SUPPORT SERVICES - 0.7%** |  |
| 5439 | Republic Services, Inc. | 1152687 |
|  | **CONTAINERS & PACKAGING - 0.7%** |  |
| 30275 | International Paper Company | 1192532 |
|  | **ELECTRIC UTILITIES - 8.7%** |  |
| 15190 | Constellation Energy Corporation | 5366171 |
| 23151 | Entergy Corporation | 2139847 |
| 33422 | NextEra Energy, Inc. | 2683118 |
| 49858 | Southern Company (The) | 4347618 |
| 2382 | Talen Energy Corporation<sup>(a)</sup> | 892869 |
|  |  | 15429623 |
|  | **ELECTRICAL EQUIPMENT - 7.6%** |  |
| 10485 | GE Vernova, LLC | 6852681 |
| 17164 | Trane Technologies PLC | 6680229 |
|  |  | 13532910 |
|  | **HOME CONSTRUCTION - 1.2%** |  |
| 15145 | DR Horton, Inc. | 2181334 |
|  | **INDUSTRIAL SUPPORT SERVICES - 1.0%** |  |
| 2186 | United Rentals, Inc. | 1769174 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE LARGE CAP FOCUS FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 97.8% (Continued)** |  |
|  | **INSURANCE - 1.4%** |  |
| 9291 | Arthur J. Gallagher & Company | $2404418 |
|  | **MACHINERY - 0.7%** |  |
| 2038 | Caterpillar, Inc. | 1167509 |
|  | **MEDICAL EQUIPMENT & DEVICES - 5.2%** |  |
| 23226 | Boston Scientific Corporation<sup>(a)</sup> | 2214599 |
| 39251 | Medtronic PLC | 3770451 |
| 2315 | Mettler-Toledo International, Inc.<sup>(a)</sup> | 3227550 |
|  |  | 9212600 |
|  | **OIL & GAS PRODUCERS - 2.1%** |  |
| 60643 | Williams Companies, Inc. (The) | 3645251 |
|  | **RETAIL - DISCRETIONARY - 7.3%** |  |
| 8880 | Ferguson Enterprises, Inc. | 1976954 |
| 8655 | Home Depot, Inc. (The) | 2978185 |
| 8355 | Lowe's Companies, Inc. | 2014892 |
| 64816 | O'Reilly Automotive, Inc.<sup>(a)</sup> | 5911867 |
|  |  | 12881898 |
|  | **SEMICONDUCTORS - 18.8%** |  |
| 10169 | Advanced Micro Devices, Inc.<sup>(a)</sup> | 2177793 |
| 26003 | Broadcom, Inc. | 8999638 |
| 2213 | KLA Corporation | 2688972 |
| 12765 | Lam Research Corporation | 2185113 |
| 943 | Monolithic Power Systems, Inc. | 854697 |
| 64173 | NVIDIA Corporation | 11968265 |
| 14199 | Taiwan Semiconductor Manufacturing Company Ltd. - ADR | 4314934 |
|  |  | 33189412 |
|  | **SOFTWARE - 13.1%** |  |
| 11942 | Cadence Design Systems, Inc.<sup>(a)</sup> | 3732830 |
| 8316 | Intuit, Inc. | 5508685 |
| 11236 | Palo Alto Networks, Inc.<sup>(a)</sup> | 2069671 |
| 10938 | Roper Technologies, Inc. | 4868832 |
| 11688 | SAP S.E. - ADR | 2839132 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE LARGE CAP FOCUS FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 97.8% (Continued)** |  |
|  | **SOFTWARE - 13.1% (Continued)** |  |
| 26975 | ServiceNow, Inc.<sup>(a)</sup> | $4132300 |
|  |  | 23151450 |
|  | **SPECIALTY FINANCE - 5.7%** |  |
| 27499 | American Express Company | 10173255 |
|  | **TECHNOLOGY HARDWARE - 4.5%** |  |
| 25743 | Arista Networks, Inc.<sup>(a)</sup> | 3373105 |
| 14340 | Dell Technologies, Inc., Class C | 1805119 |
| 7409 | Motorola Solutions, Inc. | 2840018 |
|  |  | 8018242 |
|  | **TECHNOLOGY SERVICES - 5.4%** |  |
| 5929 | CDW Corporation | 807530 |
| 16771 | S&P Global, Inc. | 8764357 |
|  |  | 9571887 |
|  | **TRANSPORTATION & LOGISTICS - 1.0%** |  |
| 12086 | Old Dominion Freight Line, Inc. | 1895085 |
|  | **TOTAL COMMON STOCKS (Cost $147,979,895)** | 172984296 |
|  | **TOTAL INVESTMENTS - 97.8% (Cost $147,979,895)** | $172984296 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES- 2.2%** | 3884836 |
|  | **NET ASSETS - 100.0%** | $176869132 |

---

---

| | |
|:---|:---|
| ADR | - American Depositary Receipt |
| LLC | - Limited Liability Company |
| PLC | - Public Limited Company |
| S.E. | - Societas Europaea |

---

 

<sup>(a)</sup> Non-income producing security.

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **ASSET BACKED SECURITIES — 2.0%** |  |  |  |  |
|  | **AUTO LOAN — 1.0%** |  |  |  |  |
| 2070000 | CarMax Auto Owner Trust 2024-2 D |  | 6.4200 | 10/15/30 | $2134297 |
|  | **OTHER ABS — 1.0%** |  |  |  |  |
| 1975000 | PFS Financing Corporation Series C A<sup>(a),(b)</sup> | SOFR30A + 0.800% | 4.7840 | 04/17/28 | 1976631 |
|  | **TOTAL ASSET BACKED SECURITIES (Cost $4,099,666)** |  |  |  | 4110928 |
| **Principal** |  |  | **Coupon Rate** |  |  |
| **Amount ($)** |  | **Spread** | **(%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 66.6%** |  |  |  |  |
|  | **ASSET MANAGEMENT — 1.1%** |  |  |  |  |
| 1000000 | CI Credit GP, LLC<sup>(c),(d),(e),(f)</sup> |  | 5.5000 | 12/15/30 | 1000000 |
| 750000 | Hope Global Investments<sup>(c),(d),(e)</sup> |  | 4.6000 | 10/10/28 | 741233 |
| 500000 | Hope Global Investments<sup>(c),(d),(e)</sup> |  | 5.0000 | 09/11/29 | 494738 |
|  |  |  |  |  | 2235971 |
|  | **BANKING — 9.4%** |  |  |  |  |
| 2500000 | Fifth Third Bancorp<sup>(b)</sup> | SOFRRATE + 0.685% | 1.7070 | 11/01/27 | 2453080 |
| 2575000 | First Horizon Corporation<sup>(b)</sup> | SOFRRATE + 1.766% | 5.5140 | 03/07/31 | 2666704 |
| 1000000 | Huntington Bancshares, Inc. |  | 2.5500 | 02/04/30 | 934263 |
| 2000000 | Huntington Bancshares, Inc.<sup>(b)</sup> | H15T5Y + 2.653% | 6.2500 | Perpetual | 2009050 |
| 3225000 | JPMorgan Chase & Company<sup>(b)</sup> | SOFRRATE + 1.330% | 6.0700 | 10/22/27 | 3276789 |
| 2500000 | M&T BANK CORPORATION<sup>(b)</sup> | SOFRRATE + 0.930% | 4.8330 | 01/16/29 | 2541137 |
| 2750000 | Royal Bank of Canada |  | 1.1500 | 07/14/26 | 2711780 |
| 2800000 | Truist Financial Corporation Series I<sup>(b)</sup> | SOFRRATE + 1.309% | 5.0710 | 05/20/31 | 2879737 |
|  |  |  |  |  | 19472540 |
|  | **BIOTECH & PHARMA — 1.0%** |  |  |  |  |
| 2000000 | Zoetis, Inc. |  | 3.9000 | 08/20/28 | 2000099 |
|  | **CHEMICALS — 0.9%** |  |  |  |  |
| 1850000 | Sherwin-Williams Company (The) |  | 4.5500 | 03/01/28 | 1873394 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **CORPORATE BONDS — 66.6% (Continued)** |  |  |  |  |
|  | **COMMERCIAL SUPPORT SERVICES — 0.7%** |  |  |  |  |
| 1500000 | Waste Management, Inc. |  | 4.9500 | 07/03/27 | $1526088 |
|  | **CONSTRUCTION MATERIALS — 1.8%** |  |  |  |  |
| 1725000 | Advanced Drainage Systems, Inc.<sup>(a)</sup> |  | 5.0000 | 09/30/27 | 1728886 |
| 1900000 | Quikrete Holdings, Inc.<sup>(a)</sup> |  | 6.3750 | 03/01/32 | 1978953 |
|  |  |  |  |  | 3707839 |
|  | **ELECTRIC UTILITIES — 9.2%** |  |  |  |  |
| 2000000 | AES Corporation (The) |  | 1.3750 | 01/15/26 | 1997723 |
| 2325000 | Ameren Illinois Company |  | 3.8000 | 05/15/28 | 2321197 |
| 2000000 | Constellation Energy Generation, LLC |  | 5.6000 | 03/01/28 | 2065004 |
| 3250000 | Duke Energy Florida, LLC |  | 2.5000 | 12/01/29 | 3071900 |
| 1525000 | Georgia Power Company Series 2016-A |  | 3.2500 | 04/01/26 | 1522614 |
| 2650000 | MidAmerican Energy Company |  | 3.1000 | 05/01/27 | 2625944 |
| 2700000 | National Rural Utilities Cooperative Finance |  | 4.8500 | 02/07/29 | 2765469 |
| 1000000 | NextEra Energy Capital Holdings, Inc. |  | 4.9000 | 02/28/28 | 1019388 |
| 1750000 | NextEra Energy Capital Holdings, Inc.<sup>(b)</sup> | US0003M + 2.409% | 4.8000 | 12/01/77 | 1726019 |
|  |  |  |  |  | 19115258 |
|  | **ELECTRICAL EQUIPMENT — 1.2%** |  |  |  |  |
| 2475000 | Lennox International, Inc. |  | 5.5000 | 09/15/28 | 2557771 |
|  | **ENGINEERING & CONSTRUCTION — 3.0%** |  |  |  |  |
| 1550000 | Installed Building Products, Inc.<sup>(a)</sup> |  | 5.7500 | 02/01/28 | 1556953 |
| 2375000 | MasTec, Inc.<sup>(a)</sup> |  | 4.5000 | 08/15/28 | 2363959 |
| 2000000 | Quanta Services, Inc. |  | 4.7500 | 08/09/27 | 2026018 |
|  |  |  |  |  | 5946930 |
|  | **FORESTRY, PAPER & WOOD PRODUCTS — 1.0%** |  |  |  |  |
| 2175000 | Louisiana-Pacific Corporation<sup>(a)</sup> |  | 3.6250 | 03/15/29 | 2109939 |
|  | **HOME & OFFICE PRODUCTS — 0.6%** |  |  |  |  |
| 1250000 | Somnigroup International, Inc.<sup>(a)</sup> |  | 4.0000 | 04/15/29 | 1219681 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **CORPORATE BONDS — 66.6% (Continued)** |  |  |  |  |
|  | **HOME CONSTRUCTION — 1.6%** |  |  |  |  |
| 1700000 | M/I Homes, Inc. |  | 4.9500 | 02/01/28 | $1703591 |
| 1600000 | Patrick Industries, Inc.<sup>(a)</sup> |  | 4.7500 | 05/01/29 | 1590270 |
|  |  |  |  |  | 3293861 |
|  | **INDUSTRIAL SUPPORT SERVICES — 0.8%** |  |  |  |  |
| 1575000 | United Rentals North America, Inc. |  | 3.8750 | 11/15/27 | 1565434 |
|  | **INSTITUTIONAL FINANCIAL SERVICES — 1.2%** |  |  |  |  |
| 2500000 | Nasdaq, Inc. |  | 5.3500 | 06/28/28 | 2581494 |
|  | **INSURANCE — 4.5%** |  |  |  |  |
| 2750000 | Aflac, Inc. |  | 1.1250 | 03/15/26 | 2735679 |
| 2650000 | Assurant, Inc. |  | 3.7000 | 02/22/30 | 2576897 |
| 2500000 | Brown & Brown, Inc. |  | 4.5000 | 03/15/29 | 2513923 |
| 1425000 | Pacific Life Global Funding II<sup>(a)</sup> |  | 1.3750 | 04/14/26 | 1414831 |
|  |  |  |  |  | 9241330 |
|  | **MACHINERY — 1.8%** |  |  |  |  |
| 1700000 | Mueller Water Products, Inc.<sup>(a)</sup> |  | 4.0000 | 06/15/29 | 1661143 |
| 2250000 | Xylem, Inc. |  | 1.9500 | 01/30/28 | 2160914 |
|  |  |  |  |  | 3822057 |
|  | **OIL & GAS PRODUCERS — 5.3%** |  |  |  |  |
| 2500000 | Cheniere Energy Partners, L.P. |  | 4.5000 | 10/01/29 | 2506963 |
| 2350000 | ConocoPhillips Company |  | 4.7000 | 01/15/30 | 2396577 |
| 2275000 | Diamondback Energy, Inc. |  | 3.5000 | 12/01/29 | 2209832 |
| 1400000 | EQT Corporation |  | 5.7000 | 04/01/28 | 1446254 |
| 2525000 | Plains All American Pipeline, L.P. / PAA Finance |  | 3.5500 | 12/15/29 | 2455866 |
|  |  |  |  |  | 11015492 |
|  | **REAL ESTATE INVESTMENT TRUSTS — 6.4%** |  |  |  |  |
| 1675000 | Alexandria Real Estate Equities, Inc. |  | 3.8000 | 04/15/26 | 1673149 |
| 2000000 | American Tower Corporation |  | 5.2500 | 07/15/28 | 2057403 |
| 3000000 | AvalonBay Communities, Inc. |  | 2.0500 | 01/15/32 | 2636864 |
| 2500000 | Equinix, Inc. |  | 1.5500 | 03/15/28 | 2373317 |
| 412000 | HAT Holdings I, LLC / HAT Holdings II, LLC<sup>(a)</sup> |  | 8.0000 | 06/15/27 | 427958 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **CORPORATE BONDS — 66.6% (Continued)** |  |  |  |  |
|  | **REAL ESTATE INVESTMENT TRUSTS — 6.4% (Continued)** |  |  |  |  |
| 1500000 | Iron Mountain, Inc.<sup>(a)</sup> |  | 5.2500 | 03/15/28 | $1508759 |
| 2500000 | Welltower OP, LLC |  | 2.7000 | 02/15/27 | 2468512 |
|  |  |  |  |  | 13145962 |
|  | **REAL ESTATE SERVICES — 1.3%** |  |  |  |  |
| 2625000 | CBRE Services, Inc. |  | 4.8000 | 06/15/30 | 2665265 |
|  | **RETAIL - DISCRETIONARY — 5.3%** |  |  |  |  |
| 1600000 | Asbury Automotive Group, Inc. |  | 4.5000 | 03/01/28 | 1601141 |
| 2500000 | AutoZone, Inc. |  | 4.5000 | 02/01/28 | 2525773 |
| 1800000 | Builders FirstSource, Inc.<sup>(a)</sup> |  | 5.0000 | 03/01/30 | 1796118 |
| 2400000 | Home Depot, Inc. (The) |  | 4.7500 | 06/25/29 | 2463205 |
| 2650000 | Lowe's Companies, Inc. |  | 4.2500 | 03/15/31 | 2642367 |
|  |  |  |  |  | 11028604 |
|  | **SEMICONDUCTORS — 3.3%** |  |  |  |  |
| 2000000 | Amkor Technology, Inc.<sup>(a)</sup> |  | 5.8750 | 10/01/33 | 2043757 |
| 1000000 | Broadcom, Inc. |  | 4.1100 | 09/15/28 | 1003290 |
| 2675000 | NXP BV / NXP Funding, LLC / NXP USA, Inc. |  | 2.5000 | 05/11/31 | 2424693 |
| 1325000 | Synaptics, Inc.<sup>(a)</sup> |  | 4.0000 | 06/15/29 | 1284092 |
|  |  |  |  |  | 6755832 |
|  | **SOFTWARE — 2.0%** |  |  |  |  |
| 2675000 | Roper Technologies, Inc. |  | 4.2000 | 09/15/28 | 2684177 |
| 1400000 | Workday, Inc. |  | 3.5000 | 04/01/27 | 1392538 |
|  |  |  |  |  | 4076715 |
|  | **SPECIALTY FINANCE — 1.4%** |  |  |  |  |
| 1750000 | American Express Company<sup>(b)</sup> | SOFRRATE + 0.810% | 4.3510 | 07/20/29 | 1763645 |
| 1150000 | American Express Company<sup>(b)</sup> | SOFRINDX + 1.020% | 5.0850 | 01/30/31 | 1186761 |
|  |  |  |  |  | 2950406 |
|  | **TECHNOLOGY SERVICES — 1.2%** |  |  |  |  |
| 2575000 | Verisk Analytics, Inc. |  | 4.1250 | 03/15/29 | 2572674 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  |  | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **CORPORATE BONDS — 66.6% (Continued)** | **CORPORATE BONDS — 66.6% (Continued)** | **CORPORATE BONDS — 66.6% (Continued)** |  |  |
|  | **WHOLESALE - CONSUMER STAPLES — 0.6%** | **WHOLESALE - CONSUMER STAPLES — 0.6%** | **WHOLESALE - CONSUMER STAPLES — 0.6%** |  |  |
| 1250000 | Sysco Corporation |  | 2.4000 | 02/15/30 | $1165047 |
|  | **TOTAL CORPORATE BONDS (Cost $135,922,202)** | **TOTAL CORPORATE BONDS (Cost $135,922,202)** | **TOTAL CORPORATE BONDS (Cost $135,922,202)** |  | 137645683 |
| **Principal** |  |  | **Coupon Rate** |  |  |
| **Amount ($)** |  |  | **(%)** | **Maturity** | **Fair Value** |
|  | **MUNICIPAL BONDS — 3.0%** |  |  |  |  |
|  | **COUNTY — 0.5%** |  |  |  |  |
| 1115000 | City & County of Honolulu, HI |  | 2.5180 | 10/01/26 | 1106319 |
|  | **SINGLE-FAMILY HOUSING — 2.5%** |  |  |  |  |
| 305000 | Illinois Housing Development Authority |  | 5.0940 | 04/01/30 | 313577 |
| 1000000 | Illinois Housing Development Authority |  | 5.2440 | 04/01/31 | 1043275 |
| 525000 | Illinois Housing Development Authority |  | 5.0530 | 04/01/32 | 539559 |
| 25000 | Maryland Community Development Administration |  | 3.2420 | 09/01/48 | 24936 |
| 490000 | Ohio Housing Finance Agency |  | 6.2500 | 03/01/32 | 540067 |
| 2150000 | Virginia Housing Development Authority |  | 4.8570 | 10/01/29 | 2212228 |
| 500000 | Virginia Housing Development Authority |  | 4.9140 | 04/01/30 | 515708 |
|  |  |  |  |  | 5189350 |
|  | **TOTAL MUNICIPAL BONDS (Cost $6,175,974)** |  |  |  | 6295669 |
| **Principal** |  |  | **Coupon Rate** |  |  |
| **Amount ($)** |  | **Spread** | **(%)** | **Maturity** | **Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 24.3%** |  |  |  |  |
|  | **AGENCY FIXED RATE — 12.7%** |  |  |  |  |
| 2529496 | Fannie Mae Pool MA5589 |  | 4.5000 | 01/01/40 | 2534608 |
| 1987030 | Fannie Mae Pool MA5914 |  | 4.0000 | 12/01/40 | 1963923 |
| 1742889 | Fannie Mae Pool MA5072 |  | 5.5000 | 06/01/53 | 1774818 |
| 1706168 | Fannie Mae Pool CB7331 |  | 5.5000 | 10/01/53 | 1739001 |
| 1358075 | Fannie Mae Pool MA5165 |  | 5.5000 | 10/01/53 | 1382328 |
| 791404 | Fannie Mae Pool FS9447 |  | 6.0000 | 12/01/53 | 815700 |
| 1788787 | Freddie Mac Pool SB8333 |  | 4.5000 | 10/01/39 | 1792401 |
| 2885859 | Freddie Mac Pool SB8355 |  | 3.5000 | 12/01/39 | 2810146 |
| 2243980 | Freddie Mac Pool SB8346 |  | 4.0000 | 12/01/39 | 2218412 |
| 2289341 | Freddie Mac Pool SB8347 |  | 4.0000 | 01/01/40 | 2263256 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 26.1% (Continued)** | **U.S. GOVERNMENT & AGENCIES — 26.1% (Continued)** | **U.S. GOVERNMENT & AGENCIES — 26.1% (Continued)** |  |  |
|  | **AGENCY FIXED RATE — 12.7% (Continued)** | **AGENCY FIXED RATE — 12.7% (Continued)** | **AGENCY FIXED RATE — 12.7% (Continued)** |  |  |
| 1452457 | Freddie Mac Pool SB1623 |  | 4.0000 | 08/01/40 | $1435908 |
| 1733111 | Freddie Mac Pool RR0036 |  | 4.0000 | 11/01/40 | 1712957 |
| 2000000 | Freddie Mac Pool RR0053 |  | 4.5000 | 01/01/41 | 2003580 |
| 959726 | Freddie Mac Pool SD8258 |  | 5.0000 | 10/01/52 | 962758 |
| 873306 | Ginnie Mae II Pool MA7107 |  | 2.5000 | 01/20/36 | 830129 |
|  |  |  |  |  | 26239925 |
|  | **AGENCY HYBRID ARMS** — **0.0%<sup>(g)</sup>** | **AGENCY HYBRID ARMS** — **0.0%<sup>(g)</sup>** | **AGENCY HYBRID ARMS** — **0.0%<sup>(g)</sup>** |  |  |
| 4827 | Ginnie Mae II Pool 82903<sup>(b)</sup> | H15T1Y + 1.500% | 5.3750 | 08/20/41 | 4935 |
|  | **ARMS** — **0.0%<sup>(g)</sup>** |  |  |  |  |
| 780 | Fannie Mae Pool 791573<sup>(b)</sup> | H15T1Y + 2.170% | 6.1700 | 08/01/34 | 801 |
| 7691 | Ginnie Mae II Pool 80569<sup>(b)</sup> | H15T1Y + 1.500% | 5.6250 | 01/20/32 | 7777 |
| 895 | Ginnie Mae II Pool 80659<sup>(b)</sup> | H15T1Y + 1.500% | 4.7500 | 12/20/32 | 904 |
|  |  |  |  |  | 9482 |
|  | **GOVERNMENT OWNED, NO GUARANTEE — 7.5%** | **GOVERNMENT OWNED, NO GUARANTEE — 7.5%** | **GOVERNMENT OWNED, NO GUARANTEE — 7.5%** |  |  |
| 2750000 | Federal Home Loan Mortgage Corporation |  | 6.7500 | 03/15/31 | 3137928 |
| 2500000 | Federal National Mortgage Association |  | 6.2500 | 05/15/29 | 2711886 |
| 2750000 | Federal National Mortgage Association |  | 7.1250 | 01/15/30 | 3107127 |
| 1500000 | Federal National Mortgage Association |  | 7.2500 | 05/15/30 | 1716058 |
| 2500000 | Federal National Mortgage Association |  | 6.6250 | 11/15/30 | 2822204 |
| 2000000 | Federal National Mortgage Association |  | 4.0300 | 12/11/30 | 1994795 |
|  |  |  |  |  | 15489998 |
|  | **GOVERNMENT SPONSORED — 5.9%** | **GOVERNMENT SPONSORED — 5.9%** | **GOVERNMENT SPONSORED — 5.9%** |  |  |
| 1250000 | Federal Farm Credit Banks Funding Corporation |  | 3.5000 | 06/23/27 | 1249553 |
| 2250000 | Federal Farm Credit Banks Funding Corporation |  | 4.3750 | 02/28/28 | 2285213 |
| 1500000 | Federal Farm Credit Banks Funding Corporation |  | 3.7800 | 06/08/28 | 1494084 |
| 1250000 | Federal Farm Credit Banks Funding Corporation |  | 3.3750 | 10/24/28 | 1245141 |
| 1750000 | Federal Farm Credit Banks Funding Corporation |  | 4.0000 | 04/01/30 | 1772160 |
| 1500000 | Federal Farm Credit Banks Funding Corporation |  | 1.4500 | 06/11/30 | 1353444 |

---

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal**<br>**Amount ($)** |  | <br>**Spread** | **Coupon Rate**<br>**(%)** | <br>**Maturity** |<br>**Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 26.1% (Continued)** | **U.S. GOVERNMENT & AGENCIES — 26.1% (Continued)** | **U.S. GOVERNMENT & AGENCIES — 26.1% (Continued)** |  |  |
|  | **GOVERNMENT SPONSORED — 5.9% (Continued)** | **GOVERNMENT SPONSORED — 5.9% (Continued)** | **GOVERNMENT SPONSORED — 5.9% (Continued)** |  |  |
| 1000000 | Federal Farm Credit Banks Funding Corporation |  | 4.0000 | 01/13/31 | $1010270 |
| 1795000 | Federal Farm Credit Banks Funding Corporation |  | 3.2500 | 07/28/32 | 1722527 |
|  |  |  |  |  | 12132392 |
|  | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $53,466,458)** | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $53,466,458)** | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $53,466,458)** |  | 53876732 |
|  | **TOTAL INVESTMENTS - 97.7% (Cost $199,664,300)** | **TOTAL INVESTMENTS - 97.7% (Cost $199,664,300)** | **TOTAL INVESTMENTS - 97.7% (Cost $199,664,300)** |  | $201929012 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 2.3%** | **OTHER ASSETS IN EXCESS OF LIABILITIES - 2.3%** | **OTHER ASSETS IN EXCESS OF LIABILITIES - 2.3%** |  | 4691860 |
|  | **NET ASSETS - 100.0%** | **NET ASSETS - 100.0%** | **NET ASSETS - 100.0%** |  | $206620872 |

---

---

| | |
|:---|:---|
| ABS | Asset Backed Security |
| LLC | Limited Liability Company |
| L.P. | Limited Partnership |
| H15T1Y | US Treasury Yield Curve Rate T Note Constant Maturity 1 Year |
| H15T5Y | US Treasury Yield Curve Rate T Note Constant Maturity 5 Year |
| SOFR30A | United States 30 Day Average SOFR Secured Overnight Financing Rate |
| SOFRINDX | United States SOFR Index |
| SOFRRATE | United States SOFR Secured Overnight Financing Rate |
| US0003M | ICE LIBOR USD 3 Month |

---

(a) Security
 exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt
 from registration, normally to qualified institutional buyers. As of December 31, 2025, the total market value of 144A securities
 is $24,661,932 or 11.9% of net assets.

(b) Variable
 or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments
 on the underlying pool of assets.

(c) Illiquid
 security. The total fair value of these securities as of December 31, 2025, was $2,235,971, representing 1.1% of net assets.

(d) Restricted
 security.

(e) Private
 investment.

(f) The
 value of this security has been determined using significant unobservable inputs in good faith under policies of the Board of Trustees.

(g) Percentage
 rounds to less than 0.1%.

See accompanying notes which are an integral part of these financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF ASSETS AND LIABILITIES (Unaudited)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |<br>**Eventide**<br>**Balanced** | **Eventide**<br>**Core Bond**<br>**Fund** | **Eventide**<br>**Dividend**<br>**Growth Fund** | **Eventide**<br>**Exponential**<br>**Technologies Fund** |<br>**Eventide**<br>**Gilead Fund** |
| **ASSETS** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Investment securities: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments at cost | $332560962 | $158090516 | $942594273 | $69836269 | $1423779865 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments at cost |  |  |  |  | 46787158 |
| &nbsp;&nbsp;&nbsp;Total Investments at cost | 332560962 | 158090516 | 942594273 | 69836269 | 1470567023 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments at value | $374004922 | $157697686 | $1139316646 | $89857274 | $2748414052 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments at value |  |  |  |  | 84284712 |
| &nbsp;&nbsp;&nbsp;Total investments at value | 374004922 | 157697686 | 1139316646 | 89857274 | 2832698764 |
| &nbsp;&nbsp;&nbsp;Cash held at custodian | 2979682 | 1927498 | 13179239 | 1149642 | 92134031 |
| &nbsp;&nbsp;&nbsp;Cash held at broker | 118222 |  | 114082 | 32701 | 184301 |
| &nbsp;&nbsp;&nbsp;Receivable for Fund shares sold | 302073 | 184959 | 754745 | 19584 | 2012726 |
| &nbsp;&nbsp;&nbsp;Dividends and interest receivable | 1894126 | 1653736 | 839295 | 24071 | 929025 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 52706 | 8877 | 159992 | 28322 | 89944 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL ASSETS** | 379351731 | 161472756 | 1154363999 | 91111594 | 2928048791 |
| **LIABILITIES** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Payable for Fund shares redeemed | 258251 | 44577 | 1475703 | 130553 | 1518571 |
| &nbsp;&nbsp;&nbsp;Advisory fees payable | 195828 | 21750 | 730971 | 72971 | 2487772 |
| &nbsp;&nbsp;&nbsp;Distribution (12b-1) fees payable | 115368 | 18610 | 196853 | 27017 | 173801 |
| &nbsp;&nbsp;&nbsp;Compliance officer fees payable | 2035 | 2046 | 3445 |  |  |
| &nbsp;&nbsp;&nbsp;Payable to related parties | 61537 | 28340 | 159618 | 20191 | 243544 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | 49084 | 74485 | 57446 | 62871 | 418735 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL LIABILITIES** | 682103 | 189808 | 2624036 | 313603 | 4842423 |
| **NET ASSETS** | $**378669628** | $**161282948** | $**1151739963** | $**90797991** | $**2923206368** |
| **Composition of Net Assets:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Paid in capital | $334665665 | $176615341 | $942188558 | $102821010 | $1437349878 |
| &nbsp;&nbsp;&nbsp;Accumulated earnings (losses) | 44003963 | (15332393) | 209551405 | (12023019) | 1485856490 |
| **NET ASSETS** | $**378669628** | $**161282948** | $**1151739963** | $**90797991** | $**2923206368** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF ASSETS AND LIABILITIES (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |<br>**Eventide**<br>**Balanced** | **Eventide**<br>**Core Bond**<br>**Fund** | **Eventide**<br>**Dividend**<br>**Growth Fund** | **Eventide**<br>**Exponential**<br>**Technologies Fund** |<br>**Eventide**<br>**Gilead Fund** |
| **Net Asset Value Per Share:** |  |  |  |  |  |
| Class N Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**15412820** | $**38443997** | $**70630966** | $**15775764** | $**292129016** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **1079560** | **4613559** | **3709121** | **1091757** | **5348971** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $**14.28** | $**8.33** | $**19.04** | $**14.45** | $**54.61** |
| Class A Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**41430329** | $**1822930** | $**65793856** | $**8611310** | $**329960163** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **2899650** | **217823** | **3453359** | **596602** | **6097385** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding) and redemption price per share | $**14.29** | $**8.37** | $**19.05** | $**14.43** | $**54.12** |
| &nbsp;&nbsp;&nbsp;Maximum offering price per share (net asset value plus maximum sales charge of 5.75%) | $**15.16** | $**8.88** | $**20.21** | $**15.31** | $**57.42** |
| Class C Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**16918049** | $**602938** | $**26627698** | $**2018421** | $**140379536** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **1193712** | **72849** | **1423200** | **145781** | **3075026** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $**14.17** | $**8.28** | $**18.71** | $**13.85** | $**45.65** |
| Class I Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**304908430** | $**120413083** | $**988687443** | $**64392496** | $**2160737653** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **21381590** | **14448851** | **51872174** | **4405150** | **37943546** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $**14.26** | $**8.33** | $**19.06** | $**14.62** | $**56.95** |

---

<sup>(a)</sup> Unlimited number of shares of beneficial interest authorized, no par value.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF ASSETS AND LIABILITIES (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Eventide**<br>**Healthcare &**<br>**Life Sciences Fund** | **Eventide**<br>**Large Cap**<br>**Focus Fund** | **Eventide**<br>**Limited-Term**<br>**Bond Fund** |
| **ASSETS** |  |  |  |
| &nbsp;&nbsp;&nbsp;Investment securities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments at cost | $1101913001 | $147979895 | $199664300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments at cost | 60438512 |  |  |
| &nbsp;&nbsp;&nbsp;Investments at cost | 1162351513 | 147979895 | 199664300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments at value | $1586016392 | $172984296 | $201929012 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments at value | 57478410 |  |  |
| &nbsp;&nbsp;&nbsp;Total investments at value | 1643494802 | 172984296 | 201929012 |
| &nbsp;&nbsp;&nbsp;Cash held at custodian | 42403902 | 3821434 | 2646450 |
| &nbsp;&nbsp;&nbsp;Cash held at broker | 123227 |  |  |
| &nbsp;&nbsp;&nbsp;Receivable for securities sold | 6670910 |  |  |
| &nbsp;&nbsp;&nbsp;Receivable for Fund shares sold | 741027 | 298859 | 357469 |
| &nbsp;&nbsp;&nbsp;Dividends and interest receivable | 439782 | 94089 | 2010857 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 53491 | 67659 | 48241 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL ASSETS** | 1693927141 | 177266337 | 206992029 |
| **LIABILITIES** |  |  |  |
| &nbsp;&nbsp;&nbsp;Payable for investments purchased | 2593942 |  |  |
| &nbsp;&nbsp;&nbsp;Payable for Fund shares redeemed | 679151 | 171898 | 270548 |
| &nbsp;&nbsp;&nbsp;Advisory fees payable | 1587433 | 88224 | 23467 |
| &nbsp;&nbsp;&nbsp;Distribution (12b-1) fees payable | 99196 |  | 9788 |
| &nbsp;&nbsp;&nbsp;Compliance officer fees payable |  | 1572 | 1152 |
| &nbsp;&nbsp;&nbsp;Payable to related parties | 170213 | 27656 | 26409 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | 351043 | 107855 | 39793 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL LIABILITIES** | 5480978 | 397205 | 371157 |
| **NET ASSETS** | $**1688446163** | $**176869132** | $**206620872** |
| **Composition of Net Assets:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Paid in capital | $1085272717 | $152599943 | $213351232 |
| &nbsp;&nbsp;&nbsp;Accumulated earnings (losses) | 603173446 | 24269189 | (6730360) |
| **NET ASSETS** | $**1688446163** | $**176869132** | $**206620872** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF ASSETS AND LIABILITIES (Unaudited) (Continued)** |
| **December 31, 2025** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Eventide**<br>**Healthcare &**<br>**Life Sciences Fund** | **Eventide**<br>**Large Cap**<br>**Focus Fund** | **Eventide**<br>**Limited-Term**<br>**Bond Fund** |
| **Net Asset Value Per Share:** |  |  |  |
| Class N Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**81042390** | $**9355504** | $**19030393** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **1596266** | **607922** | **1871018** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $**50.77** | $**15.39** | $**10.17** |
| Class A Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**141884929** | $**7353069** | $**4782703** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **2818700** | **479024** | **468968** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding) and redemption price per share | $**50.34** | $**15.35** | $**10.20** |
| &nbsp;&nbsp;&nbsp;Maximum offering price per share (net asset value plus maximum sales charge of 5.75%) | $**53.41** | $**16.29** | $**10.82** |
| Class C Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**51352923** | $**1709289** | $**1578491** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **1132051** | **113846** | **155929** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $**45.36** | $**15.01** | $**10.12** |
| Class I Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**1414165921** | $**158451270** | $**181229285** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **27125462** | **10257197** | **17331072** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $**52.13** | $**15.45** | $**10.46** |

---

<sup>(a)</sup> Unlimited number of shares of beneficial interest authorized, no par value.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF OPERATIONS (Unaudited)** |
| **For the Six Months Ended December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |<br>**Eventide**<br>**Balanced** | **Eventide**<br>**Core Bond**<br>**Fund** | **Eventide**<br>**Dividend**<br>**Growth Fund** | **Eventide**<br>**Exponential**<br>**Technologies Fund** |<br>**Eventide**<br>**Gilead Fund** |
| **INVESTMENT INCOME** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Dividend income | $3946516 | $— | $8355653 | $59276 | $4453706 |
| &nbsp;&nbsp;&nbsp;Interest | 1639988 | 3680202 | 370813 | 66769 | 2209861 |
| &nbsp;&nbsp;&nbsp;Less: Foreign dividend withholding taxes |  |  |  | (3435) | (115372) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL INVESTMENT INCOME** | 5586504 | 3680202 | 8726466 | 122610 | 6548195 |
| **EXPENSES** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Investment advisory fees | 1171250 | 261788 | 4423542 | 474576 | 14378302 |
| &nbsp;&nbsp;&nbsp;Distribution (12b-1) fees: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class N | 16783 | 38590 | 77353 | 17421 | 297903 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class A | 50434 | 1711 | 83707 | 10501 | 404149 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class C | 85099 | 3023 | 137862 | 10539 | 712957 |
| &nbsp;&nbsp;&nbsp;Shareholder servicing fees | 144541 | 124831 | 608884 | 71122 | 1165877 |
| &nbsp;&nbsp;&nbsp;Financial administration/fund accounting fees | 81005 | 31932 | 169183 | 26102 | 392619 |
| &nbsp;&nbsp;&nbsp;Legal administration/management services fees | 40919 | 16132 | 127041 | 9940 | 305963 |
| &nbsp;&nbsp;&nbsp;Registration fees | 36800 | 25760 | 59800 | 34960 | 59800 |
| &nbsp;&nbsp;&nbsp;Transfer agent fees | 26768 | 16358 | 48627 | 15555 | 117313 |
| &nbsp;&nbsp;&nbsp;Printing and postage expenses | 16589 | 6751 | 92000 | 11371 | 79896 |
| &nbsp;&nbsp;&nbsp;Custodian fees | 12433 | 6438 | 34605 | 6068 | 71872 |
| &nbsp;&nbsp;&nbsp;Legal fees | 12365 | 7117 | 8473 | 7618 | 8122 |
| &nbsp;&nbsp;&nbsp;Compliance officer fees | 11123 | 8190 | 21970 | 4173 | 39234 |
| &nbsp;&nbsp;&nbsp;Trustees fees and expenses | 9686 | 9647 | 9673 | 9686 | 7290 |
| &nbsp;&nbsp;&nbsp;Audit fees | 7544 | 5958 | 21620 | 6525 | 104214 |
| &nbsp;&nbsp;&nbsp;Insurance expense | 6440 | 1840 | 10120 | 1840 | 55200 |
| &nbsp;&nbsp;&nbsp;Other expenses | 1840 | 1840 | 3680 | 1840 | 7360 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL EXPENSES** | 1731619 | 567906 | 5938140 | 719837 | 18208071 |
| &nbsp;&nbsp;&nbsp;Less: Fees waived/reimbursed by the Adviser |  | (129597) |  | (28634) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET EXPENSES** | 1731619 | 438309 | 5938140 | 691203 | 18208071 |
| **NET INVESTMENT INCOME (LOSS)** | 3854885 | 3241893 | 2788326 | (568593) | (11659876) |
| **REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments | 6207683 | 384215 | 23345977 | 16357207 | 233521950 |
| &nbsp;&nbsp;&nbsp;**Net realized gain (loss):** | 6207683 | 384215 | 23345977 | 16357207 | 233521950 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments | (925467) | 1609540 | (10404501) | (8999792) | 111160934 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments (See Note 5) |  |  |  |  | 44009510 |
| &nbsp;&nbsp;&nbsp;**Net change in unrealized appreciation (depreciation):** | (925467) | 1609540 | (10404501) | (8999792) | 155170444 |
| **NET REALIZED AND UNREALIZED GAIN FROM INVESTMENTS** | 5282216 | 1993755 | 12941476 | 7357415 | 388692394 |
| **NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS** | $**9137101** | $**5235648** | $**15729802** | $**6788822** | $**377032518** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF OPERATIONS (Unaudited) (Continued)** |
| **For the Six Months Ended December 31, 2025** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Eventide**<br>**Healthcare &**<br>**Life Sciences Fund** | **Eventide**<br>**Large Cap**<br>**Focus Fund** | **Eventide**<br>**Limited-Term**<br>**Bond Fund** |
| **INVESTMENT INCOME** |  |  |  |
| &nbsp;&nbsp;&nbsp;Dividend income | $— | $885546 | $— |
| &nbsp;&nbsp;&nbsp;Interest | 1421298 | 68405 | 3985530 |
| &nbsp;&nbsp;&nbsp;Less: Foreign dividend withholding taxes | (7938) | (3102) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL INVESTMENT INCOME** | 1413360 | 950849 | 3985530 |
| **EXPENSES** |  |  |  |
| &nbsp;&nbsp;&nbsp;Investment advisory fees | 7767275 | 639596 | 282579 |
| &nbsp;&nbsp;&nbsp;Distribution (12b-1) fees: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class N | 69659 | 9745 | 18135 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class A | 149310 | 7631 | 5781 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class C | 223185 | 7080 | 8193 |
| &nbsp;&nbsp;&nbsp;Shareholder servicing fees | 676204 | 166749 | 87481 |
| &nbsp;&nbsp;&nbsp;Financial administration/fund accounting fees | 201363 | 41124 | 42037 |
| &nbsp;&nbsp;&nbsp;Legal administration/management services fees | 147586 | 18352 | 19086 |
| &nbsp;&nbsp;&nbsp;Transfer agent fees | 75845 | 21324 | 14852 |
| &nbsp;&nbsp;&nbsp;Printing and postage expenses | 57307 | 10387 | 17404 |
| &nbsp;&nbsp;&nbsp;Registration fees | 46000 | 41400 | 36800 |
| &nbsp;&nbsp;&nbsp;Audit fees | 36772 | 9019 | 8639 |
| &nbsp;&nbsp;&nbsp;Custodian fees | 36058 | 6004 | 5005 |
| &nbsp;&nbsp;&nbsp;Insurance expense | 26680 | 920 | 2760 |
| &nbsp;&nbsp;&nbsp;Compliance officer fees | 20124 | 7178 | 7610 |
| &nbsp;&nbsp;&nbsp;Legal fees | 11686 | 12302 | 9263 |
| &nbsp;&nbsp;&nbsp;Trustees fees and expenses | 10122 | 9686 | 9686 |
| &nbsp;&nbsp;&nbsp;Other expenses | 5520 | 1840 | 1840 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL EXPENSES** | 9560696 | 1010337 | 577151 |
| &nbsp;&nbsp;&nbsp;Less: Fees waived/reimbursed by the Adviser |  | (161871) | (105392) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET EXPENSES** | 9560696 | 848466 | 471759 |
| **NET INVESTMENT INCOME (LOSS)** | (8147336) | 102383 | 3513771 |
| **REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) from: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments | 283485379 | 630569 | (15702) |
| &nbsp;&nbsp;&nbsp;**Net realized gain (loss):** | 283485379 | 630569 | (15702) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments | 285895574 | 2686070 | 1316952 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments (See Note 5) | 30025101 |  |  |
| &nbsp;&nbsp;&nbsp;**Net change in unrealized appreciation (depreciation):** | 315920675 | 2686070 | 1316952 |
| **NET REALIZED AND UNREALIZED GAIN FROM INVESTMENTS** | 599406054 | 3316639 | 1301250 |
| **NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS** | $**591258718** | $**3419022** | $**4815021** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** | |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $3854885 | $7277439 |
| &nbsp;&nbsp;&nbsp;Net realized gain | 6207683 | 23798429 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) | (925467) | 273040 |
| Net increase in net assets resulting from operations | 9137101 | 31348908 |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;From Accumulated Earnings |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (788052) | (343693) |
| &nbsp;&nbsp;&nbsp;Class A | (2039892) | (592586) |
| &nbsp;&nbsp;&nbsp;Class C | (776049) | (171720) |
| &nbsp;&nbsp;&nbsp;Class I | (15689816) | (6417037) |
| Total distributions to shareholders | (19293809) | (7525036) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 1726826 | 5425454 |
| &nbsp;&nbsp;&nbsp;Class A | 6711943 | 10050801 |
| &nbsp;&nbsp;&nbsp;Class C | 1455278 | 3676253 |
| &nbsp;&nbsp;&nbsp;Class I | 36031999 | 79882967 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 732406 | 320908 |
| &nbsp;&nbsp;&nbsp;Class A | 1916965 | 541839 |
| &nbsp;&nbsp;&nbsp;Class C | 742409 | 161394 |
| &nbsp;&nbsp;&nbsp;Class I | 14815582 | 5855202 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (5210948) | (10887263) |
| &nbsp;&nbsp;&nbsp;Class A | (3233039) | (5652475) |
| &nbsp;&nbsp;&nbsp;Class C | (1688379) | (4011035) |
| &nbsp;&nbsp;&nbsp;Class I | (52217141) | (101665264) |
| Net increase (decrease) in net assets from shares of beneficial interest | 1783901 | (16301219) |
| **TOTAL INCREASE (DECREASE) IN NET ASSETS** | (8372807) | 7522653 |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 387042435 | 379519782 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**378669628** | $**387042435** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** | |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 116457 | 379280 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 50927 | 22262 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (353003) | (755446) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (185619) | (353904) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 450916 | 703397 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 133092 | 37532 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (217221) | (393817) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 366787 | 347112 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 98721 | 256631 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 52086 | 11261 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (114407) | (279902) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 36400 | (12010) |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 2432045 | 5556351 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 1029854 | 406334 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (3524888) | (7087635) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (62989) | (1124950) |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** | |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $3241893 | $6146010 |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) | 384215 | (1388720) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation | 1609540 | 3590668 |
| Net increase in net assets resulting from operations | 5235648 | 8347958 |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;From Accumulated Earnings |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (804288) | (1457744) |
| &nbsp;&nbsp;&nbsp;Class A | (33349) | (31197) |
| &nbsp;&nbsp;&nbsp;Class C | (10078) | (19228) |
| &nbsp;&nbsp;&nbsp;Class I | (2518491) | (4645541) |
| Total distributions to shareholders | (3366206) | (6153710) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 2315228 | 6594772 |
| &nbsp;&nbsp;&nbsp;Class A | 888849 | 364509 |
| &nbsp;&nbsp;&nbsp;Class C | 28834 | 186531 |
| &nbsp;&nbsp;&nbsp;Class I | 26888828 | 57015246 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 802600 | 1454517 |
| &nbsp;&nbsp;&nbsp;Class A | 33262 | 31036 |
| &nbsp;&nbsp;&nbsp;Class C | 9898 | 18491 |
| &nbsp;&nbsp;&nbsp;Class I | 1676089 | 3031515 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (2760924) | (6539391) |
| &nbsp;&nbsp;&nbsp;Class A | (85753) | (38702) |
| &nbsp;&nbsp;&nbsp;Class C | (87504) | (61906) |
| &nbsp;&nbsp;&nbsp;Class I | (19066598) | (52785061) |
| Net increase in net assets from shares of beneficial interest | 10642809 | 9271557 |
| **TOTAL INCREASE IN NET ASSETS** | 12512251 | 11465805 |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 148770697 | 137304892 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**161282948** | $**148770697** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** | |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 277942 | 801510 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 96289 | 177427 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (330950) | (796295) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 43281 | 182642 |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 105597 | 44589 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 3973 | 3768 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (10262) | (4718) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 99308 | 43639 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 3469 | 22941 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 1196 | 2273 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (10639) | (7652) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (5974) | 17562 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 3221761 | 6939005 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 201077 | 369931 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (2289580) | (6454977) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 1133258 | 853959 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** | |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $2788326 | $6167647 |
| &nbsp;&nbsp;&nbsp;Net realized gain | 23345977 | 56088289 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) | (10404501) | 32216411 |
| Net increase in net assets resulting from operations | 15729802 | 94472347 |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;From Accumulated Earnings |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (4760710) | (395039) |
| &nbsp;&nbsp;&nbsp;Class A | (1991702) | (282723) |
| &nbsp;&nbsp;&nbsp;Class C | (788774) |  |
| &nbsp;&nbsp;&nbsp;Class I | (29040720) | (6375869) |
| Total distributions to shareholders | (36581906) | (7053631) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 8023497 | 29707917 |
| &nbsp;&nbsp;&nbsp;Class A | 6694037 | 21230753 |
| &nbsp;&nbsp;&nbsp;Class C | 2388111 | 9391939 |
| &nbsp;&nbsp;&nbsp;Class I | 195580759 | 543513016 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 2152274 | 387623 |
| &nbsp;&nbsp;&nbsp;Class A | 1918287 | 273316 |
| &nbsp;&nbsp;&nbsp;Class C | 753262 |  |
| &nbsp;&nbsp;&nbsp;Class I | 28113656 | 5640651 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (15583398) | (48828521) |
| &nbsp;&nbsp;&nbsp;Class A | (7240086) | (11453642) |
| &nbsp;&nbsp;&nbsp;Class C | (2991355) | (3918430) |
| &nbsp;&nbsp;&nbsp;Class I | (249903460) | (294590525) |
| Net increase (decrease) in net assets from shares of beneficial interest | (30094416) | 251354097 |
| **TOTAL INCREASE (DECREASE) IN NET ASSETS** | (50946520) | 338772813 |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 1202686483 | 863913670 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**1151739963** | $**1202686483** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** | |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 409441 | 1588817 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 112476 | 20467 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (794683) | (2585707) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (272766) | (976423) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 341497 | 1121380 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 100222 | 14439 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (368527) | (606903) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 73192 | 528916 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 123579 | 506317 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 40153 |  |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (154400) | (209307) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 9332 | 297010 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 9953011 | 28790641 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 1465866 | 298143 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (12703830) | (15726135) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (1284953) | 13362649 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** |  |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss | $(568593) | $(1236875) |
| &nbsp;&nbsp;&nbsp;Net realized gain | 16357207 | 10770538 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) | (8999792) | 2805100 |
| Net increase in net assets resulting from operations | 6788822 | 12338763 |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 1459741 | 3229416 |
| &nbsp;&nbsp;&nbsp;Class A | 575007 | 842122 |
| &nbsp;&nbsp;&nbsp;Class C | 46510 | 221228 |
| &nbsp;&nbsp;&nbsp;Class I | 18219631 | 24547146 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (6488362) | (5292622) |
| &nbsp;&nbsp;&nbsp;Class A | (663456) | (2056176) |
| &nbsp;&nbsp;&nbsp;Class C | (316086) | (877078) |
| &nbsp;&nbsp;&nbsp;Class I | (26111104) | (51152017) |
| Net decrease in net assets from shares of beneficial interest | (13278119) | (30537981) |
| **TOTAL DECREASE IN NET ASSETS** | (6489297) | (18199218) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 97287288 | 115486506 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**90797991** | $**97287288** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** | |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 104532 | 260846 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (457111) | (421353) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (352579) | (160507) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 40243 | 67380 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (47730) | (167294) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (7487) | (99914) |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 3459 | 18259 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (23365) | (72221) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (19906) | (53962) |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 1291164 | 1972841 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (1846118) | (4082214) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (554954) | (2109373) |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** | |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss | $(11659876) | $(24104866) |
| &nbsp;&nbsp;&nbsp;Net realized gain | 233521950 | 395938818 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation | 155170444 | 4950162 |
| Net increase in net assets resulting from operations | 377032518 | 376784114 |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (33320111) | (4820502) |
| &nbsp;&nbsp;&nbsp;Class A | (37654283) | (3949917) |
| &nbsp;&nbsp;&nbsp;Class C | (18693488) | (2226342) |
| &nbsp;&nbsp;&nbsp;Class I | (238279303) | (26484044) |
| Total distributions to shareholders | (327947185) | (37480805) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 11809945 | 31028381 |
| &nbsp;&nbsp;&nbsp;Class A | 14539575 | 23458379 |
| &nbsp;&nbsp;&nbsp;Class C | 2664910 | 6120741 |
| &nbsp;&nbsp;&nbsp;Class I | 460501827 | 372043932 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 30797598 | 4569532 |
| &nbsp;&nbsp;&nbsp;Class A | 34880452 | 3671233 |
| &nbsp;&nbsp;&nbsp;Class C | 18299801 | 2175853 |
| &nbsp;&nbsp;&nbsp;Class I | 207385012 | 23101297 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (44278487) | (214388138) |
| &nbsp;&nbsp;&nbsp;Class A | (30511997) | (75482610) |
| &nbsp;&nbsp;&nbsp;Class C | (18727548) | (50191326) |
| &nbsp;&nbsp;&nbsp;Class I | (603472433) | (1024515333) |
| Net increase (decrease) in net assets from shares of beneficial interest | 83888655 | (898408059) |
| **TOTAL INCREASE (DECREASE) IN NET ASSETS** | 132973988 | (559104750) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 2790232380 | 3349337130 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**2923206368** | $**2790232380** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** |  |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 203937 | 628223 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 565924 | 88113 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (763911) | (4257788) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 5950 | (3541452) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 254482 | 475760 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 646893 | 71328 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (540051) | (1526527) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 361324 | (979439) |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 54735 | 143311 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 402193 | 48699 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (383048) | (1174308) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 73880 | (982298) |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 7616573 | 7269688 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 3655006 | 430032 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (10000333) | (19909056) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 1271246 | (12209336) |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** |  |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss | $(8147336) | $(15555357) |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) | 283485379 | (102612386) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized depreciation | 315920675 | 112061054 |
| Net increase (decrease) in net assets resulting from operations | 591258718 | (6106689) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 8341175 | 9067271 |
| &nbsp;&nbsp;&nbsp;Class A | 5061929 | 7849699 |
| &nbsp;&nbsp;&nbsp;Class C | 1041524 | 2315607 |
| &nbsp;&nbsp;&nbsp;Class I | 279367090 | 282230941 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (16027119) | (42738482) |
| &nbsp;&nbsp;&nbsp;Class A | (10565752) | (32541536) |
| &nbsp;&nbsp;&nbsp;Class C | (5671104) | (20154252) |
| &nbsp;&nbsp;&nbsp;Class I | (310229865) | (493968741) |
| Net decrease in net assets from shares of beneficial interest | (48682122) | (287939493) |
| **TOTAL INCREASE (DECREASE) IN NET ASSETS** | 542576596 | (294046182) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 1145869567 | 1439915749 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**1688446163** | $**1145869567** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** |  |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 189369 | 271626 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (392445) | (1266000) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (203076) | (994374) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 120088 | 234866 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (262536) | (979214) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (142448) | (744348) |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 26580 | 76653 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (152042) | (667547) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (125462) | (590894) |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 6305077 | 8291869 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (7102651) | (14654078) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (797574) | (6362209) |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **STATEMENT OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** |  |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $102383 | $468178 |
| &nbsp;&nbsp;&nbsp;Net realized gain | 630569 | 1634873 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation | 2686070 | 14793770 |
| Net increase in net assets resulting from operations | 3419022 | 16896821 |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;From Accumulated Earnings |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (54107) | (588763) |
| &nbsp;&nbsp;&nbsp;Class A | (40495) | (97241) |
| &nbsp;&nbsp;&nbsp;Class C | (6772) | (15297) |
| &nbsp;&nbsp;&nbsp;Class I | (991032) | (4748135) |
| Total distributions to shareholders | (1092406) | (5449436) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 1025706 | 8576462 |
| &nbsp;&nbsp;&nbsp;Class A | 3267413 | 2398308 |
| &nbsp;&nbsp;&nbsp;Class C | 734043 | 760700 |
| &nbsp;&nbsp;&nbsp;Class I | 35939910 | 97554183 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 51540 | 583567 |
| &nbsp;&nbsp;&nbsp;Class A | 40426 | 96969 |
| &nbsp;&nbsp;&nbsp;Class C | 6772 | 15209 |
| &nbsp;&nbsp;&nbsp;Class I | 947482 | 4498959 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (1125864) | (13716586) |
| &nbsp;&nbsp;&nbsp;Class A | (401536) | (195278) |
| &nbsp;&nbsp;&nbsp;Class C | (56380) | (118297) |
| &nbsp;&nbsp;&nbsp;Class I | (29280020) | (54691740) |
| Net increase in net assets from shares of beneficial interest | 11149492 | 45762456 |
| **TOTAL INCREASE IN NET ASSETS** | 13476108 | 57209841 |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 163393024 | 106183183 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**176869132** | $**163393024** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **STATEMENT OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** |  |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 65914 | 594653 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 3335 | 40471 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (72450) | (958678) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (3201) | (323554) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 209631 | 168731 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 2623 | 6740 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (25909) | (14036) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 186345 | 161435 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 48373 | 54985 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 451 | 1075 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (3677) | (8544) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 45147 | 47516 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 2300552 | 6782956 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 61022 | 311160 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (1875734) | (3799719) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 485840 | 3294397 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** |  |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $3513771 | $5674693 |
| &nbsp;&nbsp;&nbsp;Net realized loss | (15702) | (411501) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation | 1316952 | 3761607 |
| Net increase in net assets resulting from operations | 4815021 | 9024799 |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;From Accumulated Earnings |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (347340) | (641154) |
| &nbsp;&nbsp;&nbsp;Class A | (87053) | (159723) |
| &nbsp;&nbsp;&nbsp;Class C | (24830) | (43540) |
| &nbsp;&nbsp;&nbsp;Class I | (3137966) | (4795342) |
| Total distributions to shareholders | (3597189) | (5639759) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 2577761 | 3245212 |
| &nbsp;&nbsp;&nbsp;Class A | 798658 | 1423790 |
| &nbsp;&nbsp;&nbsp;Class C | 190999 | 430944 |
| &nbsp;&nbsp;&nbsp;Class I | 51086021 | 72438989 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 347203 | 640240 |
| &nbsp;&nbsp;&nbsp;Class A | 84080 | 154867 |
| &nbsp;&nbsp;&nbsp;Class C | 24830 | 43461 |
| &nbsp;&nbsp;&nbsp;Class I | 2901301 | 4502624 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (1371044) | (4852608) |
| &nbsp;&nbsp;&nbsp;Class A | (508864) | (1907385) |
| &nbsp;&nbsp;&nbsp;Class C | (250638) | (468802) |
| &nbsp;&nbsp;&nbsp;Class I | (19684242) | (55654936) |
| Net increase in net assets from shares of beneficial interest | 36196065 | 19996396 |
| **TOTAL INCREASE IN NET ASSETS** | 37413897 | 23381436 |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 169206975 | 145825539 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**206620872** | $**169206975** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Six Months Ended**<br>**December 31, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2025** |
|  | **(Unaudited)** |  |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 253689 | 323561 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 34230 | 63922 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (135042) | (484366) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 152877 | (96883) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 78481 | 141565 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 8268 | 15420 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (49967) | (190011) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 36782 | (33026) |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 18886 | 43235 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 2459 | 4359 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (24800) | (47069) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (3455) | 525 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 4889319 | 7038609 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 278212 | 437711 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (1887055) | (5414576) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 3280476 | 2061744 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $14.66 | $13.78 | $12.44 | $12.12 | $14.21 | $11.38 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.14 | 0.25 | 0.19 | 0.16 | 0.10 | 0.08 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.22 | 0.89 | 1.35 | 0.47 | (1.35) | 2.95 |
| Total from investment operations | 0.36 | 1.14 | 1.54 | 0.63 | (1.25) | 3.03 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.14) | (0.26) | (0.20) | (0.15) | (0.21) | (0.18) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.60) |  |  | (0.12) | (0.63) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.04) |  |  |
| Total distributions | (0.74) | (0.26) | (0.20) | (0.31) | (0.84) | (0.20) |
| Net asset value, end of period/year | $14.28 | $14.66 | $13.78 | $12.44 | $12.12 | $14.21 |
| Total return (2) | 2.46% (6)(7) | 8.34% | 12.52% | 5.35% | (9.58)% | 26.81% |
| Net assets, at end of period/year (000s) | $15413 | $18547 | $22308 | $30618 | $34856 | $39947 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.00% (8) | 1.02% | 1.09% | 1.10% | 1.01% | 1.05% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.00% (8) | 1.02% | 1.02% | 1.02% | 1.02% | 1.02% |
| Ratio of net investment income to average net assets (4)(5) | 1.84% (8) | 1.74% | 1.51% | 1.34% | 0.69% | 0.59% |
| Portfolio Turnover Rate | 18% (7) | 55% | 43% | 48% | 66% | 73% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements/recapture by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Includes adjustments in accordance
 with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting
 purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(7) Not annualized.

(8) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $14.69 | $13.81 | $12.46 | $12.14 | $14.22 | $11.38 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.14 | 0.25 | 0.19 | 0.16 | 0.09 | 0.07 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.19 | 0.88 | 1.36 | 0.47 | (1.33) | 2.96 |
| Total from investment operations | 0.33 | 1.13 | 1.55 | 0.63 | (1.24) | 3.03 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.13) | (0.25) | (0.20) | (0.15) | (0.21) | (0.17) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.60) |  |  | (0.12) | (0.63) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.04) |  |  |
| Total distributions | (0.73) | (0.25) | (0.20) | (0.31) | (0.84) | (0.19) |
| Net asset value, end of period/year | $14.29 | $14.69 | $13.81 | $12.46 | $12.14 | $14.22 |
| Total return (2) | 2.29% (7) | 8.27% | 12.53% (6) | 5.29% | (9.55)% | 26.84% |
| Net assets, at end of period/year (000s) | $41430 | $37205 | $30175 | $25577 | $25744 | $23139 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.05% (8) | 1.07% | 1.14% | 1.15% | 1.06% | 1.10% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.05% (8) | 1.07% | 1.07% | 1.07% | 1.07% | 1.07% |
| Ratio of net investment income to average net assets (4)(5) | 1.79% (8) | 1.72% | 1.47% | 1.32% | 0.65% | 0.55% |
| Portfolio Turnover Rate | 18% (7) | 55% | 43% | 48% | 66% | 73% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the adviser not waived a portion
 of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements/recapture by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Includes adjustments in accordance
 with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting
 purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(7) Not annualized.

(8) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $14.58 | $13.70 | $12.38 | $12.06 | $14.15 | $11.34 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | 0.08 | 0.14 | 0.09 | 0.07 | (0.01) | (0.03) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.19 | 0.89 | 1.34 | 0.47 | (1.35) | 2.95 |
| Total from investment operations | 0.27 | 1.03 | 1.43 | 0.54 | (1.36) | 2.92 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.08) | (0.15) | (0.11) | (0.06) | (0.10) | (0.09) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.60) |  |  | (0.12) | (0.63) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.04) |  |  |
| Total distributions | (0.68) | (0.15) | (0.11) | (0.22) | (0.73) | (0.11) |
| Net asset value, end of period/year | $14.17 | $14.58 | $13.70 | $12.38 | $12.06 | $14.15 |
| Total return (2) | 1.85% (6) | 7.52% | 11.58% | 4.54% | (10.33)% | 25.85% |
| Net assets, at end of period/year (000s) | $16918 | $16869 | $16020 | $16181 | $18146 | $18883 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.80% (7) | 1.82% | 1.89% | 1.90% | 1.81% | 1.85% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.80% (7) | 1.82% | 1.82% | 1.82% | 1.82% | 1.82% |
| Ratio of net investment income (loss) to average net assets (4)(5) | 1.04% (7) | 0.96% | 0.72% | 0.56% | (0.10)% | (0.21)% |
| Portfolio Turnover Rate | 18% (6) | 55% | 43% | 48% | 66% | 73% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements/recapture by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income (loss) to average net assets do not reflect the expenses of the underlying investment companies in
 which the Fund invests.

(5) Recognition of net investment income
 (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $14.66 | $13.78 | $12.44 | $12.12 | $14.22 | $11.38 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.16 | 0.28 | 0.22 | 0.19 | 0.12 | 0.11 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.20 | 0.89 | 1.35 | 0.47 | (1.35) | 2.95 |
| Total from investment operations | 0.36 | 1.17 | 1.57 | 0.66 | (1.23) | 3.06 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.16) | (0.29) | (0.23) | (0.18) | (0.24) | (0.20) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.60) |  |  | (0.12) | (0.63) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.04) |  |  |
| Total distributions | (0.76) | (0.29) | (0.23) | (0.34) | (0.87) | (0.22) |
| Net asset value, end of period/year | $14.26 | $14.66 | $13.78 | $12.44 | $12.12 | $14.22 |
| Total return (2) | 2.43% (6) | 8.55% | 12.75% | 5.57% | (9.46)% | 27.12% |
| Net assets, at end of period/year (000s) | $304908 | $314422 | $311017 | $260688 | $269421 | $279142 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 0.80% (7) | 0.82% | 0.89% | 0.90% | 0.81% | 0.85% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 0.80% (7) | 0.82% | 0.82% | 0.82% | 0.82% | 0.82% |
| Ratio of net investment income to average net assets (4)(5) | 2.04% (7) | 1.95% | 1.72% | 1.57% | 0.90% | 0.81% |
| Portfolio Turnover Rate | 18% (6) | 55% | 43% | 48% | 66% | 73% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements/recapture by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Period Ended**<br>**June 30, 2021 \*** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $8.23 | $8.08 | $8.15 | $8.41 | $9.66 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.17 | 0.33 | 0.28 | 0.17 | 0.08 | 0.05 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.11 | 0.14 | (0.09) | (0.25) | (1.20) | (0.29) |
| Total from investment operations | 0.28 | 0.47 | 0.19 | (0.08) | (1.12) | (0.24) |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.18) | (0.32) | (0.26) | (0.18) | (0.11) | (0.05) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  |  | (0.02) | (0.05) |
| Total distributions | (0.18) | (0.32) | (0.26) | (0.18) | (0.13) | (0.10) |
| Net asset value, end of period/year | $8.33 | $8.23 | $8.08 | $8.15 | $8.41 | $9.66 |
| Total return (2) | 3.36% (6) | 5.93% | 2.34% | (0.89)% | (11.69)% | (2.39)% (6) |
| Net assets, at end of period/year (000s) | $38444 | $37596 | $35467 | $37445 | $58166 | $56644 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.88% (7) | 0.88% | 0.90% | 1.01% | 0.96% | 0.89% (7) |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.71% (7) | 0.78% | 0.78% | 0.78% | 0.78% | 0.78% (7) |
| Ratio of net investment income to average net assets (4)(5) | 4.07% (7) | 3.99% | 3.46% | 2.09% | 0.88% | 0.53% (7) |
| Portfolio Turnover Rate | 14% (6) | 24% | 33% | 57% | 56% | 52% (6) |

---

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Period Ended**<br>**June 30, 2021 \*** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $8.26 | $8.12 | $8.18 | $8.44 | $9.71 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.17 | 0.33 | 0.28 | 0.18 | 0.07 | 0.05 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.11 | 0.13 | (0.09) | (0.26) | (1.22) | (0.27) |
| Total from investment operations | 0.28 | 0.46 | 0.19 | (0.08) | (1.15) | (0.22) |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.17) | (0.32) | (0.25) | (0.18) | (0.10) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  |  | (0.02) | (0.05) |
| Total distributions | (0.17) | (0.32) | (0.25) | (0.18) | (0.12) | (0.07) |
| Net asset value, end of period/year | $8.37 | $8.26 | $8.12 | $8.18 | $8.44 | $9.71 |
| Total return (2) | 3.46% (6) | 5.73% | 2.42% | (0.90)% | (11.91)% | (2.28)% (6) |
| Net assets, at end of period/year (000s) | $1823 | $979 | $608 | $412 | $197 | $384 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.93% (7) | 0.93% | 0.95% | 1.06% | 1.01% | 0.94% (7) |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.76% (7) | 0.83% | 0.83% | 0.83% | 0.83% | 0.83% (7) |
| Ratio of net investment income to average net assets (4)(5) | 4.02% (7) | 3.94% | 3.47% | 2.19% | 0.78% | 0.51% (7) |
| Portfolio Turnover Rate | 14% (6) | 24% | 33% | 57% | 56% | 52% (6) |

---

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the adviser not waived a portion
 of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Period Ended**<br>**June 30, 2021 \*** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $8.17 | $8.03 | $8.11 | $8.37 | $9.63 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | 0.14 | 0.26 | 0.22 | 0.11 | 0.01 | (0.02) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.11 | 0.14 | (0.09) | (0.25) | (1.20) | (0.28) |
| Total from investment operations | 0.25 | 0.40 | 0.13 | (0.14) | (1.19) | (0.30) |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.14) | (0.26) | (0.21) | (0.12) | (0.06) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  |  | (0.01) | (0.05) |
| Total distributions | (0.14) | (0.26) | (0.21) | (0.12) | (0.07) | (0.07) |
| Net asset value, end of period/year | $8.28 | $8.17 | $8.03 | $8.11 | $8.37 | $9.63 |
| Total return (2) | 3.08% (6) | 5.04% | 1.53% | (1.67)% | (12.37)% | (3.02)% (6) |
| Net assets, at end of period/year (000s) | $603 | $644 | $492 | $221 | $224 | $163 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.68% (7) | 1.68% | 1.70% | 1.81% | 1.76% | 1.69% (7) |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.51% (7) | 1.58% | 1.58% | 1.58% | 1.58% | 1.58% (7) |
| Ratio of net investment income (loss) to average net assets (4)(5) | 3.27% (7) | 3.19% | 2.74% | 1.35% | 0.09% | (0.20)% (7) |
| Portfolio Turnover Rate | 14% (6) | 24% | 33% | 57% | 56% | 52% (6) |

---

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income/(loss) to average net assets do not reflect the expenses of the underlying investment companies in
 which the Fund invests.

(5) Recognition of net investment income
 (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Period Ended**<br>**June 30, 2021 \*** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $8.23 | $8.08 | $8.15 | $8.41 | $9.66 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.18 | 0.35 | 0.30 | 0.20 | 0.09 | 0.07 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.10 | 0.14 | (0.10) | (0.26) | (1.19) | (0.29) |
| Total from investment operations | 0.28 | 0.49 | 0.20 | (0.06) | (1.10) | (0.22) |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.18) | (0.34) | (0.27) | (0.20) | (0.13) | (0.07) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  |  | (0.02) | (0.05) |
| Total distributions | (0.18) | (0.34) | (0.27) | (0.20) | (0.15) | (0.12) |
| Net asset value, end of period/year | $8.33 | $8.23 | $8.08 | $8.15 | $8.41 | $9.66 |
| Total return (2) | 3.46% (6) | 6.14% | 2.54% | (0.67)% | (11.51)% | (2.24)% (6) |
| Net assets, at end of period/year (000s) | $120413 | $109551 | $100738 | $39300 | $13877 | $64377 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.68% (7) | 0.68% | 0.70% | 0.81% | 0.76% | 0.69% (7) |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.51% (7) | 0.58% | 0.58% | 0.58% | 0.58% | 0.58% (7) |
| Ratio of net investment income to average net assets (4)(5) | 4.27% (7) | 4.19% | 3.77% | 2.45% | 1.00% | 0.80% (7) |
| Portfolio Turnover Rate | 14% (6) | 24% | 33% | 57% | 56% | 52% (6) |

---

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $19.41 | $17.72 | $14.65 | $13.43 | $15.86 | $10.88 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.03 | 0.08 | 0.06 | 0.11 | 0.05 | 0.04 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.20 | 1.70 | 3.07 | 1.31 | (2.01) | 5.08 |
| Total from investment operations | 0.23 | 1.78 | 3.13 | 1.42 | (1.96) | 5.12 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.03) | (0.09) | (0.06) | (0.10) | (0.18) | (0.14) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.57) |  |  | (0.09) | (0.29) |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.01) |  |  |
| Total distributions | (0.60) | (0.09) | (0.06) | (0.20) | (0.47) | (0.14) |
| Net asset value, end of period/year | $19.04 | $19.41 | $17.72 | $14.65 | $13.43 | $15.86 |
| Total return (2) | 1.17% (6) | 10.08% | 21.40% | 10.66% | (12.90)% | 47.21% |
| Net assets, at end of period/year (000s) | $70631 | $77293 | $87873 | $91912 | $74940 | $70566 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.13% (7) | 1.14% | 1.16% | 1.23% | 1.14% | 1.19% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.13% (7) | 1.15% | 1.15% | 1.15% | 1.15% | 1.15% |
| Ratio of net investment income to average net assets (4)(5) | 0.31% (7) | 0.45% | 0.40% | 0.75% | 0.34% | 0.27% |
| Portfolio Turnover Rate | 22% (6) | 58% | 38% | 50% | 50% | 35% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived or recaptured a portion of the Fund's expenses in
 certain periods, total returns would have been lower/higher.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements/recapture by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $19.42 | $17.73 | $14.66 | $13.43 | $15.85 | $10.87 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.03 | 0.07 | 0.05 | 0.10 | 0.05 | 0.03 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.20 | 1.71 | 3.07 | 1.32 | (2.01) | 5.08 |
| Total from investment operations | 0.23 | 1.78 | 3.12 | 1.42 | (1.96) | 5.11 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.03) | (0.09) | (0.05) | (0.06) | (0.17) | (0.13) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.57) |  |  | (0.09) | (0.29) |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.04) |  |  |
| Total distributions | (0.60) | (0.09) | (0.05) | (0.19) | (0.46) | (0.13) |
| Net asset value, end of period/year | $19.05 | $19.42 | $17.73 | $14.66 | $13.43 | $15.85 |
| Total return (2) | 1.15% (6) | 10.03% | 21.35% | 10.68% | (12.88)% | 47.22% |
| Net assets, at end of period/year (000s) | $65794 | $65648 | $50563 | $36722 | $29243 | $17865 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.18% (7) | 1.19% | 1.21% | 1.28% | 1.19% | 1.24% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.18% (7) | 1.20% | 1.20% | 1.20% | 1.20% | 1.20% |
| Ratio of net investment income to average net assets (4)(5) | 0.26% (7) | 0.40% | 0.34% | 0.69% | 0.31% | 0.22% |
| Portfolio Turnover Rate | 22% (6) | 58% | 38% | 50% | 50% | 35% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above **table** is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming
 reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the adviser not
 waived or recaptured a portion of the Fund's expenses in certain periods, total returns would have been lower/higher.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements/recapture by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $19.11 | $17.52 | $14.54 | $13.34 | $15.77 | $10.86 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | (0.05) | (0.07) | (0.06) | (0.01) | (0.07) | (0.08) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.22 | 1.66 | 3.04 | 1.31 | (2.00) | 5.06 |
| Total from investment operations | 0.17 | 1.59 | 2.98 | 1.30 | (2.07) | 4.98 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  |  |  |  | (0.07) | (0.07) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.57) |  |  | (0.09) | (0.29) |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.01) |  |  |
| Total distributions | (0.57) |  |  | (0.10) | (0.36) | (0.07) |
| Net asset value, end of period/year | $18.71 | $19.11 | $17.52 | $14.54 | $13.34 | $15.77 |
| Total return (2) | 0.87% (7) | 9.19 | 20.50 | 9.78% | (13.57)% | 45.93% |
| Net assets, at end of period/year (000s) | $26628 | $27018 | $19564 | $14889 | $9975 | $4508 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.93% (8) | 1.94 | 1.96 | 2.03% | 1.94% | 1.99% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.93% (8) | 1.95 | 1.95 | 1.95% | 1.95% | 1.95% |
| Ratio of net investment income (loss) to average net assets (4)(5) | (0.49)% (8) | (0.36) | (0.40) | (0.05)% | (0.42)% | (0.53)% |
| Portfolio Turnover Rate | 22% (7) | 58 | 38 | 50% | 50% | 35% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived or recaptured a portion of the Fund's expenses in
 certain periods, total returns would have been lower/higher.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements/recapture by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income/(loss) to average net assets do not reflect the expenses of the underlying investment companies in
 which the Fund invests.

(5) Recognition of net investment income
 (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) As required by SEC standard per share
 data calculation methodology, this represents a balancing figure derived from the other amounts in the financial highlights tables that
 captures all other changes affecting net asset value per share. This per share loss amount does not correlate to the aggregate of the
 net investment income in the Statement of Operations for the fiscal year, primarily due to the timing of sales and repurchases of the
 Fund's shares in relation to underlying income.

(7) Not annualized.

(8) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $19.43 | $17.74 | $14.66 | $13.44 | $15.87 | $10.88 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.05 | 0.12 | 0.09 | 0.13 | 0.09 | 0.07 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.20 | 1.70 | 3.08 | 1.32 | (2.02) | 5.07 |
| Total from investment operations | 0.25 | 1.82 | 3.17 | 1.45 | (1.93) | 5.14 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.05) | (0.13) | (0.09) | (0.11) | (0.21) | (0.15) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.57) |  |  | (0.09) | (0.29) |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.03) |  |  |
| Total distributions | (0.62) | (0.13) | (0.09) | (0.23) | (0.50) | (0.15) |
| Net asset value, end of period/year | $19.06 | $19.43 | $17.74 | $14.66 | $13.44 | $15.87 |
| Total return (2) | 1.27% (6) | 10.30% | 21.70% | 10.87% | (12.72)% | 47.49% |
| Net assets, at end of period/year (000s) | $988687 | $1032728 | $705913 | $430286 | $305801 | $237256 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 0.93% (7) | 0.94% | 0.96% | 1.03% | 0.94% | 0.99% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 0.93% (7) | 0.95% | 0.95% | 0.95% | 0.95% | 0.95% |
| Ratio of net investment income to average net assets (4)(5) | 0.51% (7) | 0.65% | 0.61% | 0.96% | 0.55% | 0.48% |
| Portfolio Turnover Rate | 22% (6) | 58% | 38% | 50% | 50% | 35% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived or recaptured a portion of the Fund's expenses in
 certain periods, total returns would have been lower/higher.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements/recapture by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021 \*** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $13.47 | $11.96 | $12.00 | $10.92 | $19.08 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.09) | (0.16) | (0.17) | (0.13) | (0.25) | (0.25) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.07 | 1.67 | 0.13 | 1.20 | (7.69) | 9.33 |
| Total from investment operations | 0.98 | 1.51 | (0.04) | 1.07 | (7.94) | 9.08 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (0.23) | (0.02) |
| Total distributions |  |  |  |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees (1) |  |  |  | 0.01 | 0.01 | 0.02 |
| Net asset value, end of period/year | $14.45 | $13.47 | $11.96 | $12.00 | $10.92 | $19.08 |
| Total return (2) | 7.28% (6) | 12.63% | (0.33)% | 9.89% | (42.00)% | 91.00% |
| Net assets, at end of period/year (000s) | $15776 | $19462 | $19201 | $22186 | $12479 | $15730 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.64% (7) | 1.74% | 1.69% | 1.70% | 1.63% | 1.73% |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.58% (7) | 1.63% | 1.63% | 1.63% | 1.63% | 1.63% |
| Ratio of net investment loss to average net assets (4)(5) | (1.32)% (7) | (1.28)% | (1.36)% | (1.23)% | (1.54)% | (1.50)% |
| Portfolio Turnover Rate | 64% (6) | 126% | 70% | 80% | 69% | 60% |

---

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(5) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021 \*** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $13.46 | $11.96 | $12.00 | $10.93 | $19.08 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.10) | (0.17) | (0.17) | (0.14) | (0.25) | (0.26) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.07 | 1.67 | 0.13 | 1.20 | (7.68) | 9.34 |
| Total from investment operations | 0.97 | 1.50 | (0.04) | 1.06 | (7.93) | 9.08 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (0.23) | (0.02) |
| Total distributions |  |  |  |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees (1) |  |  |  | 0.01 | 0.01 | 0.02 |
| Net asset value, end of period/year | $14.43 | $13.46 | $11.96 | $12.00 | $10.93 | $19.08 |
| Total return (2) | 7.21% (6) | 12.54% | (0.33)% | 9.79% | (41.95)% | 91.00% |
| Net assets, at end of period/year (000s) | $8611 | $8133 | $8421 | $8257 | $7377 | $7662 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.69% (7) | 1.79% | 1.74% | 1.75% | 1.68% | 1.78% |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.63% (7) | 1.68% | 1.68% | 1.68% | 1.68% | 1.68% |
| Ratio of net investment loss to average net assets (4)(5) | (1.37)% (7) | (1.33)% | (1.41)% | (1.28)% | (1.58)% | (1.55)% |
| Portfolio Turnover Rate | 64% (6) | 126% | 70% | 80% | 69% | 60% |

---

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the adviser not waived a portion
 of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(5) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021 \*** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $12.96 | $11.61 | $11.74 | $10.77 | $18.96 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.14) | (0.25) | (0.25) | (0.21) | (0.37) | (0.38) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.03 | 1.60 | 0.12 | 1.17 | (7.60) | 9.35 |
| Total from investment operations | 0.89 | 1.35 | (0.13) | 0.96 | (7.97) | 8.97 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (0.23) | (0.02) |
| Total distributions |  |  |  |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees (1) |  |  |  | 0.01 | 0.01 | 0.01 |
| Net asset value, end of period/year | $13.85 | $12.96 | $11.61 | $11.74 | $10.77 | $18.96 |
| Total return (2) | 6.87% (6) | 11.63% | (1.11)% | 9.01% | (42.43)% | 89.80% |
| Net assets, at end of period/year (000s) | $2018 | $2148 | $2550 | $2635 | $2422 | $2065 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 2.44% (7) | 2.54% | 2.49% | 2.50% | 2.43% | 2.53% |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 2.38% (7) | 2.43% | 2.43% | 2.43% | 2.43% | 2.43% |
| Ratio of net investment loss to average net assets (4)(5) | (2.12)% (7) | (2.08)% | (2.16)% | (2.03)% | (2.33)% | (2.30)% |
| Portfolio Turnover Rate | 64% (6) | 126% | 70% | 80% | 69% | 60% |

---

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(5) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021 \*** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $13.62 | $12.07 | $12.08 | $10.97 | $19.12 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.08) | (0.14) | (0.14) | (0.11) | (0.22) | (0.22) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.08 | 1.69 | 0.13 | 1.21 | (7.71) | 9.34 |
| Total from investment operations | 1.00 | 1.55 | (0.01) | 1.10 | (7.93) | 9.12 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (0.23) | (0.02) |
| Total distributions |  |  |  |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees (1) |  |  |  | 0.01 | 0.01 | 0.02 |
| Net asset value, end of period/year | $14.62 | $13.62 | $12.07 | $12.08 | $10.97 | $19.12 |
| Total return (2) | 7.34% (6) | 12.84% | (0.08)% | 10.12% | (41.86)% | 91.40% |
| Net assets, at end of period/year (000s) | $64392 | $67544 | $85315 | $82735 | $72567 | $96821 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.44% (7) | 1.54% | 1.49% | 1.50% | 1.43% | 1.53% |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.38% (7) | 1.43% | 1.43% | 1.43% | 1.43% | 1.43% |
| Ratio of net investment loss to average net assets (4)(5) | (1.12)% (7) | (1.08)% | (1.16)% | (1.02)% | (1.33)% | (1.30)% |
| Portfolio Turnover Rate | 64% (6) | 126% | 70% | 80% | 69% | 60% |

---

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(5) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $54.04 | $48.15 | $48.25 | $44.10 | $69.91 | $47.16 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.27) | (0.46) | (0.38) | (0.27) | (0.53) | (0.51) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 7.71 | 6.99 | 0.28 | 6.70 | (21.01) | 23.77 |
| Total from investment operations | 7.44 | 6.53 | (0.10) | 6.43 | (21.54) | 23.26 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (6.87) | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Total distributions | (6.87) | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Net asset value, end of period/year | $54.61 | $54.04 | $48.15 | $48.25 | $44.10 | $69.91 |
| Total return (2) | 13.82% (6) | 13.63% | (0.21)% (5) | 15.29% (5) | (32.65)% | 49.43% |
| Net assets, at end of period/year (000s) | $292129 | $288736 | $427768 | $526825 | $529869 | $827811 |
| Ratio of net expenses to average net assets (3) | 1.35% (7) | 1.38% | 1.36% | 1.38% | 1.31% | 1.31% |
| Ratio of net investment loss to average net assets (3)(4) | (0.90)% (7) | (0.91)% | (0.79)% | (0.59)% | (0.86)% | (0.85)% |
| Portfolio Turnover Rate | 9% (6) | 60% | 36% | 34% | 27% | 19% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(4) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Includes adjustments in accordance
 with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting
 purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $53.61 | $47.80 | $47.94 | $43.83 | $69.53 | $46.92 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.27) | (0.48) | (0.41) | (0.29) | (0.55) | (0.54) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 7.65 | 6.93 | 0.27 | 6.68 | (20.88) | 23.66 |
| Total from investment operations | 7.38 | 6.45 | (0.14) | 6.39 | (21.43) | 23.12 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (6.87) | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Total distributions | (6.87) | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Net asset value, end of period/year | $54.12 | $53.61 | $47.80 | $47.94 | $43.83 | $69.53 |
| Total return (2) | 13.82% (6) | 13.56% | (0.29)% (5) | 15.30% (5) | (32.67)% | 49.39% |
| Net assets, at end of period/year (000s) | $329960 | $307538 | $320983 | $351924 | $302171 | $458726 |
| Ratio of net expenses to average net assets (3) | 1.40% (7) | 1.43% | 1.41% | 1.43% | 1.36% | 1.36% |
| Ratio of net investment loss to average net assets (3)(4) | (0.95)% (7) | (0.96)% | (0.85)% | (0.65)% | (0.91)% | (0.91)% |
| Portfolio Turnover Rate | 9% (6) | 60% | 36% | 34% | 27% | 19% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any and does not reflect the impact of sales charges.

(3) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(4) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Includes adjustments in accordance
 with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting
 purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $46.35 | $41.71 | $42.13 | $39.09 | $62.97 | $42.86 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.42) | (0.74) | (0.67) | (0.55) | (0.91) | (0.89) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 6.59 | 6.02 | 0.25 | 5.87 | (18.70) | 21.51 |
| Total from investment operations | 6.17 | 5.28 | (0.42) | 5.32 | (19.61) | 20.62 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (6.87) | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Total distributions | (6.87) | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Net asset value, end of period/year | $45.65 | $46.35 | $41.71 | $42.13 | $39.09 | $62.97 |
| Total return (2) | 13.37% (6) | 12.73% | (1.00)% (5) | 14.38% (5) | (33.21)% | 48.23% |
| Net assets, at end of period/year (000s) | $140380 | $139105 | $166155 | $218201 | $235967 | $404272 |
| Ratio of net expenses to average net assets (3) | 2.15% (7) | 2.18% | 2.16% | 2.18% | 2.11% | 2.11% |
| Ratio of net investment loss to average net assets (3)(4) | (1.70)% (7) | (1.71)% | (1.59)% | (1.40)% | (1.67)% | (1.65)% |
| Portfolio Turnover Rate | 9% (6) | 60% | 36% | 34% | 27% | 19% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(4) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Includes adjustments in accordance
 with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting
 purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $56.03 | $49.80 | $49.82 | $45.36 | $71.65 | $48.22 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.21) | (0.37) | (0.30) | (0.19) | (0.41) | (0.40) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 8.00 | 7.24 | 0.28 | 6.93 | (21.61) | 24.34 |
| Total from investment operations | 7.79 | 6.87 | (0.02) | 6.74 | (22.02) | 23.94 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (6.87) | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Total distributions | (6.87) | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Net asset value, end of period/year | $56.95 | $56.03 | $49.80 | $49.82 | $45.36 | $71.65 |
| Total return (2) | 13.95% (6) | 13.86% | (0.04)% (5) | 15.56% (5) | (32.52)% | 49.76% |
| Net assets, at end of period/year (000s) | $2160738 | $2054852 | $2434432 | $2663688 | $2408991 | $3522353 |
| Ratio of net expenses to average net assets (3) | 1.15% (7) | 1.18% | 1.16% | 1.18% | 1.11% | 1.11% |
| Ratio of net investment loss to average net assets (3)(4) | (0.70)% (7) | (0.71)% | (0.60)% | (0.40)% | (0.66)% | (0.65)% |
| Portfolio Turnover Rate | 9% (6) | 60% | 36% | 34% | 27% | 19% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(4) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Includes adjustments in accordance
 with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting
 purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $33.21 | $33.30 | $36.63 | $26.52 | $46.19 | $43.33 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.27) | (0.44) | (0.42) | (0.37) | (0.57) | (0.72) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 17.83 | 0.35 | (2.91) | 10.48 | (14.74) | 5.52 |
| Total from investment operations | 17.56 | (0.09) | (3.33) | 10.11 | (15.31) | 4.80 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  |  |  |  | (0.63) |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (3.73) | (1.94 |
| Total distributions |  |  |  |  | (4.36) | (1.94 |
| Paid-in-capital from redemption fees (1) |  |  |  |  |  | 0.00 |
| Net asset value, end of period/year | $50.77 | $33.21 | $33.30 | $36.63 | $26.52 | $46.19 |
| Total return (2) | 52.88% (7) | (0.27)% | (9.09)% (6) | 38.12% (6) | (35.99)% (6) | 10.34 |
| Net assets, at end of period/year (000s) | $81042 | $59748 | $93027 | $133006 | $115954 | $227441 |
| Ratio of net expenses to average net assets (3) | 1.49% (8) | 1.51% | 1.52% | 1.50% | 1.50% | 1.48 |
| Ratio of net investment loss to average net assets (3)(4) | (1.29)% (8) | (1.31)% | (1.24)% | (1.14)% | (1.49)% | (1.47) |
| Portfolio Turnover Rate | 56% (7) | 41% | 71% | 79% | 59% | 62 |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(4) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Amount represents less than $0.01
 per share.

(6) Includes adjustments in accordance
 with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting
 purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(7) Not annualized.

(8) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $32.93 | $33.04 | $36.37 | $26.34 | $45.91 | $43.10 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.28) | (0.45) | (0.44) | (0.38) | (0.58) | (0.74) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 17.69 | 0.34 | (2.89) | 10.41 | (14.64) | 5.49 |
| Total from investment operations | 17.41 | (0.11) | (3.33) | 10.03 | (15.22) | 4.75 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  |  |  |  | (0.62) |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (3.73) | (1.94 |
| Total distributions |  |  |  |  | (4.35) | (1.94 |
| Paid-in-capital from redemption fees (1) |  |  |  |  |  | 0.00 |
| Net asset value, end of period/year | $50.34 | $32.93 | $33.04 | $36.37 | $26.34 | $45.91 |
| Total return (2) | 52.87% (7) | (0.33)% | (9.16)% (6) | 38.08% (6) | (36.02)% (6) | 10.28 |
| Net assets, at end of period/year (000s) | $141885 | $97510 | $122423 | $151885 | $114642 | $191709 |
| Ratio of net expenses to average net assets (3) | 1.54% (8) | 1.56% | 1.57% | 1.55% | 1.55% | 1.53 |
| Ratio of net investment loss to average net assets (3)(4) | (1.34)% (8) | (1.35)% | (1.29)% | (1.19)% | (1.54)% | (1.52) |
| Portfolio Turnover Rate | 56% (7) | 41% | 71% | 79% | 59% | 62 |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any and does not reflect the impact of sales charges.

(3) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(4) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Amount represents less than $0.01
 per share.

(6) Includes adjustments in accordance
 with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting
 purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(7) Not annualized.

(8) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $29.79 | $30.11 | $33.39 | $24.37 | $42.78 | $40.56 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.39) | (0.64) | (0.63) | (0.57) | (0.80) | (1.04) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 15.96 | 0.32 | (2.65) | 9.59 | (13.60) | 5.20 |
| Total from investment operations | 15.57 | (0.32) | (3.28) | 9.02 | (14.40) | 4.16 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  |  |  |  | (0.28) |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (3.73) | (1.94 |
| Total distributions |  |  |  |  | (4.01) | (1.94 |
| Paid-in-capital from redemption fees (1) |  |  |  |  |  | 0.00 |
| Net asset value, end of period/year | $45.36 | $29.79 | $30.11 | $33.39 | $24.37 | $42.78 |
| Total return (2) | 52.27% (7) | (1.06)% | (9.82)% (6) | 37.01% (6) | (36.51)% (6) | 9.45 |
| Net assets, at end of period/year (000s) | $51353 | $37460 | $55661 | $76849 | $66540 | $120351 |
| Ratio of net expenses to average net assets (3) | 2.29% (8) | 2.31% | 2.32% | 2.30% | 2.30% | 2.28 |
| Ratio of net investment loss to average net assets (3)(4) | (2.09)% (8) | (2.10)% | (2.04)% | (1.94)% | (2.29)% | (2.27) |
| Portfolio Turnover Rate | 56% (7) | 41% | 71% | 79% | 59% | 62 |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(4) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Amount represents less than $0.01
 per share.

(6) Includes adjustments in accordance
 with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting
 purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(7) Not annualized.

(8) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $34.06 | $34.09 | $37.45 | $27.05 | $47.04 | $44.02 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.24) | (0.38) | (0.37) | (0.31) | (0.49) | (0.64) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 18.31 | 0.35 | (2.99) | 10.71 | (15.03) | 5.60 |
| Total from investment operations | 18.07 | (0.03) | (3.36) | 10.40 | (15.52) | 4.96 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  |  |  |  | (0.74) |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (3.73) | (1.94 |
| Total distributions |  |  |  |  | (4.47) | (1.94 |
| Paid-in-capital from redemption fees (1) |  |  |  |  |  | 0.00 |
| Net asset value, end of period/year | $52.13 | $34.06 | $34.09 | $37.45 | $27.05 | $47.04 |
| Total return (2) | 53.05% (7) | (0.09)% | (8.97)% (6) | 38.45% (6) | (35.85)% (6) | 10.54 |
| Net assets, at end of period/year (000s) | $1414166 | $951152 | $1168805 | $1441422 | $1024430 | $1573091 |
| Ratio of net expenses to average net assets (3) | 1.29% (8) | 1.31% | 1.32% | 1.30% | 1.30% | 1.28 |
| Ratio of net investment loss to average net assets (3)(4) | (1.09)% (8) | (1.10)% | (1.04)% | (0.94)% | (1.29)% | (1.28) |
| Portfolio Turnover Rate | 56% (7) | 41% | 71% | 79% | 59% | 62 |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(4) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Amount represents less than $0.01
 per share.

(6) Includes adjustments in accordance
 with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting
 purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(7) Not annualized.

(8) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023 \*** |
|  | **(Unaudited)** | | | |
| Net asset value, beginning of period/year | $15.17 | $14.01 | $11.44 | $10.00 |
| Activity from investment operations: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | (0.00) | 0.02 | (0.00) | (0.01) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain on investments | 0.31 | 1.64 | 2.57 | 1.45 |
| Total from investment operations | 0.31 | 1.66 | 2.57 | 1.44 |
| Less distributions from: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.03) | (0.02) |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.06) | (0.48) |  |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.00 |
| Total distributions | (0.09 | (0.50) |  | (0.00 |
| Net asset value, end of period/year | $15.39 | $15.17 | $14.01 | $11.44 |
| Total return (2) | 2.03 | 12.09% | 22.47 | 14.43 |
| Net assets, at end of period/year (000s) | $9356 | $9268 | $13097 | $330 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.32 | 1.33% | 1.38 | 2.84 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.14 | 1.14% | 1.14 | 1.15 |
| Ratio of net investment loss to average net assets (4)(5) | (0.06) | 0.14% | (0.02) | (0.15) |
| Portfolio Turnover Rate | 13 | 50% | 101 | 48 |

---

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(5) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Amount represents less than $0.01
 per share.

(7) As required by SEC standard per share
 data calculation methodology, this represents a balancing figure derived from the other amounts in the financial highlights tables that
 captures all other changes affecting net asset value per share. This per share loss amount does not correlate to the aggregate of the
 net investment income in the Statement of Operations for the fiscal year, primarily due to the timing of sales and repurchases of the
 Fund's shares in relation to underlying income.

(8) The ratio includes 0.01% for the year
 ended June 30, 2023 attributed to line of credit fees.

(9) Not annualized.

(10) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023 \*** |
|  | **(Unaudited)** | | | |
| Net asset value, beginning of period/year | $15.13 | $13.99 | $11.42 | $10.00 |
| Activity from investment operations: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | (0.00) | 0.01 | (0.00) | (0.00) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain on investments | 0.31 | 1.63 | 2.57 | 1.43 |
| Total from investment operations | 0.31 | 1.64 | 2.57 | 1.43 |
| Less distributions from: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.03) | (0.02) |  | 0.00 |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.06) | (0.48) |  |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.01 |
| Total distributions | (0.09 | (0.50) |  | (0.01 |
| Net asset value, end of period/year | $15.35 | $15.13 | $13.99 | $11.42 |
| Total return (2) | 2.02 | 11.94% | 22.50 | 14.26 |
| Net assets, at end of period/year (000s) | $7353 | $4428 | $1836 | $190 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.37 | 1.38% | 1.43 | 2.89 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.19 | 1.19% | 1.19 | 1.20 |
| Ratio of net investment loss to average net assets (4)(5) | (0.11) | 0.09% | (0.03) | (0.25) |
| Portfolio Turnover Rate | 13 | 50% | 101 | 48 |

---

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the adviser not waived a portion
 of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(5) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Amount represents less than $0.01
 per share.

(7) As required by SEC standard per share
 data calculation methodology, this represents a balancing figure derived from the other amounts in the financial highlights tables that
 captures all other changes affecting net asset value per share. This per share loss amount does not correlate to the aggregate of the
 net investment income in the Statement of Operations for the fiscal year, primarily due to the timing of sales and repurchases of the
 Fund's shares in relation to underlying income.

(8) Includes adjustments in accordance
 with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting
 purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(9) The ratio includes 0.01% for the year
 ended June 30, 2023 attributed to line of credit fees.

(10) Not annualized.

(11) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023 \*** |
|  | **(Unaudited)** | | | |
| Net asset value, beginning of period/year | $14.83 | $13.79 | $11.36 | $10.00 |
| Activity from investment operations: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.07) | (0.09) | (0.09) | (0.09) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain on investments | 0.31 | 1.61 | 2.52 | 1.45 |
| Total from investment operations | 0.24 | 1.52 | 2.43 | 1.36 |
| Less distributions from: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.06) | (0.48 |  |  |
| Total distributions | (0.06) | (0.48 |  |  |
| Net asset value, end of period/year | $15.01 | $14.83 | $13.79 | $11.36 |
| Total return (2) | 1.62% (8) | 11.24 | 21.39 | 13.60% |
| Net assets, at end of period/year (000s) | $1709 | $1019 | $292 | $27 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 2.12% (9) | 2.13 | 2.18 | 3.64% (7) |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.94% (9) | 1.94 | 1.94 | 1.95% (7) |
| Ratio of net investment loss to average net assets (4)(5) | (0.86)%(9) | (0.66) | (0.68) | (0.93)% |
| Portfolio Turnover Rate | 13% (8) | 50 | 101 | 48% |

---

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements/recapture by the adviser.

(4) The ratios of expenses to average
 net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the
 Fund invests.

(5) Recognition of net investment loss
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) As required by SEC standard per share
 data calculation methodology, this represents a balancing figure derived from the other amounts in the financial highlights tables that
 captures all other changes affecting net asset value per share. This per share loss amount does not correlate to the aggregate of the
 net investment income in the Statement of Operations for the fiscal year, primarily due to the timing of sales and repurchases of the
 Fund's shares in relation to underlying income.

(7) The ratio includes 0.01% for the year
 ended June 30, 2023 attributed to line of credit fees.

(8) Not annualized.

(9) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** |  | **Year Ended**<br>**June 30, 2023 \*** |
|  | **(Unaudited)** | | |  | |
| Net asset value, beginning of period/year | $15.22 | $14.04 | $11.44 |  | $10.00 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.01 | 0.04 | 0.03 |  | 0.01 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain on investments | 0.32 | 1.65 | 2.57 | (4) | 1.44 |
| Total from investment operations | 0.33 | 1.69 | 2.60 |  | 1.45 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.04) | (0.03) |  |  | (0.00) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.06) | (0.48) |  |  |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  |  | (0.01 |
| Total distributions | (0.10 | (0.51) |  |  | (0.01 |
| Net asset value, end of period/year | $15.45 | $15.22 | $14.04 |  | $11.44 |
| Total return (2) | 2.14 | 12.32% | 22.73 | % | 14.55 |
| Net assets, at end of period/year (000s) | $158451 | $148678 | $90959 |  | $12808 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.12 | 1.13% | 1.18 | % | 2.64 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.94 | 0.94% | 0.94 | % | 0.95 |
| Ratio of net investment income (loss) to average net assets (4)(5) | 0.14 | 0.34% | 0.24 | % | 0.08 |
| Portfolio Turnover Rate | 13 | 50% | 101 | % | 48 |

---

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests. (5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment
 companies in which the Fund invests.

(6) Amount represents less than $0.01
 per share.

(7) The ratio includes 0.01% for the year
 ended June 30, 2023 attributed to line of credit fees.

(8) Not annualized.

(9) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $10.10 | $9.89 | $9.68 | $9.72 | $10.49 | $10.62 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.19 | 0.35 | 0.28 | 0.16 | 0.04 | 0.06 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.08 | 0.22 | 0.22 | (0.04 | (0.69) | (0.01) |
| Total from investment operations | 0.27 | 0.57 | 0.50 | 0.12 | (0.65) | 0.05 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.20) | (0.36) | (0.29) | (0.16) | (0.07) | (0.07) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  |  | (0.07) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.00 | (0.05) | (0.04) |
| Total distributions | (0.20) | (0.36) | (0.29) | (0.16 | (0.12) | (0.18) |
| Net asset value, end of period/year | $10.17 | $10.10 | $9.89 | $9.68 | $9.72 | $10.49 |
| Total return (2) | 2.64% (7) | 5.80% | 5.18% | 1.29 | (6.26)% | 0.48% |
| Net assets, at end of period/year (000s) | $19030 | $17359 | $17949 | $17698 | $5622 | $6906 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.80% (8) | 0.80% | 0.89% | 0.91 | 0.84% | 0.86% |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.68% (8) | 0.75% | 0.75% | 0.75 | 0.75% | 0.75% |
| Ratio of net investment income to average net assets (4)(5) | 3.69% (8) | 3.50% | 2.87% | 1.66 | 0.42% | 0.54% |
| Portfolio Turnover Rate | 1% (7) | 7% | 33% | 34 | 48% | 72% |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Amount represents less than $0.01
 per share.

(7) Not annualized.

(8) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $10.13 | $9.91 | $9.70 | $9.75 | $10.51 | $10.65 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.19 | 0.35 | 0.27 | 0.14 | 0.04 | 0.03 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.07 | 0.22 | 0.22 | (0.03 | (0.69) | 0.01 |
| Total from investment operations | 0.26 | 0.57 | 0.49 | 0.11 | (0.65) | 0.04 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.19) | (0.35) | (0.28) | (0.16) | (0.06) | (0.07) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  |  | (0.07) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.00 | (0.05) | (0.04 |
| Total distributions | (0.19) | (0.35) | (0.28) | (0.16 | (0.11) | (0.18 |
| Paid-in-capital from redemption fees (1) |  |  |  |  |  |  |
| Net asset value, end of period/year | $10.20 | $10.13 | $9.91 | $9.70 | $9.75 | $10.51 |
| Total return (2) | 2.61% (8) | 5.84% | 5.09% | 1.14 | (6.20)% | 0.45 |
| Net assets, at end of period/year (000s) | $4783 | $4378 | $4612 | $19390 | $22210 | $29596 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.85% (9) | 0.85% | 0.94% | 0.96 | 0.89% | 0.91 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.73% (9) | 0.80% | 0.80% | 0.80 | 0.80% | 0.80 |
| Ratio of net investment income to average net assets (4)(5) | 3.64% (9) | 3.45% | 2.70% | 1.47 | 0.37% | 0.27 |
| Portfolio Turnover Rate | 1% (8) | 7% | 33% | 34 | 48% | 72 |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the adviser not waived a portion
 of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Due to the timing of shareholder transactions,
 and allocations of expenses among share classes, the per unit amounts presented may not coincide with the aggregate presentation on the
 Statements of Operations.

(7) Amount represents less than $0.01
 per share.

(8) Not annualized.

(9) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $10.06 | $9.84 | $9.64 | $9.68 | $10.44 | $10.60 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | 0.14 | 0.27 | 0.20 | 0.07 | (0.04) | (0.05) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.07 | 0.22 | 0.21 | (0.02 | (0.68) | 0.01 |
| Total from investment operations | 0.21 | 0.49 | 0.41 | 0.05 | (0.72) | (0.04 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.15) | (0.27) | (0.21) | (0.09) | (0.02) | (0.01) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  |  | (0.07) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.00 | (0.02) | (0.04 |
| Total distributions | (0.15) | (0.27) | (0.21) | (0.09 | (0.04) | (0.12 |
| Net asset value, end of period/year | $10.12 | $10.06 | $9.84 | $9.64 | $9.68 | $10.44 |
| Total return (2) | 2.14% (8) | 5.10% | 4.26% | 0.49 | (6.94)% | (0.38 |
| Net assets, at end of period/year (000s) | $1578 | $1603 | $1564 | $1618 | $1678 | $1545 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.60% (9) | 1.60% | 1.69% | 1.71 | 1.64% | 1.66 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.48% (9) | 1.55% | 1.55% | 1.55 | 1.55% | 1.55 |
| Ratio of net investment income (loss) to average net assets (4)(5) | 2.89% (9) | 2.70% | 2.05% | 0.74 | (0.37)% | (0.50) |
| Portfolio Turnover Rate | 1% (8) | 7% | 33% | 34 | 48% | 72 |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements/recapture by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Due to the timing of shareholder transactions,
 and allocations of expenses among share classes, the per unit amounts presented may not coincide with the aggregate presentation on the
 Statements of Operations.

(7) Amount represents less than $0.01
 per share.

(8) Not annualized.

(9) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Six Months Ended**<br>**December 31, 2025** | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
|  | **(Unaudited)** | | | | | |
| Net asset value, beginning of period/year | $10.38 | $10.15 | $9.93 | $9.97 | $10.75 | $10.89 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.20 | 0.38 | 0.31 | 0.16 | 0.07 | 0.05 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.08 | 0.23 | 0.22 | (0.02 | (0.71) | 0.01 |
| Total from investment operations | 0.28 | 0.61 | 0.53 | 0.14 | (0.64) | 0.06 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.20) | (0.38) | (0.31) | (0.18) | (0.08) | (0.09) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  |  | (0.07) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.00 | (0.06) | (0.04 |
| Total distributions | (0.20) | (0.38) | (0.31) | (0.18 | (0.14) | (0.20 |
| Paid-in-capital from redemption fees (1) |  |  |  |  |  |  |
| Net asset value, end of period/year | $10.46 | $10.38 | $10.15 | $9.93 | $9.97 | $10.75 |
| Total return (2) | 2.77% (8) | 6.06% | 5.35% | 1.46 | (6.02)% | 0.65 |
| Net assets, at end of period/year (000s) | $181229 | $145867 | $121701 | $88666 | $152546 | $144089 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.60% (9) | 0.60% | 0.69% | 0.71 | 0.64% | 0.66 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.48% (9) | 0.55% | 0.55% | 0.55 | 0.55% | 0.55 |
| Ratio of net investment income to average net assets (4)(5) | 3.89% (9) | 3.71% | 3.10% | 1.68 | 0.64% | 0.49 |
| Portfolio Turnover Rate | 1% (8) | 7% | 33% | 34 | 48% | 72 |

---

(1) Per share amounts calculated using
 the average shares method.

(2) Total return in the above table is
 historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment
 of dividends and capital gain distributions, if any. Had the adviser not waived a portion of the Fund's expenses in certain periods,
 total returns would have been lower.

(3) Represents the ratio of expenses to
 average net assets absent fee waivers and/or expense reimbursements by the adviser.

(4) The ratios of expenses to average
 net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which
 the Fund invests.

(5) Recognition of net investment income
 is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Due to the timing of shareholder transactions,
 and allocations of expenses among share classes, the per unit amounts presented may not coincide with the aggregate presentation on the
 Statements of Operations.

(7) Amount represents less than $0.01
 per share.

(8) Not annualized.

(9) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)*** |
| **December 31, 2025** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(1)** **ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES** 

Mutual Fund Series Trust (the "***Trust***"), was organized as an Ohio business trust on February 27, 2006. The Trust is registered as an open-end management investment company under the Investment Company Act of 1940, as amended ("***1940 Act***") . The Trust currently consists of thirty-five series. These financial statements include the following series: Eventide Balanced Fund, Eventide Core Bond Fund, Eventide Dividend Growth Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund and the Eventide Limited-Term Bond Fund (each a "***Fund***" or collectively the "***Funds***"). Each Fund except Eventide Exponential Technologies Fund is a diversified series of the Trust. Eventide Exponential Technologies Fund is a non-diversified series of the Trust. The Funds' investment adviser is Eventide Asset Management, LLC (the "***Adviser***").

Eventide Balanced Fund commenced operations on July 15, 2015. The Fund's investment objective is current income while maintaining the potential for capital appreciation.

Eventide Core Bond Fund commenced operations on July 31, 2020. The Fund's investment objective is total return consistent with income generation.

Eventide Dividend Growth Fund commenced operations on September 29, 2017. The Fund's investment objectives are dividend growth and long term capital appreciation. The Fund's secondary objective is dividend income.

Eventide Exponential Technologies Fund commenced operations on June 30, 2020. The Fund's investment objective is long-term capital appreciation.

Eventide Gilead Fund commenced operations on July 8, 2008. The Fund's investment objective is long-term capital appreciation.

Eventide Healthcare & Life Sciences Fund commenced operations on December 27, 2012. The Fund's investment objective is long-term capital appreciation.

Eventide Large Cap Focus Fund commenced operations on June 30, 2022. The Fund's investment objective is long-term capital appreciation.

Eventide Limited-Term Bond Fund (formerly Epiphany FFV Strategic Income Fund) Class A and Class I shares commenced operations on July 28, 2010. On March 29, 2017, the Board of Trustees of Epiphany Funds voted to reclassify all outstanding Class C Shares of the Epiphany FFV Strategic Income Fund to Class I shares to be effective on May 30, 2017 (the ***"Conversion Date"***). On the Conversion Date, each Class C share was reclassified as Class I shares equal in value to the Class C shares owned by that shareholder. The Fund's investment objective is income.

Each Fund offers four classes of shares, Class N, Class A, Class C and Class I. Each class differs as to sales and redemption charges and ongoing fees.

**Operating Segments** – The Funds have adopted Financial Accounting Standards Board (***"FASB"***) Accounting Standards Update (***"ASU"***) 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. Adoption of the standard impacted financial statement disclosures only and did not affect each Fund's financial position or the results of its operations. An operating segment is defined in Topic 280 as a component of a public entity that engages in business activities from which it may recognize revenues and incur expenses, has operating results that are regularly reviewed by the public entity's chief operating decision maker (***"CODM"***) to make decisions about resources to be allocated to the segment and assess its performance, and has discrete financial information available. The CODM is comprised of the portfolio manager(s) of the Funds and the Chief Financial Officer of the Trust. Each Fund operates as a single operating segment. Each Fund's income, expenses, assets, changes in net assets resulting from operations and performance are regularly monitored and assessed as a whole by the CODM responsible for oversight functions of each Fund, using the information presented in the financial statements and financial highlights.

The following is a summary of significant accounting policies consistently followed by the Funds and are in accordance with generally accepted accounting principles in the United States of America (***"GAAP"***). The Funds are investment companies and accordingly follow the investment company accounting and reporting guidance of the FASB Accounting Standards Codification Topic 946 "Financial Services – Investment Companies" including ASU 2013-08.

a) &nbsp;&nbsp;&nbsp;&nbsp;Securities Valuation – Securities listed on an exchange are valued at the last reported sale price at the close of the regular trading session of the exchange on the business day the value is being determined, or in the case of securities listed on NASDAQ, at the NASDAQ Official Closing Price (***"NOCP"***). In the absence of a sale, such securities shall be valued at the last bid price on the day of valuation. Debt securities (other than short-term obligations) are valued each day by an independent pricing service approved by the Board of Trustees (the ***"Board"***) using methods which include current market quotations from a major market maker in the securities and based on methods which include the consideration of yields or prices of securities of comparable quality, coupon, maturity and type. The Funds may invest in portfolios of open-end or closed-end investment companies (the ***"underlying funds"***). Open-end investment companies are valued at their respective net asset values as reported by such investment companies. The underlying funds value securities in their portfolios for which market quotations are readily available at their market values (generally the last reported sale price) and all other securities and assets at their fair value by the methods

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

established by the boards of trustees of the underlying funds. The shares of many closed-end investment companies, after their initial public offering, frequently trade at a price per share, which is different than the net asset value per share. The difference represents a market premium or market discount of such shares. There can be no assurances that the market discount or market premium on shares of any closed-end investment company purchased by the Funds will not change. The independent pricing service does not distinguish between smaller-sized bond positions known as "odd lots" and larger institutional-sized bond positions known as "round lots". The Funds may fair value a particular bond if the Adviser does not believe that the round lot value provided by the independent pricing service reflects fair value of the Fund's holding. Short term debt obligations having 60 days or less remaining until maturity, at time of purchase, may be valued at amortized cost, provided each such valuations represent fair value. Options are valued at their closing price on the exchange they are traded on. When no closing price is available, options are valued at their mean price.

The Funds may hold investments, such as private investments, interests in commodity pools, other non-traded securities or temporarily illiquid securities, for which market quotations are not readily available or are determined to be unreliable. These securities are valued using the "fair value" pursuant to the Rule 2a-5 procedures (the "***Procedures***") approved by the Board. The Board has designated the Adviser as its valuation designee (the "***Valuation Designee***") to execute these Procedures. The Board may also enlist third party consultants such as a valuation specialist at a public accounting firm, valuation consultant or financial officer of a security issuer, on an as-needed basis to assist the Valuation Designee in determining a security-specific fair value. The Board is responsible for reviewing and approving fair value methodologies utilized by the Valuation Designee, approval of which shall be based upon whether the Valuation Designee followed the valuation procedures established by the Board.

The Funds utilize various methods to measure the fair value of most of their investments on a recurring basis. GAAP establishes a hierarchy that prioritizes inputs to valuation methods. The three levels of input are:

Level 1 – Unadjusted quoted prices in active markets for identical assets and liabilities that the Funds have the ability to access.

Level 2 – Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument in an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.

Level 3 – Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Funds' own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.

The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following tables summarize the inputs used as of December 31, 2025 for the Funds' assets measured at fair value:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Eventide Balanced Fund**<br>**Assets**<br>**Security Classifications** |<br>**Level 1** |<br>**Level 2** |<br>**Level 3** |<br>**Totals** |
| Common Stocks <sup>(a)</sup> | $193899509 | $— | $— | $193899509 |
| Asset Backed Securities <sup>(a)</sup> |  | 4551124 |  | 4551124 |
| Collateralized Mortgage Obligations <sup>(a)</sup> |  | 1918427 |  | 1918427 |
| Corporate Bonds <sup>(a)</sup> |  | 85502550 |  | 85502550 |
| Municipal Bonds <sup>(a)</sup> |  | 15687616 |  | 15687616 |
| U.S. Government & Agencies <sup>(a)</sup> |  | 72326722 |  | 72326722 |
| Short-Term Investments | 118974 |  |  | 118974 |
| &nbsp;&nbsp;&nbsp;**Total** | $194018483 | $179986439 | $— | $374004922 |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Eventide Core Bond Fund**<br>**Assets**<br>**Security Classifications** |<br>**Level 1** |<br>**Level 2** |<br>**Level 3** |<br>**Totals** |
| Asset Backed Securities <sup>(a)</sup> | $— | $3761259 | $— | $3761259 |
| Corporate Bonds <sup>(a)</sup> |  | 77742493 | 1000000 | 78742493 |
| Municipal Bonds <sup>(a)</sup> |  | 12174705 |  | 12174705 |
| U.S. Government & Agencies <sup>(a)</sup> |  | 63019229 |  | 63019229 |
| &nbsp;&nbsp;&nbsp;**Total** | $— | $156697686 | $1000000 | $157697686 |
| **Eventide Dividend Growth Fund** |  |  |  |  |
| **Assets** |  |  |  |  |
| **Security Classifications** | **Level 1** | **Level 2** | **Level 3** | **Totals** |
| Common Stocks <sup>(a)</sup> | $1139197286 | $— | $— | $1139197286 |
| Short-Term Investments | 119360 |  |  | 119360 |
| &nbsp;&nbsp;&nbsp;**Total** | $1139316646 | $— | $— | $1139316646 |
| **Eventide Exponential Technologies Fund** |  |  |  |  |
| **Assets** |  |  |  |  |
| **Security Classifications** | **Level 1** | **Level 2** | **Level 3** | **Totals** |
| Common Stocks <sup>(a)</sup> | $89094876 | $— | $— | $89094876 |
| Corporate Bonds <sup>(a)</sup> |  | 749017 |  | 749017 |
| Short-Term Investments | 13381 |  |  | 13381 |
| &nbsp;&nbsp;&nbsp;**Total** | $89108257 | $749017 | $— | $89857274 |
| **Eventide Gilead Fund** |  |  |  |  |
| **Assets** |  |  |  |  |
| **Security Classifications** | **Level 1** | **Level 2** | **Level 3** | **Totals** |
| Common Stocks <sup>(a)</sup> | $2788632442 | $— | $— | $2788632442 |
| Contingent Value Rights <sup>(a)</sup> |  |  | 4663883 | 4663883 |
| Corporate Bonds <sup>(a)</sup> |  | 25845999 | 8000000 | 33845999 |
| Short-Term Investments | 5556440 |  |  | 5556440 |
| &nbsp;&nbsp;&nbsp;**Total** | $2794188882 | $25845999 | $12663883 | $2832698764 |
| **Eventide Healthcare & Life Sciences Fund** |  |  |  |  |
| **Assets** |  |  |  |  |
| **Security Classifications** | **Level 1** | **Level 2** | **Level 3** | **Totals** |
| Common Stocks <sup>(a)</sup> | $1581362276 | $— | $— | $1581362276 |
| Contingent Value Rights <sup>(a)</sup> |  |  | 5652814 | 5652814 |
| Private Investments <sup>(a)</sup> |  |  | 49346623 | 49346623 |
| Convertible Bonds <sup>(a)</sup> |  |  | 242533 | 242533 |
| Warrant <sup>(a)</sup> |  |  | 3261956 | 3261956 |
| Short-Term Investments | 3628600 |  |  | 3628600 |
| &nbsp;&nbsp;&nbsp;**Total** | $1584990876 | $— | $58503926 | $1643494802 |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Eventide Large Cap Focus Fund**<br>**Assets**<br>**Security Classifications** |<br>**Level 1** |<br>**Level 2** |<br>**Level 3** |<br>**Totals** |
| Common Stocks <sup>(a)</sup> | $172984296 | $— | $— | $172984296 |
| &nbsp;&nbsp;&nbsp;**Total** | $172984296 | $— | $— | $172984296 |
| **Eventide Limited-Term Bond Fund** |  |  |  |  |
| **Assets** |  |  |  |  |
| **Security Classifications** | **Level 1** | **Level 2** | **Level 3** | **Totals** |
| Asset Backed Securities <sup>(a)</sup> | $— | $4110928 | $— | $4110928 |
| Corporate Bonds <sup>(a)</sup> |  | 136645683 | 1000000 | 137645683 |
| Municipal Bonds <sup>(a)</sup> |  | 6295669 |  | 6295669 |
| U.S. Government & Agencies <sup>(a)</sup> |  | 53876732 |  | 53876732 |
| &nbsp;&nbsp;&nbsp;**Total** | $— | $200929012 | $1000000 | $201929012 |

---

(a) For a detailed break-out of investments
 by security classification, please refer to the Schedule of Investments.

The following is a reconciliation of assets in which level 3 inputs were used in determining value:

---

| | | | |
|:---|:---|:---|:---|
| **Eventide Core Bond Fund** | | | |
|  | Corporate Bonds | Total |  |
| Beginning balance 6/30/2025 | $— | $— |  |
| Total realized gain (loss) |  |  |  |
| Change in unrealized appreciation (depreciation) |  |  |  |
| Cost of purchases | 1000000 | 1000000 |  |
| Proceeds from sales |  |  |  |
| Non-taxable merger |  |  |  |
| Dividend reinvest |  |  |  |
| Net transfers in/out of level 3\* |  |  |  |
| Ending balance 12/31/2025 | $1000000 | $1000000 |  |
| **Eventide Gilead Fund** |  |  |  |
|  | Contingent |  |  |
|  | Value Rights | Corporate Bonds | Total |
| Beginning balance 6/30/2025 | $4493951 | $5000000 | $9493951 |
| Total realized gain (loss) |  |  |  |
| Change in unrealized appreciation (depreciation) | 169932 |  | 169932 |
| Cost of purchases |  | 8000000 | 8000000 |
| Proceeds from sales |  |  |  |
| Corporate action |  |  |  |
| Dividend reinvest |  |  |  |
| Net transfers in/out of level 3 |  | (5000000) | (5000000) |
| Ending balance 12/31/2025 | $4663883 | $8000000 | $12663883 |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** |
|  | Contingent | Private | Convertible |  |  |
|  | Value Rights | Investments | Bonds | Warrants | Total |
| Beginning balance 6/30/2025 | $1725025 | $39379883 | $242533 | $— | $41347441 |
| Total realized gain (loss) |  | (14535086) |  |  | (14535086) |
| Change in unrealized appreciation (depreciation) | 65229 | 24966761 |  |  | 25031990 |
| Cost of purchases |  | 7999983 |  |  | 7999983 |
| Proceeds from sales |  |  |  |  |  |
| Corporate action | 3862560 | (8464918) |  | 3261956 | (1340402) |
| Dividend reinvest |  |  |  |  |  |
| Net transfers in/out of level 3 |  |  |  |  |  |
| Ending balance 12/31/2025 | $5652814 | $49346623 | $242533 | $3261956 | $58503926 |
| **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** |
|  | Corporate Bonds | Total |  |  |  |
| Beginning balance 6/30/2025 | $— | $— |  |  |  |
| Total realized gain (loss) |  |  |  |  |  |
| Change in unrealized appreciation (depreciation) |  |  |  |  |  |
| Cost of purchases | 1000000 | 1000000 |  |  |  |
| Proceeds from sales |  |  |  |  |  |
| Corporate action |  |  |  |  |  |
| Dividend reinvest |  |  |  |  |  |
| Net transfers in/out of level 3 |  |  |  |  |  |
| Ending balance 12/31/2025 | $1000000 | $1000000 |  |  |  |

---

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private investments were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Fund** | &nbsp;&nbsp;**Description** | &nbsp;&nbsp;**Valuation<br> Technique(s)** | &nbsp;&nbsp;**Unobservable<br> Input** | &nbsp;&nbsp;**Input** | &nbsp;&nbsp;**Impact to<br> Valuation from<br> an increase in<br> Input<sup>A</sup>** |
| &nbsp;&nbsp;Eventide Core Bond Fund<br> Eventide Gilead Fund<br> Eventide Limited-Term Bond Fund | &nbsp;&nbsp;CI Credit GP LLC 5.5% 12/15/30 | &nbsp;&nbsp;Market Approach | &nbsp;&nbsp;Recent transaction price | &nbsp;&nbsp;$100.00 | &nbsp;&nbsp;Increase |
| &nbsp;&nbsp;Eventide Gilead Fund | &nbsp;&nbsp;Vision Fund International 5.1% 12/15/29 | &nbsp;&nbsp;Market Approach | &nbsp;&nbsp;Recent transaction price | &nbsp;&nbsp;$100.00 | &nbsp;&nbsp;Increase |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Avalyn Pharma Inc. Series C1, <br> Avalyn Pharma Inc. Series D1 | &nbsp;&nbsp;Market Approach | &nbsp;&nbsp;Recent transaction price | &nbsp;&nbsp;$0.80 | &nbsp;&nbsp;Increase |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;BioSplice Therapeutics, Inc. Series, B-1, <br> BioSplice Therapeutics, Inc. Series C <br> PIK BioSplice Series C Warrant | &nbsp;&nbsp;Cash Value | &nbsp;&nbsp;Cash | &nbsp;&nbsp;$8.1M | &nbsp;&nbsp;Increase |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Casma Therapeutics, Inc. Series B1, <br> Casma Therapeutics, Inc. Series B2, <br> Casma Therapeutics, Inc. Series C1, <br> Casma Therapeutics, Inc. Series C2 | &nbsp;&nbsp;Discount | &nbsp;&nbsp;Discount, Recent transaction price | &nbsp;&nbsp;83%, $0.46 | &nbsp;&nbsp;Decrease, Increase |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Evida BioSciences, Inc. | &nbsp;&nbsp;Discount | &nbsp;&nbsp;Discount, Recent transaction price | &nbsp;&nbsp;$57.8M, 38% | &nbsp;&nbsp;Decrease, Increase |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Fund** | &nbsp;&nbsp;**Description** | &nbsp;&nbsp;**Valuation**<br> **Technique(s)** | &nbsp;&nbsp;**Unobservable**<br> **Input** | &nbsp;&nbsp;**Input** | &nbsp;&nbsp;**Impact to**<br> **Valuation from**<br> **an increase in**<br> **Input<sup>A</sup>** |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Flare Therapeutics, Inc. Series A, <br> Flare Therapeutics, Inc. Series A2, <br> Flare Therapeutics, Inc. Series B | &nbsp;&nbsp;Probability- Weighted Expected Return | &nbsp;&nbsp;Revenue, Revenue multiple, Recovery multiple, Strategic sale, IPO, Downside, Dissolution | &nbsp;&nbsp;$1B,<br> 9x-12x,<br> 50%-75%,<br> 1.8%,<br> 1.8%,<br> 1.8%,<br> 94.7% | &nbsp;&nbsp;Increase, Increase, Increase, Increase, Increase, Decrease, Decrease |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Freenome Holdings, Inc. Series D, <br> Freenome Holdings, Inc. Series F | &nbsp;&nbsp;Market Approach | &nbsp;&nbsp;Recent transaction price | &nbsp;&nbsp;$725M | &nbsp;&nbsp;Increase |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Goldfinch Biopharma, Inc. Series A, <br> Goldfinch Biopharma, Inc. Series B, <br> Goldfinch Biopharma, Inc. Series B2 | &nbsp;&nbsp;Residual Value | &nbsp;&nbsp;Net assets | &nbsp;&nbsp;$12.1M | &nbsp;&nbsp;Increase |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Kardigan, Inc. Series B | &nbsp;&nbsp;Market Approach | &nbsp;&nbsp;Recent transaction price | &nbsp;&nbsp;$21.37 | &nbsp;&nbsp;Increase |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Kardium, Inc. Series D8 | &nbsp;&nbsp;Market Approach | &nbsp;&nbsp;Recent transaction price | &nbsp;&nbsp;$0.65 | &nbsp;&nbsp;Increase |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Kojin Therapeutics, Inc. Series A-1, <br> Kojin Therapeutics, Inc. Series A-2 | &nbsp;&nbsp;Residual Value | &nbsp;&nbsp;Net assets | &nbsp;&nbsp;$0 | &nbsp;&nbsp;Increase |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Metsera - CRV | &nbsp;&nbsp;Present Value | &nbsp;&nbsp;Discount rate, Probability of Success, Milestone | &nbsp;&nbsp;12%,<br> 65%-80%,<br> $4.60-$9.65 per share | &nbsp;&nbsp;Decrease, Increase, Increase |
| &nbsp;&nbsp;Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Ovid Therapeutics Inc. Series A Warrant <br> Ovid Therapeutics Inc. Series B Warrant | &nbsp;&nbsp;Option Pricing Model | &nbsp;&nbsp;Probability of Success | &nbsp;&nbsp;45% | &nbsp;&nbsp;Increase |
| &nbsp;&nbsp;Eventide Gilead Fund Eventide Healthcare & Life Sciences Fund | &nbsp;&nbsp;Peloton Therapeutics, Inc. - CRV | &nbsp;&nbsp;Present Value | &nbsp;&nbsp;Discount rate, Probability of success, Milestone | &nbsp;&nbsp;10%,<br> 0%-100%,<br> $50M-$1.1B | &nbsp;&nbsp;Decrease, Increase, Increase |

---

<sup>A</sup> Represents the directional change in the fair value of the Level 3 investments that could have resulted from an increase in the corresponding input as of period end. A decrease to the unobservable input would have had the opposite effect. Significant changes in these inputs may have resulted in a significantly higher or lower fair value measurement at period end.

The total change in unrealized appreciation or depreciation included in the Statements of Operations attributable to Level 3 investments still held at December 31, 2025, was $169,932 and $25,031,990 for the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund, respectively.

b) &nbsp;&nbsp;&nbsp;&nbsp; Accounting for Options – When the Funds write an option, an amount equal to the premium received by the Funds is recorded as a liability and is subsequently adjusted to the current fair value of the option written. Premiums received from writing options that expire unexercised are treated by the Funds on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security or currency in determining whether the Funds have realized gains or losses. If a put option is exercised, the premium reduces the cost basis of the securities purchased by the Funds.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

The Adviser may use options strategies, such as puts and covered calls on individual securities, as well as options on securities indices, to generate income, to reduce portfolio volatility, or to reduce downside risk when the portfolio manager believes adverse market, political or other conditions are likely. The Adviser may also utilize a combination of puts and/or calls regarding the same security (sometimes referred to as "straddles," "collars" or "spreads") or utilize puts and calls on related securities. The Funds may purchase a call option on a stock (including securities of exchange traded funds ("***ETFs***")) it may purchase at some point in the future. When the Funds purchase an option, the premium paid is recorded as an asset. Each day the option contract is valued in accordance with the procedures for security valuation discussed above. When an offsetting option is written (a closing transaction) or the option contract expires, the Funds realize a gain or loss and the asset representing such option contract is eliminated. When a put option is exercised, the Funds realize a gain or loss from the sale of the underlying security and the proceeds of the sale are decreased by the premiums originally paid. When a call option is exercised, the Funds purchase the underlying security and the cost basis of such purchase is increased by the premium originally paid.

The notional value of the derivative instruments outstanding as of December 31, 2025 as disclosed in the amounts realized and changes in unrealized gains and losses on derivative instruments during the period as disclosed above and within the Statements of Operations serve as indicators of the volume of derivative activity of the Funds.

c) &nbsp;&nbsp;&nbsp;&nbsp;Short Sales – The Funds may sell securities short. A short sale is a transaction in which the Funds sell securities they do not own in anticipation of a decline in the market price of the securities. To deliver the securities to the buyer, the Funds must arrange through a broker to borrow the securities and, in so doing, the Funds become obligated to replace the securities borrowed at their market price at the time of replacement, whatever that price may be. The Funds will make a profit or incur a loss as a result of a short sale depending on whether the price of the securities decrease or increase between the date of the short sale and the date on which the Funds purchased the securities to replace the borrowed securities that have been sold.

d) &nbsp;&nbsp;&nbsp;&nbsp;Federal Income Tax – The Funds have qualified and intend to continue to qualify each year as regulated investment companies ("RIC") under subchapter M of the Internal Revenue Code of 1986, as amended. By complying with the requirements applicable to RICs and annually distributing substantially all net investment company taxable income and net realized capital gains, no provision for federal income tax is required. The Funds recognize the tax benefits of uncertain tax positions only where the position is "more likely than not" to be sustained assuming examination by tax authorities. Management has reviewed the Funds' tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken in the current tax year or on returns filed in previous tax years which are still open to examination by all major tax authorities (generally, federal returns are open to examination by the Internal Revenue Service for a period of three years from date of filing). The Funds recognize interest and penalties, if any, related to unrecognized tax benefits as income tax expense in the Statements of Operations when incurred. During the fiscal year, the Funds did not incur any interest or penalties. The Funds typically intend to annually distribute sufficient net investment company taxable income and net realized capital gains if any, so that they will not be subject to the excise tax on undistributed income of RICs. If the required amount of net investment income or gains is not distributed annually, the Funds could incur a tax expense.

e) &nbsp;&nbsp;&nbsp;&nbsp;Distributions to Shareholders – Distributions to shareholders, which are determined in accordance with income tax regulations and may differ from GAAP, are recorded on the ex-dividend date. Each Fund typically distributes substantially all its net investment income in the form of dividends, interest and taxable capital gains to its shareholders. These distributions are automatically reinvested in the Fund unless you request cash distributions on your application or through a written request to the Fund. Each Fund expects that its distributions will consist of both capital gains, interest and dividend income. Each Fund may make distributions (after any reductions for capital loss carry forwards) annually except for the Eventide Balanced Fund and Eventide Limited-Term Bond Fund, which are monthly, and the Eventide Dividend Growth Fund and Eventide Core Bond Fund, which are quarterly.

f) &nbsp;&nbsp;&nbsp;&nbsp;Multiple Class Allocations – Income, non-class specific expenses and realized/unrealized gains or losses are allocated to each class based on relative net assets. Distribution fees are charged to each respective share class in accordance with the distribution plan. Expenses of the Trust that are directly identifiable to a specific fund are charged to that fund. Expenses which are not readily identifiable to a specific fund, are allocated in such a manner as deemed equitable, taking into consideration the nature and type of expense and the relative sizes of the funds in the Trust.

g) &nbsp;&nbsp;&nbsp;&nbsp;Security Transactions and Investment Income – Investment and shareholder transactions are recorded on the trade date. The Funds determine the gain or loss realized from the investment transactions by comparing the specific identified cost of the security lot sold with the net sales proceeds. Dividend income is recognized on the ex-dividend date or as soon as information is available to the Funds and interest income is recognized on an accrual basis. Discounts and premiums on debt securities are amortized over their respective lives using the effective interest method, except certain callable debt securities that are held at premium and will be amortized to the earliest call date. Withholding taxes on foreign dividends have been provided for in accordance with the Funds' understanding of the applicable country's tax rules and rates. Distributions received from a Fund's investments in MLPs generally are comprised of income and return of capital. The Funds record these distributions as investment income and subsequently adjusts these distributions within the components of net assets based upon their tax treatment when the information becomes available. Distributions from REITs are initially recorded as dividend income and, to the extent such represent a return of capital or capital gain for tax purposes, are reclassified when such information becomes available.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

h) &nbsp;&nbsp;&nbsp;&nbsp;Use of Estimates – The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

i) &nbsp;&nbsp;&nbsp;&nbsp;Indemnification – The Trust indemnifies its officers and Trustees for certain liabilities that may arise from the performance of their duties to the Trust. In the normal course of business, the Trust may enter into contracts that contain a variety of representations and warranties and provide general indemnifications. The Funds' maximum exposure under these arrangements is dependent on future claims that may be made against the Funds and, therefore, cannot be estimated; however, management considers the risk of loss from such claims to be remote.

j) &nbsp;&nbsp;&nbsp;&nbsp;Redemption Fees and Sales Charges (loads) – A $15 fee may be charged for redemptions made by wire. A maximum sales charge of 5.75% is imposed on Class A shares of the Funds applies only to purchases of $250,000 or more and applies to shares sold within 18 months of purchase. The maximum deferred sales charge of 1.00% on Class C shares applies to shares sold within 12 months of purchase. The respective shareholders pay such CDSC charges, which are not an expense of the Funds. For the six months ended December 31, 2025, there were the following redemption fees paid to the Funds and CDSC fees paid to the distributor:

---

| | | | |
|:---|:---|:---|:---|
| | | **CDSC Fees** | **CDSC Fees** |
| <br>**Fund** |<br>**Redemption Fees** | **Class A** | **Class C** |
| Eventide Balanced Fund | $— | $— | $276 |
| Eventide Core Bond Fund |  |  | 18 |
| Eventide Dividend Growth Fund |  |  | 550 |
| Eventide Exponential Technologies Fund |  |  | 4 |
| Eventide Gilead Fund |  |  | 265 |
| Eventide Healthcare & Life Sciences Fund |  |  | 347 |
| Eventide Large Cap Focus Fund |  |  | 6 |
| Eventide Limited-Term Bond Fund |  |  | 19 |

---

k) &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents – Cash and cash equivalents are held with a financial institution. Cash and cash equivalents of the Funds may be placed in deposit accounts at U.S. banks and such deposits generally exceed Federal Deposit Insurance Corporation ("***FDIC***") insurance limits. The FDIC insures deposit accounts up to $250,000 for each accountholder. The counterparty is generally a single bank rather than a group of financial institutions; thus there may be a greater counterparty credit risk. The Funds place deposits only with those counterparties which are believed to be creditworthy and there has been no history of loss.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(2)** **INVESTMENT TRANSACTIONS** 

For the six months ended December 31, 2025, aggregate purchases and proceeds from sales of investment securities (excluding short-term investments) for the Funds were as follows:

---

| | | |
|:---|:---|:---|
| <br>**Fund** |<br>**Purchases of Securities** | **Proceeds From Sales of**<br>**Securities** |
| Eventide Balanced Fund | $69932457 | $74437793 |
| Eventide Core Bond Fund | 28327334 | 21267789 |
| Eventide Dividend Growth Fund | 261511844 | 308745792 |
| Eventide Exponential Technologies Fund | 59112613 | 73440532 |
| Eventide Gilead Fund | 261387424 | 513421747 |
| Eventide Healthcare & Life Sciences Fund | 761868542 | 822536078 |
| Eventide Large Cap Focus Fund | 29376193 | 21435592 |
| Eventide Limited-Term Bond Fund | 52047592 | 2592113 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(3)** **INVESTMENT ADVISORY AGREEMENT AND TRANSACTIONS WITH RELATED PARTIES** 

Eventide Asset Management, LLC acts as investment manager to the Funds pursuant to the terms of an investment advisory agreement between the Adviser and the Trust (the ***"Advisory Agreement"***). Boyd Watterson Asset Management, LLC serves as sub-adviser to the Eventide Limited-Term Bond Fund, the Eventide Core Bond Fund, and a portion of the Eventide Balanced Fund's portfolio. Under the terms of the Advisory Agreement, the Adviser directs the investment operations of the Funds in accordance with the Funds' investment policies and restrictions. The Adviser provides the Funds with investment advice and supervision and furnishes an investment program for the Funds. The fees paid by the Funds to the Adviser are described in greater detail below. The Adviser pays expenses incurred by it in connection with acting as investment adviser to the Funds other than costs (including taxes and brokerage commissions, borrowing costs, costs of investing in underlying funds and extraordinary expenses, if any) of securities purchased for the Funds and certain other expenses paid by the Funds (as detailed in the Advisory Agreement).

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

The Adviser pays for all employees, office space and facilities required by it to provide services under the Advisory Agreement, with the exception of specific items of expense (as detailed in the Advisory Agreement). For the six months ended December 31, 2025, advisory fees before the waivers and reimbursements described below.

---

| | |
|:---|:---|
| **Fund** | **Advisory Fees** |
| Eventide Balanced Fund | $1171250 |
| Eventide Core Bond Fund | 261788 |
| Eventide Dividend Growth Fund | 4423542 |
| Eventide Exponential Technologies Fund | 474576 |
| Eventide Gilead Fund | 14378302 |
| Eventide Healthcare & Life Sciences Fund | 7767275 |
| Eventide Large Cap Focus Fund | 639596 |
| Eventide Limited-Term Bond Fund | 282579 |

---

Each Fund is authorized to pay the Adviser an annual fee based on its average daily net assets. The advisory fee is paid monthly. The Adviser has contractually agreed to waive fees and/or reimburse expenses, but only to the extent necessary to maintain each Fund's total annual operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at a certain level through October 31, 2026. This agreement may be terminated by the Board only on 60 days' written notice to the Adviser and upon the termination of the Advisory Agreement between the Trust and the Adviser. Fee waivers and expense reimbursements are subject to possible recoupment by the Adviser from the Funds in future years on a rolling three-year basis (within the three years after the fees have been waived or reimbursed) if, after the recoupment is taken into account, such recoupment can be achieved within the lesser of the expense limitation in place at the time of waiver/reimbursement and the expense limitation in place at the time of recapture. Each waiver or reimbursement by the Adviser is subject to repayment by the Fund within the three years following the year in which that particular expense is incurred, if the Fund is able to make the repayment without exceeding the expense limitation in effect at that time and the repayment is approved by the Board.

The following table lists the contractual advisory fee and the expense limitation for each Fund.

---

| | | | |
|:---|:---|:---|:---|
| Fund | Contractual Advisory Fee | Expense Limitation | Expense Limitation |
| Eventide Balanced Fund | 0.60% | Class N: | 1.02% |
|  |  | Class A: | 1.07% |
|  |  | Class C: | 1.82% |
|  |  | Class I: | 0.82% |
| Eventide Core Bond Fund | 0.34% | Class N: | 0.68% |
|  |  | Class A: | 0.73% |
|  |  | Class C: | 1.48% |
|  |  | Class I: | 0.48% |
| Eventide Dividend Growth Fund | 0.73% | Class N: | 1.15% |
|  |  | Class A: | 1.20% |
|  |  | Class C: | 1.95% |
|  |  | Class I: | 0.95% |
| Eventide Exponential Technologies Fund | 0.95%\* | Class N: | 1.55% |
|  |  | Class A: | 1.60% |
|  |  | Class C: | 2.35% |
|  |  | Class I: | 1.35% |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

---

| | | | |
|:---|:---|:---|:---|
| Fund | Contractual Advisory Fee | Expense Limitation | Expense Limitation |
| Eventide Gilead Fund | 1.00% of the first $2 billion; | Class N: | 1.62% |
|  | 0.95% on the next $1 billion; | Class A: | 1.67% |
|  | 0.90% on the next $1 billion; | Class C: | 2.42% |
|  | and 0.85% thereafter | Class I: | 1.42% |
| Eventide Healthcare & Life Sciences Fund | 1.10% | Class N: | 1.63% |
|  |  | Class A: | 1.68% |
|  |  | Class C: | 2.43% |
|  |  | Class I: | 1.43% |
| Eventide Large Cap Focus Fund | 0.73% | Class N: | 1.14% |
|  |  | Class A: | 1.19% |
|  |  | Class C: | 1.94% |
|  |  | Class I: | 0.94% |
| Eventide Limited-Term Bond Fund | 0.31% | Class N: | 0.65% |
|  |  | Class A: | 0.70% |
|  |  | Class C: | 1.45% |
|  |  | Class I: | 0.45% |

---

\* Effective September 1, 2025, the contractual advisory fee of the Exponential Technologies Fund changed from 1.10% to 0.95%.

^ Effective September 1, 2025, the expense limitations of Core Bond Fund, Exponential Technologies Fund and Limited-Term Bond Fund changed.

For the six months ended December 31, 2025, the Adviser waived the following amounts.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**Fund** | **Waived Amount** |
| Eventide Balanced Fund | $— |
| Eventide Core Bond Fund | 129597 |
| Eventide Dividend Growth Fund |  |
| Eventide Exponential Technologies Fund | 28634 |
| Eventide Gilead Fund |  |
| Eventide Healthcare & Life Sciences Fund |  |
| Eventide Large Cap Focus Fund | 161871 |
| Eventide Limited-Term Bond Fund | 105392 |

---

As of December 31, 2025, the Adviser has waived/reimbursed expenses that may be recovered no later than June 30 of the years indicated below:

---

| | | | |
|:---|:---|:---|:---|
| | 2026 | 2027 | 2028 |
| Eventide Balanced Fund | $276044 | $236729 | $— |
| Eventide Core Bond Fund | 164775 | 131361 | 143748 |
| Eventide Dividend Growth Fund | 249595 | 97498 |  |
| Eventide Exponential Technologies Fund | 69721 | 68862 | 112235 |
| Eventide Large Cap Focus Fund | 107732 | 101331 | 280014 |
| Eventide Limited-Term Bond Fund | 243710 | 202441 | 76975 |

---

The Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund do not have any expenses previously waived by the Adviser that are subject to recapture and did not waive any further expenses during the sixth months ended December 31, 2025.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

Pursuant to the Management Services Agreement between the Trust and MFund Services, LLC *(**"MFund"***), MFund provides the Funds with management and legal administrative services (the ***"Management Services Agreement"***). For these services, the Funds pay MFund an annual asset-based fee in accordance with the following schedule applied at the Fund family level (i.e., all the Funds in the Trust advised by the Adviser): 0.10% of net assets up to $50 million; 0.07% of net assets from $50 million to $100 million; 0.05% of net assets from $100 million to $250 million; 0.04% of net assets from $250 million to $500 million; 0.03% of net assets from $500 million to $1 billion; 0.02% of net assets from $1 billion to $5 billion; and 0.01% of assets from $5 billion and above. In addition, the Funds reimburse MFund for any reasonable out-of-pocket expenses incurred in the performance of its duties under the Management Services Agreement. The amounts due to MFund for the Management Services Agreement are listed in the Statements of Assets and Liabilities under "Payable to related parties" and the amounts accrued for the year are shown in the Statements of Operations under "Legal administration fees/Management service fees."

Pursuant to the Compliance Services Agreement, MFund provides chief compliance officer services to the Funds. For these services, the Funds pay MFund $1,200 per month for the first fund in the fund family and $400 each additional fund; $400 for each adviser and sub-adviser; and .0025% of the assets of each Fund. In addition, the Funds reimburse MFund for any reasonable out-of-pocket expenses incurred in the performance of its duties under the Compliance Services Agreement.

Amounts due to MFund for chief compliance officer services as of December 31, 2025 are shown in the Statement of Assets and Liabilities under "Compliance officer fees payable," and the amounts accrued for the period are shown in the Statements of Operations under "Compliance officer fees."

A trustee of the Trust is also the controlling member of MFund and the investment advisers to other series of the Trust and is not paid any fees directly by the Trust for serving in such capacities. Trustees who are not "interested persons" as that term is defined in the 1940 Act are paid a quarterly retainer and receive compensation for each special Board meeting and Risk and Compliance Committee meeting attended. The fees paid to the Independent Trustees for attendance at a meeting will be shared equally by the funds of the Trust in which the meeting relates. The Lead Independent Trustee of the Trust, the Chairman of the Trust's Audit Committee and the Chairman of the Risk and Compliance Committee receive an additional quarterly retainer. The "interested persons" of the Trust receive no compensation from the Funds. The Trust reimburses each Trustee and Officer for his or her travel and other expenses related to attendance at such meetings.

Ultimus Fund Solutions, LLC (**"*UFS*"**), an affiliate of the distributor, provides administrative, fund accounting, and transfer agency services to the Funds pursuant to agreements with the Trust, for which it receives from each Fund: (i) basis points in decreasing amounts as assets reach certain breakpoints; and (ii) any related out-of-pocket expenses.

Blu Giant, LLC (***"Blu Giant"***), an affiliate of UFS and the distributor, provides EDGAR conversion and filing services as well as print management services for the Funds on an ad-hoc basis. For the provision of these services, Blu Giant receives customary fees from the Funds.

The Trust's officers are not paid any fees directly by the Trust for serving in such capacity except for the chief compliance officer.

The Trust has adopted a Master Distribution Plan Pursuant to Rule 12b-1 (the **"*Plan*"**) under the 1940 Act for each class of shares except Class I, that allows the Funds to pay distribution and shareholder servicing expenses of up to 0.25% per annum for the Class N shares, up to 0.50% per annum for the Class A shares and up to 1.00% for the Class C shares based on average daily net assets of each class. The Class N shares are currently paying 0.20% per annum of 12b-1 fees, Class A shares are currently paying 0.25% per annum of 12b-1 fees and Class C shares are currently paying 1.00% per annum of 12b-1 fees.

The 12b-1 fees may be used for a variety of purposes, including compensating dealers and other financial service organizations for eligible services provided by those parties to the Funds and their shareholders and to reimburse Northern Lights Distributors, LLC (the ***"Distributor"***) and the Adviser for distribution related expenses.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

For the six months ended December 31, 2025, the Distributor received the following in underwriter commissions from the sale of Class A and Class C shares.

---

| | |
|:---|:---|
| <br>**Fund** | **Underwriter**<br>**Commissions** |
| Eventide Balanced Fund | $17307 |
| Eventide Core Bond Fund | 3214 |
| Eventide Dividend Growth Fund | 26930 |
| Eventide Exponential Technologies Fund | 2136 |
| Eventide Gilead Fund | 37085 |
| Eventide Healthcare & Life Sciences Fund | 11487 |
| Eventide Large Cap Focus Fund | 9267 |
| Eventide Limited-Term Bond Fund | 1789 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(4)** **DISTRIBUTIONS TO SHAREHOLDERS AND TAX COMPONENTS OF CAPITAL** 

The following table represents aggregate cost for federal tax purposes, including options written, for the Funds as of December 31, 2025 and differs from market value by net unrealized appreciation/depreciation which consisted of:

---

| | | | | |
|:---|:---|:---|:---|:---|
| <br>**Fund** | **Cost for**<br>**Federal Tax**<br>**purposes** |<br>**Unrealized**<br>**Appreciation** |<br>**Unrealized**<br>**Depreciation** | **Tax Net**<br>**Unrealized**<br>**App/Dep** |
| Eventide Balanced Fund | $331428506 | $48491060 | $(8152658) | $40338402 |
| Eventide Core Bond Fund | 157913071 | 2322985 | (2893260) | (570275) |
| Eventide Dividend Growth Fund | 937456983 | 220857970 | (29272887) | 191585083 |
| Eventide Exponential Technologies Fund | 69592138 | 22950244 | (3173370) | 19776874 |
| Eventide Gilead Fund | 1447553441 | 1387877509 | (48759349) | 1339118160 |
| Eventide Healthcare & Life Sciences Fund | 1159601367 | 567863715 | (89470572) | 478393143 |
| Eventide Large Cap Focus Fund | 146779283 | 29271273 | (5418097) | 23853176 |
| Eventide Limited-Term Bond Fund | 199649540 | 2677026 | (427074) | 2249952 |

---

The tax character of fund distributions for the years ended June 30, 2025, and June 30, 2024, was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***<u>For the year ended June 30, 2025:</u>*** | ***<u>For the year ended June 30, 2025:</u>*** | ***<u>For the year ended June 30, 2025:</u>*** | ***<u>For the year ended June 30, 2025:</u>*** | ***<u>For the year ended June 30, 2025:</u>*** |
| <br>**Fund** | **Ordinary**<br>**Income** | **Long-Term**<br>**Capital Gains** | **Return of**<br>**Capital** |<br>**Total** |
| Eventide Balanced Fund | $7525036 | $— | $— | $7525036 |
| Eventide Core Bond Fund | 6153710 |  |  | 6153710 |
| Eventide Dividend Growth Fund | 6543574 | 510057 |  | 7053631 |
| Eventide Gilead Fund |  | 37480805 |  | 37480805 |
| Eventide Large Cap Focus Fund | 2551278 | 2898158 |  | 5449436 |
| Eventide Limited-Term Bond Fund | 5639759 |  |  | 5639759 |
| ***<u>For the year ended June 30, 2024:</u>*** | ***<u>For the year ended June 30, 2024:</u>*** | ***<u>For the year ended June 30, 2024:</u>*** | ***<u>For the year ended June 30, 2024:</u>*** | ***<u>For the year ended June 30, 2024:</u>*** |
|  | **Ordinary** | **Long-Term** | **Return of** |  |
| **Fund** | **Income** | **Capital Gains** | **Capital** | **Total** |
| Eventide Balanced Fund | $5888612 | $— | $— | $5888612 |
| Eventide Core Bond Fund | 3769367 |  |  | 3769367 |
| Eventide Dividend Growth Fund | 3699013 |  |  | 3699013 |
| Eventide Limited-Term Bond Fund | 4104125 |  |  | 4104125 |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

As of June 30, 2025, the components of accumulated earnings/(losses) on a tax basis were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| <br>**Fund** | **Undistributed**<br>**Ordinary**<br>**Income** | **Undistributed**<br>**Long-Term**<br>**Capital Gains** | **Post October Loss**<br>**and**<br>**Late Year Loss** | **Capital Loss**<br>**Carry**<br>**Forwards** | **Other**<br>**Book/Tax**<br>**Differences** | **Unrealized**<br>**Appreciation/**<br>**(Depreciation)** | **Total**<br>**Accumulated**<br>**Earnings/(Losses)** |
| Eventide Balanced Fund | $15304 | $12877773 | $— | $— | $— | $41267594 | $54160671 |
| Eventide Core Bond Fund | 150222 |  |  | (15185022) |  | (2167035) | (17201835) |
| Eventide Dividend Growth Fund |  | 28654745 |  |  |  | 201748764 | 230403509 |
| Eventide Exponential Technologies Fund |  |  | (600378) | (46820367) | (167762) | 28776666 | (18811841) |
| Eventide Gilead Fund |  | 272348115 | (19524674) |  |  | 1183947716 | 1436771157 |
| Eventide Healthcare & Life Sciences Fund |  |  | (142795526) | (7762214) |  | 162472468 | 11914728 |
| Eventide Large Cap Focus Fund | 78231 | 697236 |  |  |  | 21167106 | 21942573 |
| Eventide Limited-Term Bond Fund | 94711 |  |  | (8990663) |  | 947760 | (7948192) |

---

The difference between book basis and tax basis undistributed net investment income/(loss), accumulated net realized gain/(loss), and unrealized appreciation/(depreciation) from investments is primarily attributable to the tax deferral of losses on wash sales, mark-to-market on passive foreign investment companies and adjustments for C-Corporation return of capital. In addition, the amounts listed under other book/tax differences are primarily attributable to the tax deferral of losses on straddles.

Late year losses incurred after December 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such late year losses as follows:

---

| | |
|:---|:---|
| <br>**Fund** | **Late Year**<br>**Losses** |
| Eventide Exponential Technologies Fund | $600378 |
| Eventide Gilead Fund | 19524674 |
| Eventide Healthcare & Life Sciences Fund | 22140674 |

---

Capital losses incurred after October 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such capital losses as follows:

---

| | |
|:---|:---|
| <br>**Fund** | **Post October**<br>**Losses** |
| Eventide Healthcare & Life Sciences Fund | $120654852 |

---

At June 30, 2025, the Funds had capital loss carry forwards for federal income tax purposes available to offset future capital gains and utilized prior year capital loss carry forwards, as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Non-Expiring** | **Non-Expiring** | | |
| <br>**Fund** |<br>**Short-Term** |<br>**Long-Term** |<br>**Total** |<br>**CLCF**<br>**Utilized** |
| Eventide Balanced Fund | $— | $— | $— | $10658695 |
| Eventide Core Bond Fund | 4395821 | 10789201 | 15185022 |  |
| Eventide Dividend Growth Fund |  |  |  | 29982579 |
| Eventide Exponential Technologies Fund | 46820367 |  | 46820367 | 7342357 |
| Eventide Gilead Fund |  |  |  | 37418371 |
| Eventide Healthcare & Life Sciences Fund | 7762214 |  | 7762214 | 20199862 |
| Eventide Large Cap Focus Fund |  |  |  |  |
| Eventide Limited-Term Bond Fund | 2137661 | 6853002 | 8990663 |  |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

As of the fiscal year ended June 30, 2025, permanent book and tax differences resulted in reclassifications between Paid in Capital and Accumulated Earnings/(Losses) for certain Funds. These reclasses are primarily attributable to net operating losses, distributions in excess, and the use of tax equalization credits, which is applying earnings and profits credited to redeeming shareholders redemptions to the Funds Dividends Paid Deduction for income tax purposes. For the fiscal year ended June 30, 2025, the total reclassifications are as follows:

---

| | | |
|:---|:---|:---|
| <br>**Fund** |<br>**Paid In Capital** | **Accumulated**<br>**Earnings (Losses)** |
| Eventide Balanced Fund | $1028405 | $(1028405) |
| Eventide Core Bond Fund |  |  |
| Eventide Dividend Growth Fund | 1813634 | (1813634) |
| Eventide Exponential Technologies Fund | (1402242) | 1402242 |
| Eventide Gilead Fund | 17407033 | (17407033) |
| Eventide Healthcare & Life Sciences Fund |  |  |
| Eventide Large Cap Focus Fund | 370311 | (370311) |
| Eventide Limited-Term Bond Fund |  |  |

---

**(5)** **INVESTMENTS IN AFFILIATED COMPANIES** 

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities. Companies which are affiliates of the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund at December 31, 2025 are noted in the Funds' Schedule of Investments. Transactions during the period with companies which are affiliates are as follows:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** |
|  |  |  |  |  |  |  | Net Increase/ |  |  |  |
|  |  | Share Balance |  |  |  | Dividends | Decrease in |  | Market Value at | Share Balance |
|  | Market Value at | at June 30, |  |  |  | Credited to | Appreciation | Realized Gains | December 31, | at December 31, |
| Description | June 30, 2025 | 2025 | Purchases | Sales Proceeds | Corporate Actions | Income | (Depreciation) | (Losses) | 2025 | 2025 |
| Beta Bionics, Inc. | $40275202 | 2766154 | $— | $— | $— | $— | $44009510 | $— | $84284712 | 2766154 |
| Total | $40275202 | $2766154 | $— | $— | $— | $— | $44009510 | $— | $84284712 | $2766154 |
| **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** |
|  |  |  |  |  |  |  | Net Increase/ |  |  |  |
|  |  |  |  |  |  | Dividends | Decrease in |  | Market Value at | Share Balance |
|  | Market Value at | Share Balance at |  |  | Corporate | Credited to | Appreciation | Realized Gains | December 31, | at December 31, |
| Description | June 30, 2025 | June 30, 2025 | Purchases | Sales Proceeds | Actions | Income | (Depreciation) | (Losses) | 2025 | 2025 |
| Beta Bionics, Inc. | $25751457 | 1768644 | $— | $— | $— | $— | $28139126 | $— | $53890583 | 1768644 |
| Casma Therapeutics, Inc. Series B1 | 349500 | 5000000 |  |  |  |  | 52425 |  | 401925 | 5000000 |
| Casma Therapeutics, Inc. Series B2 | 349500 | 5000000 |  |  |  |  | 52425 |  | 401925 | 5000000 |
| Casma Therapeutics, Inc. Series C1 | 127247 | 1820413 |  |  |  |  | 19087 |  | 146334 | 1820413 |
| Casma Therapeutics, Inc. Series C2 | 173344 | 2479882 |  |  |  |  | 26001 |  | 199345 | 2479882 |
| Evida BioSciences, Inc. | 702261 | 1017770 |  |  |  |  | 278564 |  | 980825 | 1017770 |
| Goldfinch Biopharma, Inc. Series A |  | 5000000 |  |  |  |  |  |  |  | 5000000 |
| Goldfinch Biopharma, Inc. Series B |  | 8474576 |  |  |  |  | 971649 |  | 971649 | 8474576 |
| Goldfinch Biopharma, Inc. Series B2 |  | 4237288 |  |  |  |  | 485824 |  | 485824 | 4237288 |
| TOTAL | $27453309 | 34798573 | $— | $— | $— | $— | $30025101 | $— | $57478410 | 34798573 |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(6)** **INVESTMENT IN RESTRICTED SECURITIES** 

Restricted securities include securities that have not been registered under the Securities Act of 1933, as amended, and securities that are subject to restrictions on resale. Each Fund may invest in restricted securities that are consistent with the Fund's investment objectives and investment strategies. A Fund will not invest in a restricted security if, immediately after and as a result of the investment in such security, more than 15% of the Fund's net assets would be invested in illiquid securities. In some cases, the issuer of restricted securities has agreed to register such securities for resale, at the issuer's expense either upon demand by the Funds or in connection with another registered offering of the securities. Investments in restricted securities are valued at fair value as determined in good faith in accordance with procedures adopted by the Board. It is possible that the estimated value may differ significantly from the amount that might ultimately be realized in the near term, and the difference could be material.

As of December 31, 2025, the Eventide Core Bond Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund and Eventide Limited-Term Bond Fund were invested in the following restricted securities:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Eventide Core Bond Fund** | **Eventide Core Bond Fund** | **Eventide Core Bond Fund** | **Eventide Core Bond Fund** | **Eventide Core Bond Fund** | **Eventide Core Bond Fund** |
|  | **Initial** | | | |  |
|  | **Acquisition** | | | |  |
| **Security** | **Date** | **Shares** | **Cost** | **Value** | % **of Net Assets** |
| CI Credit GP, LLC, 5.5000%, 12/15/30 | 12/15/2025 | 1000000 | $1000000 | $1000000 | 0.6% |
| Hope Global Investments, 4.6000%, 10/10/28 | 11/15/2024 | 750000 | 750000 | 741233 | 0.5% |
| Hope Global Investments, 5.0000%, 9/11/29 | 9/2/2025 | 500000 | 500000 | 494738 | 0.3% |
| **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** |
|  | **Initial** |  |  |  |  |
|  | **Acquisition** |  |  |  |  |
| **Security** | **Date** | **Shares** | **Cost** | **Value** | % **of Net Assets** |
| Vision Fund International, 5.0000%, 12/01/28 | 12/1/2025 | 750000 | $750000 | $749017 | 0.8% |
| **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** |
|  | **Initial** |  |  |  |  |
|  | **Acquisition** |  |  |  |  |
| **Security** | **Date** | **Shares** | **Cost** | **Value** | % **of Net Assets** |
| Beta Bionics, Inc. | 8/31/2018 | 2766154 | $46787158 | $84284712 | 2.9% |
| CI Credit GP, LLC, 5.0000%, 12/15/30 | 12/15/2025 | 3000000 | 3000000 | 3000000 | 0.1% |
| Hope Global International, 4.0000%, 01/07/28 | 12/28/2023 | 2000000 | 2000000 | 1967882 | 0.1% |
| Peloton Therapeutics, Inc. - CVR | 2/14/2019 | 3982940 |  | 4663883 | 0.2% |
| Vision Fund International, 3.223% 12/15/2026 | 12/16/2021 | 5000000 | 5000000 | 4927330 | 0.2% |
| Vision Fund International, 4.7500% 03/31/2028 | 9/30/2025 | 5000000 | 5000000 | 4980030 | 0.3% |
| Vision Fund International, 5.0000% 12/01/2028 | 12/1/2025 | 5000000 | 5000000 | 4993445 | 0.2% |
| Vision Fund International, 5.0000% 06/01/2029 | 12/1/2025 | 4000000 | 4000000 | 3977312 | 0.1% |
| Vision Fund International, 5.1000% 12/15/2029 | 12/15/2025 | 5000000 | 5000000 | 5000000 | 0.2% |
| Vision Fund International, 5.5000% 06/30/2028 | 6/30/2025 | 5000000 | 5000000 | 5000000 | 0.2% |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** |
|  | **Initial** | | | |  |
|  | **Acquisition** | | | |  |
| **Security** | **Date** | **Shares** | **Cost** | **Value** | % **of Net Assets** |
| Avalyn Pharma Inc. Series C1 | 9/25/2023 | 20482289 | $15000000 | $16310047 | 1.0% |
| Avalyn Pharma Inc. Series D1 | 4/25/2025 | 4060259 | 3233184 | 3233184 | 0.2% |
| Beta Bionics, Inc. | 8/31/2018 | 1768644 | 30258115 | 53890583 | 3.2% |
| BioSplice Therapeutics, Inc. Series B-1 | 3/5/2021 | 295276 | 15000021 |  | 0.0% |
| BioSplice Therapeutics, Inc. Series C PIK, 1.5000%, 03/12/26 | 5/2/2023 | 3500000 | 3500000 | 242533 | 0.0% |
| Biosplice Therapeutics, Inc. Series C Warrant | 5/2/2023 | 111191 |  |  | 0.0% |
| Casma Therapeutics, Inc. Series B1 | 8/26/2020 | 5000000 | 3750000 | 401925 | 0.0% |
| Casma Therapeutics, Inc. Series B2 | 6/7/2021 | 5000000 | 3750000 | 401925 | 0.0% |
| Casma Therapeutics, Inc. Series C1 | 7/6/2022 | 1820413 | 837390 | 146334 | 0.0% |
| Casma Therapeutics, Inc. Series C2 | 1/31/2023 | 2479882 | 1140746 | 199345 | 0.0% |
| Evida BioSciences, Inc. | 12/31/2020 | 1017770 | 702262 | 980825 | 0.1% |
| Flare Therapeutics, Inc. Series A | 4/22/2021 | 1097561 | 1097561 | 1503659 | 0.1% |
| Flare Therapeutics, Inc. Series A2 | 5/31/2022 | 902439 | 902439 | 1236342 | 0.1% |
| Flare Therapeutics, Inc. Series B | 2/1/2023 | 1952962 | 2349999 | 2870854 | 0.2% |
| Freenome Holdings, Inc. Series D | 11/22/2021 | 930436 | 6999994 | 2276949 | 0.1% |
| Freenome Holdings, Inc. Series F | 1/26/2024 | 133941 | 990984 | 327778 | 0.0% |
| Goldfinch Biopharma, Inc. Series A | 3/15/2019 | 5000000 | 5000000 |  | 0.0% |
| Goldfinch Biopharma, Inc. Series B | 6/29/2020 | 8474576 | 10000000 | 971649 | 0.1% |
| Goldfinch Biopharma, Inc. Series B2 | 3/21/2022 | 4237288 | 5000000 | 485824 | 0.0% |
| Kardigan, Inc. Series B | 10/9/2025 | 374442 | 7999983 | 7999983 | 0.5% |
| Kardium Inc. Series D-8 | 6/6/2025 | 15450219 | 10000000 | 10000000 | 0.6% |
| Kojin Therapeutics, Inc. Series A-1 | 6/2/2021 | 763319 | 1499998 |  | 0.0% |
| Kojin Therapeutics, Inc. Series A-2 | 1/28/2022 | 763319 | 1499998 |  | 0.0% |
| Metsera, Inc. - CVR | 11/14/2025 | 396160 | 8620487 | 3862560 | 0.2% |
| OVID Therapeutics, Inc. Series A Warrants | 10/3/2025 | 2856666 |  | 1863975 | 0.1% |
| OVID Therapeutics, Inc. Series B Warrants | 10/3/2025 | 2142500 |  | 1397981 | 0.1% |
| OVID Therapeutics, Inc. | 10/3/2025 | 4285000 | 5999000 | 6984550 | 0.4% |
| Peloton Therapeutics, Inc. - CVR | 2/14/2019 | 1528871 |  | 1790254 | 0.1% |
| **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** |
|  | **Initial** |  |  |  |  |
|  | **Acquisition** |  |  |  |  |
| **Security** | **Date** | **Shares** | **Cost** | **Value** | % **of Net Assets** |
| CI Credit GP, LLC, 5.5000%, 12/15/30 | 12/15/2025 | 1000000 | $1000000 | $1000000 | 0.5% |
| Hope Global Investments, 4.6000%, 10/10/28 | 11/15/2024 | 750000 | 750000 | 741233 | 0.4% |
| Hope Global Investments, 5.0000%, 09/11/29 | 9/2/2025 | 500000 | 500000 | 494738 | 0.2% |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(7)** **SECTOR EXPOSURE RISK** 

The Eventide Exponential Technologies Fund invests primarily in equity and equity-related securities of companies that the Adviser believes are participating in and benefitting from technologies, innovations, technology themes, or technology trends. The types of companies represented in the Fund's portfolio include, but are not limited to, companies falling within the information technology, e-commerce discretionary, internet media and services, healthcare technology, healthcare devices, or transaction and payment processing services industries. Because of its focus on technology companies, the Eventide Exponential Technologies Fund's investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Exponential Technologies Fund's net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries.

The Eventide Healthcare & Life Sciences Fund invests primarily in equity and equity-related securities of companies in the healthcare and life sciences sectors that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. Because of its focus on healthcare and life science companies, the Eventide Healthcare & Life Sciences Fund's investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Healthcare & Life Sciences Fund's net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(8)** **OPTIONS RISK** 

There are risks associated with the sale and purchase of call and put options. The seller (writer) of a call option which is covered (e.g., the writer holds the underlying security) assumes the risk of a decline in the market price of an underlying security below the purchase price of an underlying security less the premium received, and gives up the opportunity for gain on the underlying security above the exercise price of the option. The seller of an uncovered call option assumes the risk of a theoretical unlimited increase in the market price of an underlying security above the exercise price of the option. The securities necessary to satisfy the exercise of the call option may be unavailable for purchase except at much higher prices. Purchasing securities to satisfy the exercise of the call option can itself cause the price of securities to rise further, sometimes by a significant amount, thereby exacerbating the loss. The buyer of a call option assumes the risk of losing its entire premium invested in the call option. The seller (writer) of a put option which is covered (e.g., the writer has a short position in the underlying security) assumes the risk of an increase in the market price of the underlying security above the sales price (in establishing the short position) of the underlying security plus the premium received, and gives up the opportunity for gain on the underlying security below the exercise price of the option. The seller of an uncovered put option assumes the risk of a decline in the market price of the underlying security below the exercise price of the option. The buyer of a put option assumes the risk of losing his entire premium invested in the put option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(9)** **MARKET RISK** 

Overall market risks may also affect the value of the Funds. The market values of securities or other investments owned by the Funds will go up or down, sometimes rapidly or unpredictably. Factors such as economic growth and market conditions, interest rate levels, exchange rates and political events affect the securities markets. Changes in market conditions and interest rates generally do not have the same impact on all types of securities and instruments. Unexpected local, regional or global events and their aftermath, such as war; acts of terrorism; financial, political or social disruptions; natural, environmental or man-made disasters; climate-change and climate-related events; the spread of infectious illnesses or other public health issues; recessions and depressions; tariffs and trade wars; or other tragedies, catastrophes and events could have a significant impact on the Funds and their investments and could result in increased premiums or discounts to a Fund's net asset value, and may impair market liquidity, thereby increasing liquidity risk. Such events can cause investor fear and panic, which can adversely affect the economies of many companies, sectors, nations, regions and the market in general, in ways that cannot necessarily be foreseen. The Funds could lose money over short periods due to short-term market movements and over longer periods during more prolonged market downturns. During a general market downturn, multiple asset classes may be negatively affected. In times of severe market disruptions you could lose your entire investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(10)** **LINE OF CREDIT** 

Effective January 22, 2025, the Funds have a $150,000,000 uncommitted line of credit provided by U.S. Bank National Association (the ***"Bank"***) under an agreement (the ***"Uncommitted Line"***), that is set to expire on January 21, 2026. Borrowings under the Uncommitted Line bear an interest at Prime Rate minus 0% per month. Any advance under the Uncommitted Line is contemplated primarily for temporary or emergency purposes, including the meeting of redemption requests that otherwise might require the untimely disposition of securities. Interest on borrowings is payable on an annualized basis. The Uncommitted Line is not a "committed" line of credit, which is to say that the Bank is not obligated to lend money to the Funds. Accordingly, it is possible that Funds may wish to borrow money for a temporary or emergency purpose but may not be able to do so. During the six months ended December 31, 2025, none of the Funds accessed the line of credit.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Unaudited)(Continued)*** |
| **December 31, 2025** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(11)** **BENEFICIAL OWNERSHIP** 

The beneficial ownership, either directly or indirectly, of more than 25% of the voting securities of a fund creates a presumption of control of the fund, under Section 2(a)(9) of the 1940 Act. As of December 31, 2025, Charles Schwab & Co, Inc. for the Exclusive Benefit of Customers held 41.29%, 38.63%, and 26.90% of the Eventide Core Bond Fund, Eventide Exponential Technologies Fund, and Eventide Limited-Term Bond Fund, respectively. As of December 31, 2025, National Financial Services LLC held 41.46% of the Eventide Core Bond Fund. As of December 31, 2025, American Enterprise Investment Services held 32.08% of the Eventide Limited-Term Bond Fund.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(12)** **ACCOUNTING PRONOUNCEMENT** 

The Funds adopted the FASB Accounting Standards Update 2023-09, "Income Taxes (Topic 740) Improvements to Income Tax Disclosures" ("ASU 2023-09"), which establishes new income tax disclosure requirements and modifies or eliminates certain existing disclosure provisions. The amendments in this ASU are intended to address investor requests for more transparency about income tax information and to improve the effectiveness of income tax disclosures. The Fund's adoption of ASU 2023-09 did not have a material impact on the Funds' financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(13)** **SUBSEQUENT EVENTS** 

Subsequent events after the date of the Statements of Assets and Liabilities have been evaluated through the date the financial statements were issued. Management has determined that no events or transactions occurred requiring adjustment or disclosure in the financial statements.

---

| |
|:---|
| **Eventide Funds** |
| ***Additional Information (Unaudited)*** |
| **December 31, 2025** |

---

**Changes in and Disagreements with Accountants**

There were no changes in or disagreements with accountants during the period covered by this report.

**Proxy Disclosures**

Not applicable.

**Remuneration Paid to Directors, Officers and Others**

Refer to the financial statements included herein.

**Statement Regarding Basis for Approval of Investment Advisory Agreement** Not applicable.

**Fund Proxy Voting Policies, Procedures and Summaries**

Information regarding how the Funds voted proxies relating to portfolio securities for the most recent 12-month period ended June 30 as well as a description of the policies and procedures that the Funds use to determine how to vote proxies is available without charge, upon request, by calling 1-877-771-3836 or by referring to the Securities and Exchange Commission's ("SEC") website at http://www.sec.gov.

**Item 8. Changes in and Disagreements with Accountants for Open-End Management Investment Companies.** 

Not applicable

**Item 9. Proxy Disclosures for Open-End Management Investment Companies.** 

Not applicable

**Item 10. Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies.** 

Included under Item 7

**Item 11. Statement Regarding Basis for Approval of Investment Advisory Contract.** 

Included under Item 7

**Item 12. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.** 

Not applicable

**Item 13. Portfolio Managers of Closed-End Management Investment Companies.**

Not applicable

**Item 14. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.** 

Not applicable

**Item 15. Submission of Matters to a Vote of Security Holders.** 

None

**Item 16. Controls and Procedures** 

(a) The registrant's Principal Executive Officer and Principal Financial Officer have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Act) are effective in design and operation and are sufficient to form the basis of the certifications required by Rule 30a-(2) under the Act, based on their evaluation of these disclosure controls and procedures as of a date within 90 days of this report on Form N-CSR.

(b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

**Item 17. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.** 

Not applicable

**Item 18. Recovery of Erroneously Awarded Compensation.**

(a)&nbsp;&nbsp;&nbsp;&nbsp; Not applicable

(b)&nbsp;&nbsp;&nbsp;&nbsp; Not applicable

**Item 19. Exhibits.** 

(a)(1) Not applicable

(a)(2) Not applicable

(a)(3) A separate certification for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a) under the Act (17 CFR 270.30a-2(a)):[Attached hereto.](ex99-cert.htm)

(a)(4) Not applicable

(b) &nbsp;&nbsp;&nbsp;&nbsp; Certifications required by Rule 30a-2(b) under the Act (17 CFR 270.30a-2(b)): [Attached hereto.](ex99-906cert.htm)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Mutual Fund Series Trust

---

| | |
|:---|:---|
| By | /s/ Michael Schoonover |
| Michael Schoonover | Michael Schoonover |
| Principal Executive Officer | Principal Executive Officer |
| Date: 3/2/2026 | Date: 3/2/2026 |

---

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

---

| | |
|:---|:---|
| By | /s/ Michael Schoonover |
| Michael Schoonover | Michael Schoonover |
| Principal Executive Officer | Principal Executive Officer |
| Date: 3/2/2026 | Date: 3/2/2026 |

---

---

| | |
|:---|:---|
| By | /s/ Erik Naviloff |
| Erik Naviloff | Erik Naviloff |
| Principal Financial Officer | Principal Financial Officer |
| Date: 3/2/2026 | Date: 3/2/2026 |

---

## Ex-99.Cert

**Certification** [Exhibit 99. CERT]

I, Michael Schoonover, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I
 have reviewed this report on Form N-CSR of Eventide Funds, a series of the Mutual Fund Series
 Trust ("registrant");

&nbsp;&nbsp;&nbsp;&nbsp;2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or
 omit to state a material fact necessary to make the statements made, in light of the circumstances
 under which such statements were made, not misleading with respect to the period covered
 by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based
 on my knowledge, the financial statements, and other financial information included in this
 report, fairly present in all material respects the financial condition, results of operations,
 changes in net assets, and cash flows (if the financial statements are required to include
 a statement of cash flows) of the registrant as of, and for, the periods presented in this
 report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The
 registrant's other certifying officer(s) and I are responsible for establishing and maintaining
 disclosure controls and procedures (as defined in rule 30a-3(c) under the Investment Company
 Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under
 the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures
 to be designed under our supervision, to ensure that material information relating to the
 registrant, including its consolidated subsidiaries, is made known to us by others within
 those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Designed
 such internal control over financial reporting, or caused such internal control over financial
 reporting to be designed under our supervision, to provide reasonable assurance regarding
 the reliability of financial reporting and the preparation of financial statements for external
 purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in
 this report our conclusions about the effectiveness of the disclosure controls and procedures,
 as of a date within 90 days prior to the filing date of this report based on such evaluation;
 and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed
 in this report any change in the registrant's internal control over financial reporting
 that occurred during the period covered by this report that has materially affected, or is
 reasonably likely to materially affect, the registrant's internal control over financial
 reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The
 registrant's other certifying officer(s) and I have disclosed to the registrant's auditors
 and the audit committee of the registrant's board of directors (or persons performing the
 equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All
 significant deficiencies and material weaknesses in the design or operation of internal control
 over financial reporting which are reasonably likely to adversely affect the registrant's
 ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Any
 fraud, whether or not material, that involves management or other employees who have a significant
 role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: 3/2/2026 | /s/ Michael Schoonover |
|  | Michael Schoonover |
|  | Principal Executive Officer |

---

**Certification** [Exhibit 99. CERT]

I, Erik Naviloff, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I
 have reviewed this report on Form N-CSR of Eventide Funds, a series of the Mutual Fund Series
 Trust ("registrant");

&nbsp;&nbsp;&nbsp;&nbsp;2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or
 omit to state a material fact necessary to make the statements made, in light of the circumstances
 under which such statements were made, not misleading with respect to the period covered
 by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based
 on my knowledge, the financial statements, and other financial information included in this
 report, fairly present in all material respects the financial condition, results of operations,
 changes in net assets, and cash flows (if the financial statements are required to include
 a statement of cash flows) of the registrant as of, and for, the periods presented in this
 report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The
 registrant's other certifying officer(s) and I are responsible for establishing and maintaining
 disclosure controls and procedures (as defined in rule 30a-3(c) under the Investment Company
 Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under
 the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures
 to be designed under our supervision, to ensure that material information relating to the
 registrant, including its consolidated subsidiaries, is made known to us by others within
 those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Designed
 such internal control over financial reporting, or caused such internal control over financial
 reporting to be designed under our supervision, to provide reasonable assurance regarding
 the reliability of financial reporting and the preparation of financial statements for external
 purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in
 this report our conclusions about the effectiveness of the disclosure controls and procedures,
 as of a date within 90 days prior to the filing date of this report based on such evaluation;
 and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed
 in this report any change in the registrant's internal control over financial reporting
 that occurred during the period covered by this report that has materially affected, or is
 reasonably likely to materially affect, the registrant's internal control over financial
 reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The
 registrant's other certifying officer(s) and I have disclosed to the registrant's auditors
 and the audit committee of the registrant's board of directors (or persons performing the
 equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All
 significant deficiencies and material weaknesses in the design or operation of internal control
 over financial reporting which are reasonably likely to adversely affect the registrant's
 ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Any
 fraud, whether or not material, that involves management or other employees who have a significant
 role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: 3/2/2026 | /s/ Erik Naviloff |
|  | Erik Naviloff |
|  | Principal Financial Officer |

---

## Exhibit 99.906

**CERTIFICATION** [Exhibit 99.906CERT]

Michael Schoonover, Principal Executive Officer, and Erik Naviloff, Principal Financial Officer of Mutual Fund Series Trust (the "Registrant"), each certify to the best of his/her knowledge that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Registrant's periodic report on Form N-CSR for the period ended December 31, 2025, (the "Form N-CSR") fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Form N-CSR fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

---

| | | | |
|:---|:---|:---|:---|
| Principal Executive Officer | Principal Executive Officer | Principal Financial Officer | Principal Financial Officer |
| Mutual Fund Series Trust | Mutual Fund Series Trust | Mutual Fund Series Trust | Mutual Fund Series Trust |
| /s/ Michael Schoonover | /s/ Michael Schoonover | /s/ Erik Naviloff | /s/ Erik Naviloff |
| Michael Schoonover | Michael Schoonover | Erik Naviloff | Erik Naviloff |
| Date: | 3/2/2026 | Date: | 3/2/2026 |

---

This certification is being furnished to the Commission solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Form N-CSR filed with the Commission.